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Abstract 
 
Introduction 
A research study was commissioned to understand and inform the new role of an Integrated 
Care (IC) Pharmacist, founded to work as part of the health and social multidisciplinary team 
(MDT) within the IC program for East Leicestershire and Rutland Clinical Commissioning 
Group (ELR CCG).  
 
Aim 
The aim of the study was to understand and inform this new role of the IC Pharmacist for 
ELRCCG and how to develop and sustain such a role. 
 
Methods 
A participatory mixed methods research strategy, which aligns with pragmatism as a 
philosophy was used. The qualitative arm of the mixed methods was predominantly 
underpinned by phenomenology and included interviews with two IC patients and seven 
professionals who were a core part of the integrated MDT and one focus group. For the 
quantitative arm, key performance indicators(KPIs) documented in line with the sponsor 
evaluation policy were analysed. 
 
Findings 
The six themes derived from the qualitative methods were: teamwork; accessibility and 
visibility; resources and enablers; reflection on the role functions; Impact of the role and  
evaluating performance of the role. For the quantitative results, all the KPIs were achieved, 
including a return of investment of 311%, a reduction of polypharmacy by the de-prescribing 
of 54 drugs, the completion of clinical medication reviews in 100% of patients and repeat 
prescription reviews in 37% of patients and the provision of four medication training sessions 
for the IC coordinators. 
 
Discussion 
The findings support existing literature by qualitatively and quantitatively showing how the 
role functions and positive outcomes achieved by pharmacists in integrated primary care 
roles can be extended to social and health integrated care teams. Role functions highlighted 
include provision of pharmaceutical care to patients and training and education to staff. 
Positive outcomes delivered by the IC pharmacists include participant empowerment and 
bridge building between health and social care professionals.Furthermore, this study 
contributes to existing knowledge by identifying enablers and showing how they can optimise 
these outcomes. A key enabler was to fully embed the IC pharmacist role within a health and 
social MDT and co-locating the MDT at a GP surgery, instead of remote offices . Ensuring 
effective teamwork which is facilitated by a shared agenda, role understanding, respect, 
accessibility and visibility is another important enabler. A third enabler identified as crucial to 
sustain the role, is funding to transform the model to a fully embedded GP hub pharmacist 
and technician team, to ensure holistic staff capacity. Finally, the study highlighted that the 
role could be evaluated through stakeholder feedback as well as the utilization of admissions 
avoidance figures after adjusting for assumptions. 
 
Conclusion 
In line with action research, both action and additional knowledge were achieved. Action was 
achieved by ultimately transforming and expanding two roles to twelve teams of pharmacists 
and pharmacy technicians. Additional knowledge contributed include the views of key 
stakeholders across health and social carer, including patients, regarding what exactly the IC 
pharmacist role is, how it is delivered and could be adapted to increase sustainability, what 
outcomes it delivers and how they can be evaluated. Further research is required to inform 
which of the models would be best suited for the local population.  
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Glossary 
Acronym or 
Term 
Definition  
Care plan  
 
A single overarching plan that records the outcome of discussion between the 
individual being cared for and the professional responsible.  
Carer  
 
An individual who provides or intends to provide practical and long term emotional 
support to someone with a long-term condition.  
CCG Clinical Commissioning Group  
CCGs are clinically led statutory NHS bodies responsible for the planning and 
commissioning of healthcare services for their local area. They are responsible for 
about 60% of the NHS budget, commission most secondary care services, 
and play a part in the commissioning of GP services.   
CSW Community Support Worker (CSW).  
CSW refers to Council employees who work under supervision to deliver a person-
centred social care service. 
Commissioning  
 
The means to secure the best care and the best value for local people. It is the 
process of changing objectives and needs, by specifying and procuring services 
for the local population, into required services  
DH Department of Health in United Kingdom  
The DH is responsible for strategic leadership and funding for both health and 
social care in England.  
ELR CCG  East Leicestershire and Rutland Clinical Commissioning Group 
Statutory organisation with the responsibility for commissioning healthcare 
services for approximately 325,000 residents in East Leicestershire & Rutland. 
Further divided into three localities:  Blaby & Lutterworth (BL), Melton, Rutland and 
Harborough(MRH) and Oadby & Wigston (OW)  
GP  General Practitioner or General Practice  
General practitioner refers to a family doctor based in the community with 
primarily responsible for the provision of comprehensive and continuing generalist 
care to individuals seeking medical care. 
General practice is the specialty of the general practitioner.  
GP Surgery or 
GP Practice  
Refer to the location where the patients are routinely seen by the GP or member of 
the team e.g. nurses, healthcare assistants or increasingly pharmacists. GP 
practices closely collaborate with other healthcare professionals like health 
visitors, midwives, mental health services and social care services. 
GP Hub  
 
General Practice Hub 
Group of GP practices formally or informally coming together to pool resources for 
economy of scale and to share services. 
GP Federation General Practice Federation 
Group of practices working together within their local area, in some sort of 
collective legal or organisational entity. 
Health care 
need  
 A need related to the treatment, control or prevention of a disease, illness, injury 
or disability, and the care or aftercare of a person with these needs, regardless of 
whether the tasks involved should be carried out by a health professional or not. 
Holistic  
 
In medical terms denotes a treatment or service which deals with the needs of the 
whole person, not just the injury or disease.  
IP Independent or non–medical Prescriber.  
Designation for healthcare professional other than a doctor or dentist in the United 
Kingdom, with the legal authority to prescribe medication, within their competency.  
ICC 
 
Integrated Care Coordinators  
These are social community support workers (as opposed to professional social 
workers), who were the coordinators in the East Leicestershire and Rutland model 
of the integrated care programme. 
KPI Key Performance Indicator.  
Used to evaluate the success of a projects, programs, other initiatives such as the 
integrated care pilot program.  
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LCC Leicestershire County Council 
County council for Leicestershire which was originally formed in 1889 and has 
responsibility for adult social and non-primary health provision, for both east 
Leicestershire and west Leicestershire population. LCC was the employer of the 
social care coordinators for the integrated care pilot project. 
Medicines 
Management 
Is the clinical, cost –effective and safe use of medicines to ensure patients obtain 
maximum outcomes from required medication with minimum harm (MHRA,2004). 
MRC Medical Research Council 
Multimorbidity  The presence of two or more long-term conditions in a person.  
NHS National Health Service  
Was launched in 1948 to provide free (at point of use) health care that is for UK 
residents. Over 98% of prescriptions in community pharmacy are under the NHS 
and NHS hospitals provide up to 80% of secondary care.  
NHS CCF National Health Service Continuing Care funding 
Synonymous with ‘Continuing Care’ or ‘Fully Funded NHS Care’. This is 100% 
funding provided by the NHS for people in full time care who are assessed as 
having a “Primary Health need” 
Outcomes  These are the change in health status following an intervention e.g. reduced pain, 
and increased mobility post knee surgery 
Partners  
 
Refers to everyone who has a professional interest and is directly involved in the 
design, development and delivery of a service 
Patient A person receiving or registered to receive health intervention treatment 
Patient-
centered  
Denotes an organization’s provision to support personalized care delivery.  
PCT Primary Care Trust  
PCTs were administrative bodies, responsible for commissioning primary, 
community and secondary health services from providers between 2001 to 2013. 
The approximately 303 PCTs were replaced by CCGs and NHS England  
Pharmaceutical 
Care  
This refers to the accountable delivery of medication therapy with the aim of 
achieving defined outcomes to improve the quality of life of a patient. The 
outcomes include: disease cure; symptom reduction or elimination, disease 
progression reduction or halting, disease or symptom prevention  
Primary Care  This is the first level contact with people acting to improve health in a community. 
In the United Kingdom, all initial (non-emergency) consultations with doctors, 
nurses or other health staff are termed primary care as opposed to secondary 
healthcare or referral services. General practice is the building block of primary 
care in the UK. 
ROI  Return on investment  
Measure of how much is gained or lost following an investment such as the 
integrated care pharmacists. It is usually expressed as a percentage of the net 
profit over the cost of the investment. 
RPS Royal Pharmaceutical Society  
The RPS (also referred to as RPharmS) is the dedicated body responsible for the 
leadership and support of the pharmacy profession in 
England, Scotland and Wales. It was created alongside General Pharmaceutical 
Council (GPhC) in 2010 from the Royal Pharmaceutical Society of Great Britain   
Risk 
stratification  
Segmenting a population to provide person-centred care to those most in need 
recognising resource constraints 
Stakeholders  
 
Refers to everyone who has a 'vested' interest in the service irrespective of their 
roles, responsibilities and contributions. Patients, carers and communities included 
Social worker  A professional who works with other professions to play a key role in helping 
children, adults and families to take control of and to improve their lives in 
conditions where their security, safety or ability to participate in civic life are 
restricted. 
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Preface 
This dissertation is titled “An Action Research Evaluation to understand and inform the role 
of the integrated care pharmacist across health and social care”.  The World Health 
Organization describes integrated care as care that is coordinated and centered around the 
patient and is the opposite of fragmented or episodic care (WHO, 2016). The following 
definition of integrated care was constructed by a patient and this has now been adopted by 
the Department of Health.  
“My care is planned with people who work TOGETHER to understand me and my carer(s), 
put ME in control, coordinate and deliver services to achieve MY best outcomes”. 
(National Voices, 2013) 
This research was completed between January 2016 and November 2017 resulting from a 
pilot study that I introduced whilst in my post as head of prescribing at the East 
Leicestershire and Rutland Clinical Commissioning Group (ELRCCG).  
I made the case for the pilot study after identifying that the multidisciplinary team within the 
integrated care program blueprint, did not include a pharmacist. I highlighted that because 
most patients requiring integrated health and social input would be expected to be taking 
multiple medication, they or their carers may benefit from pharmaceutical input. In due 
course, two integrated care pharmacists were co-located in an office alongside a team of 12 
social community support workers who were the main coordinators of the integrated care 
programme.  
In view of the integrated care pharmacist role being new, the CCG agreed to commission a 
research study to evaluate and inform the role. Ultimately, I led the research and it became 
the focus of the project that I conducted in partial fulfillment of a doctoral thesis.  
Conducting this research was challenging. However, it was extremely rewarding because in 
addition to answering the research questions, the participatory mixed methods methodology 
enabled timely development, evolution and expansion of the new pharmacist role, within the 
clinical commissioning group. It culminated in the funding of approximately twelve new 
whole-time equivalent pharmacists and supporting pharmacy technician roles, to provide 
integrated clinical pharmacy services in primary care, to the approximately 325,000 patient 
population of the East Leicestershire and Rutland Clinical Commissioning Group.  
 
Phyllis Navti  
December 2018 
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CHAPTER 1: INTRODUCTION  
Chapter Overview  
 
This introductory chapter outlines the overall aim and rationale of the research and explains 
the concept, historical development and importance of integrated care within the wider 
context of health and social care provision in the NHS. The background includes ‘A tale of 
two patients’ as illustrative fictitious case studies, with a view to help explain integrated care 
and demonstrate how it focuses upon the individual values and health needs of patients.  
The chapter also aims to explain the rationale for, and the eventual role of the Integrated 
Care Pharmacist. It is the latter that provides a focal point for evaluation. The chapter 
concludes by outlining the research objectives and the questions which this action research 
project seeks to answer.  
1.1 INTRODUCTION TO CHAPTER 1  
Pharmacotherapy or treatment with medication is the most common intervention in 
healthcare systems across the world (European Directorate for the Quality of Medicines and 
Healthcare, 2012). It is estimated that the NHS cost of pharmacotherapy increased from £13 
billion in 2010/11 to £17.4 billion in 2016/17. This equates to an average annual growth of 5 
percent (Ewbank, 2018). The main consumers of pharmacotherapy in the UK are the 26 
million patients with long term conditions (LTCs), who are also the main drivers of cost and 
activity in the National health service (NHS) and social care (NHS ENGLAND, 2018).  
 
There is very significant harm associated with pharmacotherapy which is escalating with the 
increase in complexity and volume of medication use (Cipolle et al. 2012; Strand et al.1990). 
Pharmacotherapy associated harm includes adverse drug reactions (ADR), medication 
errors and polypharmacy. ADRs were shown by a large UK study to be associated with 6.5% 
of emergency re-admissions, 72% of which were deemed avoidable with 2% leading to 
death (Pirmohamed et al. 2004). This is mirrored across the developed world with an 
Australian report showing that 12% of patients visiting their general practitioner (GP) had 
suffered from an ADR within the preceding six months (Roughead et al. 2013).  
Pharmacotherapy for LTC patients is usually managed by a multitude of health and social 
care professionals (Clements, 2009). This is despite the prevailing suboptimal integration 
between the health and social care systems (Goodwin et al. 2012). 
Therefore, there is a drive to move from fragmented to integrated health and social 
multidisciplinary, proactive and patient- centered care provision, in the primary care settings. 
(WHO, 2016; Bardsley et al. 2013; Rand et al. 2012). One of the ways of organizing 
integrated health and social primary care provision is through ‘virtual wards’. This involves 
 12 
the use of predictive modeling or risk stratification tools, to identify patients at moderate to 
high risk of emergency admissions. These patients are then provided proactive domiciliary 
care at home, by the integrated health and social multidisciplinary teams (MDT).  The 
proactive care interventions are designed to mirror the daily practices and routines of care 
provision and monitoring in hospital wards (Bardsley et al. 2013).  
 
Consequently, health and social integrated multidisciplinary teams (MDTs) are being funded 
and developed across the UK primary care setting. One of the biggest pioneer programmes 
of integrated care (IC) consisted of 16 department of health funded pilots which were 
evaluated by Rand et al (2012) between 2009 and 2011. The pilots were aimed at exploring 
different ways to provide IC to improve patient care and wellbeing. The published evaluation 
detailed some positive findings including the fact that IC led to process improvement 
including the increased use of care plans and the development of new roles. However, 
patients were less satisfied with the outcomes with some highlighting that IC resulted in a 
reduction in both access to their preferred doctor and nurse as well as involvement in their 
care planning. Nevertheless, it was noted that although reductions in planned admissions 
and outpatient attendance figures were reported, the cost of hospital use remained 
unchanged. There are several limitations of this evaluation study. Firstly, the 16 pilot sites 
received extra support as part of the pilot which most IC programs will not have access to. In 
addition, most of the evaluation data was qualitative and could thus have been biased 
because the participants could subconsciously try to provide a good impression. Also, the 
study did not mention any involvement of pharmacists as part of the multidisciplinary teams 
(MDT) described in the pilot programs. Finally, the design included the use of participant 
survey data alongside that of matched controls, instead of a randomized control trial. 
Similar findings were shown by the evaluation of 30 IC pilots by the Nuffield foundation 
which used quantitative methods and summative evaluation to find out whether the service 
models had an impact on service use and costs (Bardsley et al. 2013). A limitation of the 
Nuffield review was the limited focus on the three key aspects of clinical outcomes, improved 
safety and patient experience 
 
However, despite the increasing acknowledgement that pharmacotherapy outcomes can be 
optimized by pharmacists as medicines experts, working within integrated health and social 
MDTs (Smith et al. 2014), there was no mention or description of the pharmacist role within 
these pilots (Rand et al. 2012). More recent publications describe the role of pharmacists in 
the process of integrating within these MDTs (Daloni, 2016; Freeman et al.2016; Stone and 
Williams, 2015). However, these authors do not detail how to develop, sustain or evaluate 
the  role. 
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This study was thus designed to understand and inform the new role of the IC  pharmacist 
within East Leicestershire and Rutland (ELR) and how to develop and sustain it. It was also 
aimed at developing a process for evaluating the role.  The study focused on the following: 
 Defining the role of the pharmacist within the integrated health and social MDT.  
 Understanding the stakeholder’s perception of the outcomes that the integrated 
care pharmacist attempts to achieve and how this can be measured.  
 Understanding how to overcome the barriers and promote the facilitators to 
develop, expand and sustain the role.  
1.1.1 The East Leicestershire and Rutland Integrated Care Pharmacist role  
The East Leicestershire and Rutland (ELR) IC programme was launched in 2012. As part of 
the programme, LTC patients whose risk of deterioration would be increased without 
proactive support and review, are identified, using a risk assessment/stratification tool 
(Bardsley et al. 2013). Patients can also be referred by their health care professional based 
on their knowledge of the patient’s history. Each stratified patient is contacted by their local 
IC coordinator, who is a social community support worker by profession. The IC coordinator 
explains the programme and “admits” consenting patients to “a virtual ward”. These patients 
become IC patients which basically means that they receive a period of intense 
multidisciplinary care that mirrors hospital care, although they remain at home, as described 
above. In line with the IC process, their care is planned and delivered by a community MDT 
of health and social professionals, in liaison with the patient and their carers.  
 
The initial model of the ELR IC plan which was informed by the Rand et al (2012) report, did 
not include a pharmacist as part of the MDT, although most of the stratified patients would 
have been expected to be on multiple medication. After recognizing that this was a gap, the 
plan was revised and pharmacists were included as a core part of the ELR integrated MDT. 
The final ELR Model is illustrated below in figure 1.1 
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Figure 1.1: Integrated Care Model for East Leicestershire and Rutland  
(East Leicestershire and Rutland CCG, 2014) 
 
 
 
HERA= Business information support provided by Hera group information system 
SUS = Secondary Uses Service comprehensive repository for healthcare data in England  
 
The 33 GP practices in ELR CCG at the time were grouped to form 12 practice hubs or 
“virtual wards” and each hub was allocated an MDT.  In line with this, following a pre-pilot 
with one pharmacist , two IC pharmacists were employed to support the  practice hubs.The 
two pharmacists were based with  the  team of 12  IC coordinators, in the IC team office. 
Table 1 below details the ELR IC hubs, associated practices and IC pharmacist allocation to 
the hubs. 
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Table 1.1: Integrated Care Pharmacists and Coordinators alignment 
 
 
The IC pharmacist role for this research was derived from the role of clinical pharmacist in 
general practice, with some modifications as described in section 1.2.5 below.  
The initial job description of the pharmacists evolved overtime as they settled into their role 
and could regularly re-assess the priorities. They worked closely with the IC Coordinators for 
their patient population and both were mutually accessible to each other and eventually 
developed a close working relationship and became part of the same team.  As part of this, 
they routinely discussed each patient ahead of the multidisciplinary review, the IC 
coordinator also provided useful informal background information regarding the MDT 
colleagues ahead of meetings, which helped the pharmacist to plan better.  
 
Access to the patients and other MDT professionals for the IC Pharmacist was facilitated by 
the IC Coordinator. As a result, the IC Pharmacists could fulfil their role functions (e.g. 
medication query resolution) with minimum delay.  
Appendix one outlines the agreed workflow/pathway for the IC pharmacist role which was 
developed in consultation with the MDT, at the start of the pilot. The pathway included the 
following key steps: 
 IC patients requiring IC pharmacist input were identified by any of the MDT members 
using either the risk stratification tool or clinical judgement  
 Patients were referred to IC pharmacist via email  
Vitual Ward (VW)/ 
Practice Hub  
Number of 
GP 
practices in 
hub 
ELR CCG 
Locality 
IC Pharmacist weekly hours 
for hub/virtual ward 
IC Coordinator for Hub 
Hub/VW  1 3 Blaby &  
Lutterworth 
 
IC Pharmacist  1 for 6 hrs  IC Coordinator  1 
Hub/VW  2 3 IC Pharmacist 1 for 6 hrs IC Coordinator   2 
Hub/VW  3 2 IC Pharmacist 1 for 5 hrs IC Coordinator   3 
Hub/VW 4 2 IC Pharmacist 1 for  5 hrs IC Coordinator   4 
Hub/VW 5 3 Melton 
Rutland & 
Harborough   
  
IC Pharmacist  2  for 7 hrs IC Coordinator  5 
Hub/VW 6 3 IC Pharmacist  2  for 7 hrs IC Coordinator   6 
Hub/VW 7 2 IC Pharmacist  2  for 5 hrs IC Coordinator   7 
Hub/VW  8 2 IC Pharmacist  2  for 5 hrs IC Coordinator   8 
Hub/VW  9 2 IC Pharmacist  2  for 4.5 hrs IC Coordinator   9 
Hu/VW   10 3 Oaby & 
Wigston  
 
IC Pharmacist  2  for 3 hrs IC Coordinator   10 
Hub/VW  11 3 IC Pharmacist  2  for 3 hrs IC Coordinator   11 
Hub/VW  12 3 IC Pharmacist  2  for 3 hrs IC Coordinator   12 
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 IC patient medical records were reviewed by pharmacist and relevant social care 
information provided by the IC coordinator  
 Appointments were made for the medicines review as convenient for the patient. One 
out of three options were chosen: domiciliary visit; telephone discussion or 
appointment at the GP surgery.   
 Clinical medication review was conducted by the IC pharmacist  
 Recommendations following the review were actioned in liaison with the appropriate 
care professional and followed up   
 In addition, the IC Pharmacist ensured that the IC coordinator, alongside the other 
multidisciplinary colleagues were regularly updated with the relevant medicines related 
information relating to their patients. The pharmacist also provided medicines-related training 
in areas that were mutually agreed to be beneficial. These included inhaler counselling, 
medicines administration and medication risk management. 
 
As a core member of the integrated MDT, the IC pharmacists had regular and direct access 
to all the other MDT professionals.  However, they liaised most frequently with the GPs, 
practice nurses and IC coordinators because their roles have varying degrees of prescribing, 
dispensing, or administration of medicines, outside the regular meetings. For some of the 
wards, a few weeks after the IC Pharmacist commenced, the Pharmacist and IC Coordinator 
decided to set up a regular informal sub- group meeting to review the post medicines review 
recommendations completed by the pharmacist. The pharmacist’s medication review record 
and action plan or pharmaceutical care plan (Appendix 2) was used to discuss these 
patients at the meeting. The care plan was invaluable and accelerated the progression of the 
overall patient care plans, as illustrated in the fictitious case studies below. 
 
Therefore, unlike the clinical pharmacist in GP practice role, the job purpose and functions of 
the IC pharmacist role were purely focused on the cohort of patients identified as part of the 
IC pilot pathway, whereby they provided holistic pharmaceutical care for IC patients. The IC 
pharmacists lead the co-design, implementation and monitoring of the therapeutic plan, 
ensuring that the desired outcomes were followed through and documented. The integration 
and co-location with the IC Coordinator of the program enabled the pharmacists to achieve 
this. 
 
The actions the IC pharmacists took to deliver pharmaceutical care included medication 
reconciliation, education and training as well as clinical medication reviews which 
incorporated adverse drug reaction reviews, therapeutic drug monitoring and drug 
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information provision. Furthermore, they designed, completed and explained medication 
support tools such as medication record charts and handouts for patients and MDT 
colleagues like the IC Coordinators and Community Nurse (Appendix 3). 
 
In conclusion, the IC Pharmacist role was flexible and adapted as required in line with the 
needs of the population and all stakeholders, in recognition of the fact that each general 
practice team/hub was different. This was planned in alignment to other core services to 
enable some consistency and to ensure regular evaluation and updates of the model when 
required. The constant review and change cycle was required for the participatory mixed 
methods methodology to enable the research questions to be answered. 
 
1.2 BACKGROUND TO THE RESEARCH 
This section elaborates on the existing knowledge of key themes related to the concepts that 
influence the role of the IC pharmacist, explaining how these interconnects to lead to the 
research questions. It commences with a fictitious illustration of integrated care provision 
titled a “tale of two patients”. This is followed by a review of other components that influence 
how the pharmacist should approach the care of patients within an integrated 
multidisciplinary environment.  These components are long term conditions (LTC), which are 
the main driver of cost and activity in the health and social care. Next is a discussion of 
pharmacotherapy, the most common intervention in LTC management (NHS, 2014; 
Goodwin et al. 2012). Then, pharmacotherapy failings such as polypharmacy, medication 
errors and wastage, adverse drug reactions, and non- adherence (Strand et al. 1990) are 
reviewed. The section ends with a review of how the IC pharmacist as the medicines expert 
should contribute to the management of pharmacotherapy failings. 
 
1.2.1 A tale of two patients “Paul and Gill-two different stories /experiences of care”  
“The absence of joined up or integrated care, is the greatest frustration experienced by  
Patients and their carers” (National Voices, 2013).  
Therefore, one of the greatest contributions towards improving patient safety and quality of 
life that health and social care services could make, is to successfully deliver integrated 
care. To illustrate this, Box 1 below details two contrasting stories of care provision for two 
fictitious LTC patients; Paul and Gill, who are husband and wife. Although both lived together 
and were registered with the same general practice surgery, the husband received 
integrated care, whilst the care provided to the wife was fragmented. 
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Figure 1.2:  A tale of two patients: Paul’s story 
Paul 
Paul is a 66 years old retired teacher who lives with his 59 years old wife Gill. They have lived in the 
same bungalow for 35 years. Their only daughter moved to Canada 10 years ago 
Paul suffers from both chronic lung and ischaemic heart diseases and both are managed by 10 long-
term medication. Gill notices that Paul has become forgetful and anxious and takes him to their GP. 
The GP writes off Paul’s symptoms saying they “come with old age” and prescribes diazepam. Gill 
however insists on getting an expert opinion and Paul is referred to a specialist. He is diagnosed with 
Alzheimer’s after two appointments at the hospital 40 miles away. He is prescribed additional 
medication for Alzheimer’s. 
 
Overtime, Gill, assumes the role of Paul’s carer. As part of this role she must: 
 take him regularly to his clinic appointments  
 manage and administer his medication  
 assist him with his daily routines  
 take over his chores e.g. managing the bills & shopping 
Because it is unsafe to leave Paul alone, she must also: 
 take him to all her appointments  
 stop her twice a week get together with her friends for coffee and swimming  
 
The health professionals they meet regularly for reviews and medication fail to notice that they are not 
coping. Two months later, Gill gives Paul double the dose of all his medication to “make up” for 
forgetting the previous day. These make Paul drowsy and he falls down the stairs, fractures his ankle 
and is admitted to hospital. His care is managed by the multidisciplinary team including doctors, 
nurses, social workers and physiotherapist. The hospital ward pharmacist is not a core member of the 
multidisciplinary team but reviews and reconciles Paul’s medication and makes some 
recommendations highlighting discrepancies in Paul’s records. One week later, they are informed that 
although Paul is physically fit for hospital discharge he would be discharged to a residential home. 
They are also told that based on the assessment Paul is not deemed eligible for public funding and 
would have to self-fund his social care cost of £1900 per week.  
 
Paul and Gill insist that he should be discharged home, instead of the residential home. The hospital 
social worker proposes an alternative option to discharge Paul home under the new pilot programme 
called “integrated care”. This means that although he could be discharged home, he would be 
“admitted to a virtual ward” implying that his care would be provided by a community multidisciplinary 
team. Core members of the team would be a general practitioner, nurse, pharmacist and the social 
community support, worker who will coordinate Paul’s integrated health and social care plan. Paul 
agrees and is discharged  
 
Following his discharge, in line with the integrated care process, the IC Coordinator liaises and 
streamlines all Paul’s reviews and treatment appointments. The Coordinator is also copied henceforth 
on all communication, organizes the regular care planning meetings and completes all agreed 
administrative actions to deliver Paul’s integrated care plan. One key task is to prioritise support 
actions to enable Paul stay at home for as long as possible. An urgent action to enable this is a 
domiciliary clinical medication review by the Integrated Care Pharmacist. The Pharmacist visits their 
home and completes a clinical (level 3) medication review; detailed in table 1 below. 
Four of Paul’s medicines are discontinued by the doctor in line with the pharmacist’s 
recommendation. The Pharmacist also rings Paul regularly thereafter, to communicate and explain 
changes and to check if he has any concerns or questions.   
 
In parallel to this, the coordinator 
 organises a reassessment for continuing care that shows that Paul is eligible for NHS continuing 
care because his primary care need is ‘health’. Consequently, his care can be funded 100%; 
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 manages his integrated care plan which is reviewed and updated monthly during the 
multidisciplinary team meeting;  
 completes home assessments and equipment to facilitate mobility e.g. getting in and out of the 
bath; 
 arranges access to any multidisciplinary team member as required; 
 provides a lap top and tutorial on how to use the webcam for calls to their daughter and 
grandchildren. Paul tells his daughter that when she calls how happy he is that he is independent 
again and feels supported and empowered.  The decision is taken that residential home 
admission is no longer required.  It is agreed that his integrated care would be maintained for at 
least one more year. 
 
An illustration of Paul’s web of care is detailed below in Figure 1  
 
 
Paul’s web of care  
 
 
Illustration by Naafi Okunaye 
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Figure 1.3:  A tale of two patients: Gill’s story 
Gill 
Gill is a 59 years old retired secretary who lives with her 66 years old husband Paul. They have lived 
in the same bungalow for 35 years. Their only daughter moved to Canada 10 years ago 
 
Gill suffers from rheumatoid arthritis and type 2 diabetes which are managed by four regularly 
prescribed long-term medicines. Gill is independent and becomes her husband’s carer after he is 
diagnosed with dementia and starts getting forgetful. As his carer, she must take him everywhere.  
After she realizes that it is unsafe to leave him alone, she also 
 stops going out for twice weekly get together with her friends; 
 organises for their groceries to be delivered;  
 only leaves the house for clinic or hospital appointments. 
The health professionals they meet regularly for reviews and medication do not ask and fail to notice 
that they are not coping. Six weeks later, Gill gets depressed and anxious is prescribed two more 
medicines for these. They make her drowsy and forgetful. She continues as Paul’s carer. 
 
Two months later, Gill decides to give Paul double the dose of all his medication to “make up” for 
forgetting the previous day. These make him drowsy and he falls down the stairs, fractures his ankle 
and is admitted to hospital. Gill feels guilty and upset about her mistake and this makes her even 
more depressed. 
Ten days later after some negotiation, Paul can be discharged home under a new pilot programme 
called “integrated care”. 
Paul improves steadily under the programme.  
 
Gill asks if she could also be enrolled into the programme but she is told that she does yet meet the 
criteria. She is assigned a carer to support her with some basic tasks. However, unlike Paul, Gill  
 receives her monthly prescriptions packed and delivered in a dossette box;  
 organises and attends her review appointments with the GP, diabetic nurse, practice nurse 
hospital specialist, dietician and optometrist. 
A few weeks later, Gill receives a letter from the GP surgery informing her that her medication for 
gastritis (caused by the painkiller for arthritis) has been changed to what she understands to be a 
cheaper one. Gill does not like the taste of the new one and therefore stops taking it. Her gastritis and 
diabetes gets worse. She is started on insulin. She struggles to understand all the advice she is given 
and how to use her insulin and take her medication. 
Four months later, Gill still has 
 insufficient understanding of most of her medication because the nurse only discussed diet and 
insulin monitoring during her appointment;  
 to repeat herself when she attends every clinic appointment with the different specialist which she 
still must organise; 
 to try to remember to communicate changes that the hospital make to her care to the GP staff 
because it often does not get communicated;  
 only minimum understanding of what her blood tests and targets mean;  
 no copy of a diabetic care plan;  
 to pay for her social care.  
Gill also 
 forgets to take her evening medication regularly and is unsure how to use most of her medication; 
 is deteriorating; her diabetes, gastritis, depression and arthritis are getting worse and she is now 
also obese.    
The GP asks the new practice pharmacist if she could visit and review Gill’s medication. The 
pharmacist visits and completes a comprehensive clinical medication review. All actions are detailed 
in table 1.2 below.  
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After the six-month period, Paul and Gill are surprised at how different their care has been. 
With regards to pharmaceutical care provision, Paul’s pharmacist worked as part of an 
Urgent action was required to provide Gill with medication counselling. However, the pharmacist 
encounters the following barriers:  
 Access to the GP and diabetic nurse is difficult. 
 She leaves messages and their responses are both slow and conflicting. 
 The pharmacist finds out that a diabetic consultant letter with a medication change and another 
from the chiropodist had been misplaced. 
 Gill’s care professionals are not part of a bespoke multidisciplinary team. There are also no 
regular meetings or a coordinator and therefore the pharmacist must chase everyone individually 
to progress actions. 
 
Gill is also offered appointments that have clashed and ended up spending long hours on the phone 
trying to reschedule.  
Six months later, whilst still awaiting resolution of the issues the practice pharmacist raised, Gill is 
admitted to hospital with hypoglycaemia. In hospital, tests also showed a gastric bleed.  The decision 
is taken that she should be discharged to a nursing home, until she can cope better.  
 
 An illustration of Gill’s web of care is detailed 
 
Gill’s web of care  
 
 
Illustration by Naafi Okunaye 
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integrated MDT and had better access to the team members. This enabled timely resolution 
of actions required to optimise his medical treatment ensuring that that his care was 
streamlined, effective and recurrent. Overall, they felt that Paul’s care was integrated, 
coordinated and individualised as illustrated in his web of care in Figure 1.2 above. 
Consequently, his outcomes were achieved and he felt empowered, independent and 
satisfied, at the end of the six-month period.  
On the other hand, Gill’s, pharmaceutical care was provided by a pharmacist who was not 
part of any multidisciplinary team and thus struggled to gain access and results from a 
similar but disconnected cohort of health and social care professionals. This was because 
the processes were uncoordinated and fragmented as illustrated in her web of care in Figure 
1.3 above. Gill’s care was neither integrated, coordinated nor individualised. Accordingly, her 
condition deteriorated by the end of the six-month period. The table below summarizes the 
pharmaceutical care for Paul and Gill. 
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Table 1.2: Summary of Pharmaceutical Care provided to Paul and Gill by their pharmacists  
 
 Pharmaceutical Care provided to Paul  Pharmaceutical Care provided to Gill  
Initial 
Actions  
The IC Pharmacist reviewed all medicines and 
identified drug related problems. 
Urgent problems identified. Paul  
 was taking the same medication twice as 
prescribed under both brand and generic name  
 was still on an antiplatelet called clopidogrel 
which should have been discontinued two 
years prior.  
 was unsure how to obtain continuous supply of 
his Alzheimer drug supplied initially by the 
hospital 
 was still taking three drugs intended for short 
term hospital use only  
 had bags of hoarded unused medication 
indicating non-adherence  
The IC Pharmacist commenced resolution of the 
drug related problems and prevention of future 
drug related problems by   
 Completing a medication record chart for Paul 
to use. Chart detailed why, when & how to take 
his 12 medication 
 Counselling him on medication use e.g. 
inhalers  
 Assessing him for suitability of packing and 
using a dossette box and showing him how to 
pack it  
 Suggesting strategies to improve adherence 
eg taking medication after brushing teeth 
 Explaining how all medication work, common 
ADRs and coping strategies effects  
 Giving him a “green bag” to put all his up-to-
date medication in to ensure they are all in one 
place to be taken for GP or hospital visits 
 Explaining how to obtain Alzheimer medication  
 Collecting and discarding old stock of 
medication  
 Drafting a pharmaceutical care plan with 
recommendations and outcomes 
Recommendations included  
 Discontinuing clopidogrel which would reduce 
gastritis  
 Discontinuing gastritis treatment when 
improved  
 Discontinuing painkillers, laxative and 
antiemetic  
 Considering discontinuing diazepam  
 Presenting draft plan and 
recommendations to GP and implementing 
The practice pharmacist reviewed all medicines 
including hoarded old stock and identified drug 
related problems 
Urgent problems included the fact that Gill 
 had no understanding of her blood tests 
and targets  
 had no copy of a diabetic care plan  
 did not understand how to take 
medication including insulin  
 Was non – adherent with her medicines  
 Was generally getting worse 
 had not stopped tablet nor increased 
insulin as recommended by specialist  
The practice pharmacist commenced resolution 
of all drug related problems and prevention of 
future drug related problems by   
 Completing a medicine record chart for 
her use. Chart detailed why, when & how 
to take all the medication  
 Counselling her on how to use her 
medication especially her insulin  
 Discussing the problems with her newer 
gastritis medication and explaining it was 
just as effective and proposing a capsule 
form to mask the taste.  
 Liaising to organise diabetic nurse 
appointment for joint completion of her 
diabetic care plan  
 Suggesting adherence strategies  
 Explaining how all medication work, 
common ADRs and coping strategies  
 giving her a “green bag” to put all her up-
to-date medication in to ensure they are 
all in one place to be taken for GP or 
hospital visits 
 Drafting recommendations for the GP 
and the diabetic nurse  
Recommendations included  
 Actioning request on consultant’s letter  
 Ensuring she attended diabetic patient 
education session  
 Changing her gastritis medication to the 
capsule format  
 Reviewing her antidepressant and anxiolytic 
medication  
 Urgent meeting to jointly agree and complete 
care plan  
 Implementing outcomes of 
recommendations made  
Follow 
up 
actions 
The integrated care pharmacist 
 Communicated changes to Paul and 
community pharmacist 
 Answered questions regarding changes  
 Ensured ongoing supply 
 
The practice pharmacist 
 Updated Gill re the delays  
 Explained & answered questions regarding 
changes  
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1.2.2 HEALTH AND SOCIAL INTEGRATED CARE  
The contrasting fictitious stories above exemplify how the experiences, pharmaceutical care 
and pharmacotherapy outcomes for LTC patients can be optimized by an IC pharmacist 
working as part of an MDT. 
 
What is integrated care? 
Integrated care has become an international catchphrase and has several synonyms 
including proactive, coordinated, continuous, collaborative, shared, transmural, intermediate 
or seamless care. It is basically an umbrella designation which comprises of a range of 
programs with different scopes and values aiming to tackle fragmentation (Stein and Reider, 
2009).  
 
The World Health Organization (WHO) in its position paper defines integrated care as: 
 “A concept bringing together inputs, delivery, management and organization of 
services related to diagnosis, treatment, care, rehabilitation and health promotion. 
Integration is a means to improve services in relation to access, quality, user 
satisfaction and efficiency.” 
 (Gröne et al. 2001)   
 
This early definition by WHO from over 15 years ago, shows the complexity of the concept. It 
highlights that it involves both processes as well as outcomes. One decade later, the 
concept had been put into practice in the form of several pilots across the UK. One of the 
main conclusions from one of the evaluation reports of the UK pilots (Rand et al. 2012) and 
WHO was that integrated care represents “a locally adaptable assortment of integrating 
activities” instead of one fixed model (WHO, 2016; RAND et al. 2012). 
 
To further underscore how complicated the concept is, a review of the literature on 
integrated care revealed over 175 other definitions and a huge variation of models 
(Armitage, 2009; Lloyd and Wait, 2005). Moreover, integrated care has different 
categorizations and typologies and these are organizational, functional, service and clinical 
(WHO, 2016; Lewis et al.2011). In addition, in the health care setting, two different 
dimensions of integration have been defined. The first is horizontal integration which refers 
to integration across community services like GP practices and community nursing and 
social care services. Vertical integration is the second and is integration between primary 
and secondary care settings (RAND et al. 2012).  
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With this many levels and groupings for integrated care, it is evident that the term would 
have different meanings to different people, dependent on what stakeholder type they are as 
described in the WH0 (2016) report. Administrators in governmental organizations as the 
first stakeholder type, generally base their definitions on processes, coherency of funding, 
administration and inter-sectoral collaboration. The second stakeholder types which are care 
professionals generally focus their definition around the aligning of the functions of health or 
social systems. This includes the coordination of MDTs, building in evaluation and feedback 
and ensuring that change management is effective. The third and arguably the most 
important stakeholder group is patients and the public with more personalized definitions. 
“My care is planned with people who work TOGETHER to understand me and my 
carer(s), put ME in control, coordinate and deliver services to achieve MY best 
outcomes”  
(National Voices, 2013) 
 
This definition highlights the importance of integrated processes, specifically recommending 
the inclusion of MDT work. It also stipulates coordination of care, highlighting that integrated 
care is the opposite of fragmented care. It concludes by specifying that the outcome should 
be optimized. This patient -user led definition has been adopted by the English government. 
Choosing a patient definition correlates with the numerous publications recommending 
patient and carer involvement in integrated care schemes. This ensures that their needs and 
expectations are met (WHO, 2016; RAND et al. 2002; Kodner and Spreeuwenberg, 2002). 
Consequently, this user led definition was chosen as the definition of focus for this research.  
 
In conclusion therefore, integrated care is best understood as a team of health and social 
care professionals working proactivley and collaboratively to deliver coordinated, and 
personalized care that is patient centered around and designed to meet the needs and 
preferences of both the patients and their carers (NHS England, 2013). 
 
What is the history and implications of health and social disintegration in the United 
Kingdom? 
 "Too often the complex needs of many vulnerable people have taken second place to a 
system plagued by boundaries, barriers and turf wars." 
(Alan Milburn, UK health minister, 1998)  
 
The boundaries referred to above by the UK health minister at the time, are those that exist 
between the health and social care systems, which are legally distinct. He highlighted this 
because disintegration between health and social care was prevalent at the time. Currently, 
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although there is a drive and progression towards improvement, disintegration and 
fragmentation remain the rule, rather than the exception (DH et al. 2017).  
These boundaries widened progressively since the creation of the National Health Service 
(NHS) in 1948, which separated health and social care provision and are often denoted “the 
Berlin wall “of health and social (Clements, 2010). Since the creation of the NHS, three key 
themes resulting from constant ongoing changes within the health and social systems, have 
had an influence on partnership between health and social care.  
 
The first theme is the creation of a quasi- market which resulted from the introduction of GP 
fundholding and the splitting of the NHS into providers and commissioners in1990 (Silcock et 
al. 2004). GP fundholding was superseded by primary care groups (PCGs) which were later 
replaced by primary care trusts (PCTs) which then evolved into clinical commissioning 
groups (CCGs), who are currently the lead NHS commissioners. General practices have 
emerged from these changes as provider businesses, contracted by their local CCGs. The 
implication of this development for this research is that after GP provider contracts started 
including prescribing incentives, the role of the primary care pharmacist(PCP) was 
conceived (Silcock,2004). The initial role functions of the PCP were completion of clinical 
and administrative jobs for GP practices or primary care organizations.  Over time the focus 
has evolved in line with NHS priorities, to more patient centered work roles (Bradley, 2018).  
An example is the clinical pharmacist in GP practice role. The integrated care pharmacist is 
another derivative of the PCP role and is illustrated in figure 1.4 below. 
 
The first implication of this development is that GPs have become both employers as well as 
colleagues of other care professionals like nurses, social care workers and pharmacists. 
This is eradicating most of the historic issues caused by their secondment to general 
practice, including insufficient managerial and professional support, a different accountability 
system, different employment terms and different approaches and philosophies. However, 
on the flipside, hierarchical structures and power struggles have increased alongside this 
employer-employee relationship between GPs and fellow care professionals. This is 
deterring collaboration and team working (Schadewaldt et al. 2013). The second implication 
is that the increasing co-location of these care professionals is enabling mutual access and 
visibility and facilitating MDT and patient centered working (Freeman, 2016; Jorgenson et al. 
2014)  
 
The second theme is the shift from market competition in the NHS, which was introduced by 
GP fundholding, to collaboration, which was facilitated by the amalgamation of health and 
social budgets, authorized by the Health act of 1999.  Further changes over the years 
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facilitated even more collaboration and culminated in the creation of the Health and Well-
being boards in 2012. Following this, CCGs and local authorities were obliged to launch 
health and social integrated care programs. Consequently, informed by the published 
evaluation of the national IC pilots (Rand et al. 2012), the integrated care pioneer program was 
commenced in 2013 England. It involves twenty-five funded IC pioneer sites tasked with 
investigating innovative methods to improve integration between health and social care over five 
years (Mays, 2016). Most CCGs including ELR CCG, commenced their integrated care pilot 
around the same period. The CCG pilots are further enabled by the Better Care Fund (BCF) 
which was the first mandatory pooled budget across health and social and has become 
instrumental in expediting collaboration and integration (Humphries, 2015) 
 
The third theme is that over the years, the NHS overstretched itself from predominantly 
focusing on the treatment of sickness in a manageable number of people, to prioritizing 
prevention of sickness, in an undefined number of frail people (DH, 2012; Clements, 2010). 
This was aggravated by the fact that it has become fundamentally more difficult to 
distinguish the “sick” from the “frail or “disabled”. Overtime, it thus became increasingly 
apparent that the original design of the NHS had become neither suitable nor sustainable for 
the population. Furthermore, other associated factors such as the rising cost pressures 
resulting from people living longer with complicated needs and whilst suffering from several 
illnesses, as well as innovative and expensive treatment, exacerbated the situation. 
Consequently, over time the NHS has had to gradually redefine its role to be able to cope 
with these. A basic change is that NHS funding for social care requirements has become 
restricted to the sick in hospital whilst funding for the frail and disabled has been transferred 
either to social services or the patients themselves. (DH, 2012).  
 
A major implication of this shift from treatment of sick patients, to prevention of sickness for 
this study is that the roles of community social carers is expanding significantly, as they 
inherit the traditional duties of district nurses, for patients not eligible for NHS health funding. 
Amongst these inherited duties are certain aspects of medicines management. As a result, 
pharmacist and social carers are having to work closer together to deliver the therapeutic 
goals of their patients. The nature of the joint working is evolving with the role changes for 
both the social carers and pharmacists. Hence, one of the main role functions of the IC 
pharmacist job was to provide both proactive and reactive medication related training and 
support to the IC coordinators who were social support workers by profession. 
 
Consequently, it was recognized that these unprecedented pressures and challenges 
indirectly resulting from the social and health care divide, had led to the “tipping point” (DH, 
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2017). Therefore, breaking down the health and social care barrier was included as a key 
objective in the NHS five-year view which outlines the NHS plans (NHS England, 2014, DH, 
2014). 
 
How should integrated health and social care be delivered?  
“Any integrated model development is strongly contextually-bound, nearly impossible to 
replicate and can only be successful if it does account for unique needs and characteristics 
of the population it aims to serve”  
(WHO, 2016).  
This recommendation from the World Health Organization is based on research that shows 
that there is no ideal IC model that should be replicated and one size cannot fit all. 
Therefore, the model for each IC program should be locally determined and co-designed 
with key stakeholders. Furthermore, because there are too many different existing models to 
choose from, commissioners are recommended to build their models on ‘discovery and not 
design’ (DH et al. 2017). Consequently, the ideal starting point is to use published 
recommendations from the literature to inform local pilots. 
 
The most up-to-date comprehensive publication is the final report of the early evaluation of 
the Integrated Care and Support Pioneers Program (Erens et al. 2016).  The ongoing 
evaluation is aimed at assessing how successful all 25 pioneer IC sites are in the provision 
of coordinated care, improved patient experience and outcomes in a cost-effective way. The 
evaluation comprises several strands. The first strand is a survey to obtain the perceptions 
of participants regarding barriers and facilitators which affect achievement of the desired 
outcomes. Barriers highlighted included financial constraints (58%); incompatibility of 
information technology systems for patient information sharing (46%); contradictory national 
government policies (40%); insufficient funding for innovative services (39%); staff shortages 
(33%). Facilitators mentioned comprised having a robust local leadership (76%); building 
good work liaisons between important local partners (60%); involving patients (55%); and 
having a bottom-up approach to ensure changes are driven by local staff (52%) (Policy 
Innovation Research Unit, 2016). These barriers are mostly features of formal organizational 
structures and systems requiring national solutions whilst the facilitators relate to leadership, 
vision, trust and shared values which are under local control. Furthermore, although all 
pioneers reported that progress in achieving the 15 outcomes had been made, most of it 
was non-substantial. Most of the interim achievements were focused on the setting up and 
implementation process instead of the outcomes like care quality improvement or 
admissions reduction. The evaluation will proceed for three more years.  
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Pending the final outcome of the evaluation of the pioneers, some essential guiding 
principles to optimize integration have been identified from existing literature. These include 
ensuring schemes are patient centered and informed (Wait, 2015) commissioner driven, 
flexible, monitored and coordinated by integrated multidisciplinary teams (Curry and Ham, 
2010). Like most of the UK models, the ELR model includes most of the elements of these 
guiding principles. This was described and illustrated in section 1.1.1 above. 
 
In conclusion, irrespective of the model used, care provision to LTC patients by MDTs are 
essential for intergrated care to succeed. Consequently, the next section focuses on 
integrated health and social MDTs, in relation to this study. 
 
1.2.3 INTEGRATED MULTIDISCIPLINARY TEAMS 
Multidisciplinary working: 
 “ involves appropriately utilising , skills and best practices from multiple disciplines and 
across service boundaries to redefine, rescope and reframe health and social care delivery 
issues, reach solutions based on an improved collective understanding of complex patient 
needs” 
( NHS England, 2014). 
To support the different health and social organizations to set up MDTs, guidance was 
published by NHS England in 2014. The guidance details four multidisciplinary care models 
ranging from model one which is uni-disciplinary with separate record keeping and 
communication to model 4 which is transdisciplinary with no barriers. The MDT model within 
which the IC pharmacist for this pilot was situated is Model 3. Model 3 involves a core team 
of members from different organizations working closely together to provide care.  
Integrated MDTs have been shown to be effective in providing support for LTC patients as 
well as their carers( Erens et al. 2016; Rand et al. 2012). The support they provide include 
learning opportunities, information sharing as well as improved communication, collaboration 
and facilitation to ensure patient understanding of the care process (Christie et al. 2015). 
These lead to continuity and coordination of care which is  required to achieve a positive 
patient expereince as well as other outcomes like reduced hospital admissions (WHO,2010 ; 
Thornhill et al. 2008). 
 
However, the literature highlights several obstacles preventing the development of effective 
MDTs. These include regulatory, funding and jurisdical issues which is preventing capable 
and dedicated care professionals from working cohesively together( Thornhill et al. 2008). 
Reasons range from “turf” wars ( Clements,2010) to fear of  liabilty and malpractice issues. 
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However a metaanalysis of studies  suggest that individual MDTs could  enhance teamwork 
despite these barriers by developing a shared vision and goals, formalised processes, IT 
systems and fostering a sense of  belonging (Mulvale et al. 2016). 
 
Specifically in relation to pharmacotherapy, multi-professional involvement is recommended 
as important to increase the effectiveness of  clinical medication reviews ( Blenkinsopp et al. 
2012). The literature highlight that if the pharmacist is based in a practice and has access to 
other health professionals as part of joined up services ( as is the case with MDT working), 
communication will be enhanced, making it easier to implement any medication changes 
resulting from medication reviews (Desborough and Twigg, 2013; Blenkinsopp et al. 2012). 
Clinical medication reviews are the most common role function of the IC pharmacist job in 
managing pharmacotherapy in LTCs. Furthermore, the first of the six steps in a recently 
published EU project on polypharmacy management is a  recommendaton to ensure 
multidisciplinary clincial and policy leadeship in health care systems.(Scottish Government 
Polypharmacy model of care Group, 2018). Consequently, the next section progresses to 
review first LTCs, followed by pharmacotherapy including clinical medication reviews and 
polypharmacy. 
 
 
1.2.4 Long term conditions and pharmacotherapy   
 
Long term conditions  
 
A long-term or chronic condition is an illness that is currently impossible to cure but which 
can however be controlled by either medication or other treatments (DH, 2010). Examples 
include diabetes, chronic obstructive pulmonary disease and dementia.  
LTCs are amongst the biggest challenges faced by the NHS. One of the main reasons is the 
fact that although more people are living longer due to advances in healthcare, their 
lifestyles are not necessarily healthy (DH, 2012).  
 
Research shows that 14% of people under 40 years and 58% of people over 60 years have 
at least one LTC. Additionally, it is estimated that in the UK, there are over 26 million people 
living with a minimum of one LTC and about 10 million living with two or more (Sanderson 
and White, 2018).  It is also approximated that 25% of over 60 year olds have two or more 
long term conditions. These over 60 years old account for 50% of appointments in GP 
practices, 64% of all appointments in outpatient appointments and more than 70% of 
hospital bed days. In addition, it is worth noting that 70% of the health care budget is spent 
on supporting LTC. (NHS, 2014). These figures show that patients with LTCs are the main 
drivers of cost and activity in the NHS and social care (Goodwin et al. 2011). Therefore, 
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addressing long term conditions and its consequences has become paramount (DH et al. 
2017) and “meeting their needs” is described as the core business of the National Health 
Service (NHS, 2014; RPS, 2013). 
A further consequence is that pharmacotherapy is rising alongside the aging population as 
evident by the rise in the cost of medicines of 28.4 percent from £13.0 billion in 2010/11 to 
£18.2 billion, in 2017/18 (NHS digital, 2018). 
Pharmacotherapy 
Pharmacotherapy is defined as “a complex system integrated by interdependent joint 
processes, carried out by different actors, whose objective is to prevent, control and solve a 
patient’s health problem” (Strand et al.1990).  This highlights that therapy with medication 
instead of being simply a theoretical independent sequence of events, is in fact a 
complicated series of processes involving multidisciplinary stakeholders or “players”. 
However, pharmacotherapy can also lead to failures manifested by drug related problems 
(Salazar-Ospina et al. 2012; Strand et al.1990). Two main types of pharmacotherapy failures 
are defined. The first is non-achievement of therapeutic goals due to an ineffective 
therapeutic strategy whilst the second is unexpected drug related harm. These failures are 
multifaceted including non- adherence, adverse drug reactions (ADRs), medication errors, 
medication wastage and polypharmacy and are discussed next. 
 
Non-adherence  
Research shows that most patients are non-adherent with their medication especially when 
newly started (Barber et al. 2004). Two systematic reviews estimated that 20-60% of 
patients are non- adherent to their medication and LTC patients are the most implicated. 
(Kripalani et al. 2007; Garfield et al. 1999). Adherence to pharmacotherapy is also estimated 
by the World Health Organization to be 50% among patients with LTCs (WHO, 2003a).  
 
Adverse Drug reactions (ADRs) 
Hallas et al (1990) divided ADRs into three categories: ADRs which are “definitely 
avoidable”; ADRs which are “possibly avoidable” and ADRs which are “unavoidable”.  A 
meta-analysis of prospective studies from the 1990s estimated that ADRs are responsible 
for 5% of hospital admissions and fatal ADRs are the sixth leading cause of death after heart 
attacks and other causes (Lazarou et al.1998).  However, Pirmohamed et al (2004) later 
criticized this study highlighting that the calculated death rate resulted from extrapolated 
admission rates from 1994, although the ADRs data was from studies prior to 1981.  
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They then conducted a much larger prospective study in two large general hospitals in the 
UK, involving 18,820 patients aged over 16 years over a six-month period (Pirmohamed et 
al. 2004). Their study showed ADRs to be associated with 6.5% of emergency re-
admissions, 72% of which were deemed avoidable (for example through clinical medication 
reviews by pharmacist), with 2% leading to death.  
 They emphasized in their conclusion that  
 “We concentrated on ADRs causing hospital admissions and did not evaluate the burden 
caused by ADR occurring while patients are in hospital, or ADRs in primary care that did not 
result in hospital admission, which may at least double the figures presented here”.  
(Pirmohamed et al.2004) 
Their statement regarding doubling the 6.5% ADR related readmission figures is very 
relevant for this study because it is the basis for a fundamental assumption detailed in the 
data analysis section (3.2.2), that 10% of medication errors/discrepancies resolved by the IC 
pharmacist, resulted in one avoided admission.  
However, the limitations of the study include the fact that the decision to assign an 
admission as ADR related was subjective and therefore each patient was assessed twice. 
Moreover, it is not possible to be completely certain that a particular drug caused an ADR. 
Additionally, of significance is the fact that a more recent publication attribute 11% of 
unplanned admissions to medication harm (Scottish Government Polypharmacy model of 
care Group, 2018) 
 
Medication errors 
In a recent report, WHO highlights that there are over 26 definitions for medication errors 
(WHO, 2016).  A comprehensive definition is that by The United States National 
Coordinating Council for Medication Error Reporting and Prevention which defines 
medication errors as:  
“…any preventable event that may cause or lead to inappropriate medication use or 
patient harm while the medication is in the control of the health care professional, 
patient, or consumer. Such events may be related to professional practice, health 
care products, procedures, and systems, including prescribing, order communication, 
product labelling, packaging, and nomenclature, compounding, dispensing, 
distribution, administration, education, monitoring, and use.”  
(National Coordinating Council for Medication Error Reporting and Prevention, 2015)   
 
A review of all reported medication incidents between 1 January 2005 and 31 December in 
the UK, concluded that they represented 9.68% of all patient safety incidents (Cousins et al. 
2012). This study also showed that thirteen therapeutic groups accounted for 46% of the 
 33 
incidents, if outcomes of death or severe harm are excluded. More recently, Parand et al 
(2016) conducted a narrative systematic literature review spanning 1946 to 2013 which 
included 33 studies in which carers had main responsibility for preventing/causing 
medication administration error (MAE) in patient homes. The study showed that domiciliary 
carer MAE are between 1.9 to 33% of medications administered by 12 to 92.7% of carers. 
The MAEs included dosage errors, wrong medication or time, omitted administration, and 
incorrect administration route. Factors that contributed ranged from age of carer or patient, 
storage issues, understanding of instructions to communication medication factors. Training 
and equipment were shown as possible interventions to reduce MAEs. The authors 
recommended further studies to explore these and other ways of reducing MAEs.  
 
Medicines Waste 
The national evaluation of the scale, causes and costs of waste medicines highlighted that 
medicines waste is around £300 million per year in primary care in the UK and half of this is 
avoidable.  (York Health Economics Consortium, University of York, and the School of 
Pharmacy, University of London 2010). The root causes of medicines waste include patients’ 
conditions improving before medicines used, change of therapy, death, supply processes 
like repeat dispensing and failure in support of vulnerable patients.  
 
Polypharmacy 
Polypharmacy refers to the use of multiple medication by an individual and is prevalent in 
LTC patients. Masnoon et al (2017) conducted a meta-analysis reviewing 110 articles that 
define polypharmacy and found a total of 138 such definitions. These highlights why there is 
no universally agreed definition for it. However, the most common definition is when a 
patient takes five or more concomitant regularly taken medications (Ong et al. 2017). 
Polypharmacy is very common and increasing because of the aging population and 
associated multi-morbidity. Between 2002 and 2012, the average number of prescribed 
items per head increased from 12.4 to 18.7(NHS Digital, 2013). As shown by a UK study, the 
prevalence continues to rise progressively: 12 % of patients were dispensed at least 5 drugs 
in 1995, escalating to 22% in 2010; whilst 1.9 % of patients were dispensed at least 10 drugs 
in 1995, rising to 5.8 % in 2010 (Duerden et al. 2013). Generally, polypharmacy increases 
the incidence of adverse drug effects which could spiral and lead to even more 
polypharmacy if medication is prescribed to treat the adverse effect. Furthermore, it 
enhances the probability of medication error, intentional and unintentional non – adherence, 
medicines waste and cost. 
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The surge in pharmacotherapy mentioned above, is also associated with a rise in these 
described pharmacotherapy failures. In the next section the role of the pharmacist working 
to resolve these drug related problems in primary care, collaboratively as part of a health 
and social integrated MDT is discussed. 
 
1.2.5 The Integrated Care Pharmacist role in management of long term conditions  
There is growing evidence demonstrating that because pharmacists possess expert drug 
knowledge, skills and experience, they are best placed to lead on strategies to reduce the 
pharmacotherapy failures described above, which would improve the quality of 
pharmacotherapy (Avery et al. 2012; Barber et al. 2009). These strategies are underpinned 
by the concept of clinical pharmacy which was introduced in the late 1960s and the 
associated philosophy of pharmaceutical care which was established in the 1990s. (Ahmed 
et al. 2010). In addition, medicines management and medicines optimisation are two related 
concepts that are often confused with clinical pharmacy and pharmaceutical care (Tweedie 
and Jones, 2001).  
 
Clinical pharmacy has several definitions including that of the American College of Clinical 
Pharmacy (ACCP): 
 “A health science specialty that embodies the application, by pharmacists, of the 
scientific principles of pharmacology, toxicology, pharmacokinetics and therapeutics 
to the care of patients.” 
(American College of Clinical Pharmacy, 2008)   
 
Hepler (2004) describes how clinical pharmacy should be viewed as complementary rather 
than incompatible to pharmaceutical care, by explaining how the former is a form of 
pharmacy practice to achieve the patient centered outcomes of the later. This highlights the 
patient centered focus of pharmaceutical care which is defined as: 
 
 “The responsible provision of drug therapy for the purpose of achieving definite 
outcomes that improve a patient’s quality of life”  
(Hepler and Strand, 1990)  
 
Through the provision of pharmaceutical care aimed at reducing the pharmaceutical failures 
detailed above, the IC Pharmacist should be able to contribute to the management of LTCs. 
Pharmaceutical care involves: 
1. A review of all medicines and identification of drug related problems and desired 
outcomes  
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2. Completion of actions to resolve all drug related problems and prevent future drug 
related problems  
3. Completion of follow up actions 
4. Monitoring of the outcome achievement  
 
Pharmaceutical care to reduce these pharmacotherapy failures of non-adherence, ADRs, 
medication errors, polypharmacy and waste is supported by some key processes. These 
include clinical medication reviews including deprescribing, medicines reconciliation, patient 
counselling, and increased communication, education of stakeholders, process optimization 
and risk management. Pharmaceutical care contributes towards achieving the goals of 
medicines optimisation which are to ensure that “the right patient, get the right choice of 
medicine, at the right time” (RPS, 2013).  
 
Medicines Optimisation is defined as “a patient-focused approach to getting the best from 
investment in and use of medicines ….and requires a holistic approach, an enhanced level 
of patient centered professionalism, and partnership between clinical professionals and a 
patient”  
(RPS, 2013) 
 
Medicines optimisation is a more patient centered term compared with medicine 
management which, as explained by Barber (2001), views both the patients and the drugs 
as “objects” to be managed with the fundamental aim of supporting the achievement of the 
predominantly economic goals of medicines management. Furthermore, medicines 
optimisation involves professionals across the health and social care system and patients 
collaborating (RPS, 2013), which is in line with the integrated care concept.  
To facilitate description, the actions of the IC pharmacist to provide pharmaceutical care, 
aimed at achieving medicines optimisation, are grouped below into patient directed, 
multidisciplinary team directed and practice /system directed actions (Sharma, 2016; 
Freeman et al. 2016; Sharma, 2015).  
 
Patient directed actions of the IC pharmacist  
The most common patient –directed actions are clinical medication reviews and medicines 
reconciliation which are completed as part of pharmaceutical care. 
 
A medication review is an umbrella term describing an organized and analytical examination 
of a patient’s medication, with the aim of jointly agreeing with them, the best way of 
optimising their medication, whilst simultaneously reducing the failures of pharmacotherapy 
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(Shaw et al. 2002).  Three types of medicines reviews are described: prescription review; 
compliance and concordance review and clinical medication review. (Blenkinsopp, 2012). 
The clinical medication review type which is the relevant type for this study, is also referred 
to as a level 3 medication review and involves a face to face with the patient. It is also more 
comprehensive than a level 0 review which is usually adhoc and unstructured or level 1 
(paper based without medical records) or level 2 which uses the medical records in the 
absence of the patient. (Task Force on Medicines Partnership and NCMMSP, 2008). 
 
The benefits of monitoring the benefits and risks of treatment with several medications in 
primary care by periodically reviewing treatment was initially highlighted in the 1990s 
(Zermansky, 1996).  
A few years later, other studies (Holland et al, 2007) and those in the literature review by 
Zermansky and Silcock (2009) highlighted that although no robust evidence of admissions 
avoidance had been demonstrated by medication reviews, no reports had showed patient 
harm from the intervention. Furthermore, it was consistently suggested that falls and hospital 
admissions could have been reduced, leading to drug cost savings as a minimum.  As a 
result, they made the conclusion that clinical medication review could be both valuable and 
cost effective. They finalized by recommending a robust, multicentre, clinical trial with clearly 
described and carefully chosen interventions and outcome measures. 
Similarly, Blenkinsopp (2012), following an evaluation of published systematic and structured 
reviews highlighted that although clinical medication review leads to an improvement in the 
process outcomes of prescribing such as polypharmacy, appropriate medicine formulation 
and medication choice, no robust health economic studies demonstrating achievement of 
stronger outcomes such as reduced mortality or hospitalization were found. However, a 
small study demonstrating   reduced hospitalization for some patient categories was 
mentioned (Roughead et al .2009 cited in Blenkinsopp, 2012).  The conclusion was drawn 
that the evidence suggests that clinical medication reviews could lead to an improvement of 
knowledge and adherence in patients. Consequently, currently, it is generally accepted that 
clinical medication reviews are valuable especially when there is multi-professional 
involvement. 
 
In practice, the IC pharmacist completed pharmaceutical care plans (Appendix 3) as part of 
the clinical medication review process. The care plans were used to document and follow up 
on actions aimed at achieving defined patient goals. A pharmaceutical care plan was 
completed for the fictitious patient Paul and is detailed in table 1 above.  
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A medication review is also usually part of medicines reconciliation which is a method of 
producing the most correct and comprehensive list of medications that the patient is taking. 
The list should include the name, dosage, frequency, and route of the drugs. The list is then 
compared to the admission or discharge prescription, with the aim of ensuring that the 
correct medication is provided to the patient throughout (The Institute of Healthcare 
Improvement, 2011). Transdisciplinary collaboration between a pharmacist and a doctor as 
part of medicines reconciliation has been shown to make discharge prescriptions safer and 
more comprehensive (Holland, 2015). Medication reconciliation has been shown to prevent 
harm and medication errors by both primary and secondary care prescribers (CQC, 2009). A 
more recent study also showed that medicines reconciliation led to reduced hospital 
admissions (Mekonnen et al, 2016). Consequently, medicines reconciliation is a key task of 
the IC pharmacist role considering IC patients are moderate to high risk and likely to move 
across care settings. 
 
Regular clinical medication reviews aimed at de-prescribing are recommended for patients at 
risk of polypharmacy (Scottish Government Polypharmacy model of Care Group, 2018; 
Duerden et al. 2013). Polypharmacy as highlighted above, increases the incidence of 
adverse drug effects which could spiral and lead to even more polypharmacy if medication is 
prescribed to treat the adverse effect (Ong et al. 2017). Furthermore, polypharmacy also 
enhances the probability of medication error, intentional and unintentional non – adherence, 
medicines waste and cost. De-prescribing refers to measures to reduce polypharmacy and 
has been shown to improve outcomes (Duerden et al. 2013). Therefore, discontinuing 
prescribed medication, where the risk outweighs the benefits is recommended.  
Deprescribing reviews should be focused on the elderly, psychiatric patients, patients taking 
five or more drugs at a time, patients with more than one doctor or pharmacy, patients 
recently discharged, those with comorbidities, low educational level and impaired dexterity or 
vision those with multiple doctors and chemists, recently hospitalized patients, individuals 
with concurrent comorbidities, low educational level, and those with impaired vision or 
dexterity. Burge et al (2012) advice to consider a palliative approach where required and to 
stop medication which is no longer appropriate. The IC pharmacist used guidance such as 
STOPP/START (O’Mahony et al. 2015), BEERS criteria (BEERS, 1997) or the seven steps 
(Scottish Government Polypharmacy model of Care Group, 2018), to guide deprescribing 
reviews. Other recommended approaches to reduce polypharmacy include training experts 
to manage co-morbidity and geriatric patients, as well as researching processes to focus 
pharmaceutical care provision on empowering patients to make informed choices.  
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Multidisciplinary team directed actions of the IC pharmacist  
The most common relevant actions include MDT meeting input and output, drug information 
provision, training, communication and query answering (Freeman et al. 2016). These 
actions support the fourth principle of medicines optimisation which recommends that 
professionals should make medicines optimisation a part of routine practice and take every 
opportunity to intervene to ensure patient empowerment with their medication (RPS, 2014). 
Furthermore, the National Institute of Clinical Excellence (2015c) recommends that all social 
and health care professionals should check any information regarding medication therapy 
that is recorded as well as follow up any problems regarding medicines management for 
their patients. These professionals also include social care workers who administer 
medication for patients in the community considering that domiciliary medication 
administration error rates by carers, are a cause for concern (Parand et al. 2016). 
Recommendations to reduce risks and patient harm from carer MAE include carer training, 
home medication checks, increased communication between carers and healthcare 
professionals and deprescribing. The pharmacist also liaised with other non-core MDT 
professionals e.g. community pharmacists as part of pharmaceutical care provision.  
 
Practice/practice system directed actions of the IC pharmacist  
The IC pharmacist role for this research was predominantly patient –centered because the 
role was not located in the GP practice. Therefore, tasks primarily related to the practice and 
practice system such as drug cost optimisation through auditing and medication switches 
from brand to more cost-effective generics, managing repeat prescriptions to reduce waste 
and developing formularies were not part of the job description. However, these were 
completed opportunistically during pharmaceutical care provision. 
 
1.2.6 The history of the IC pharmacist role development  
Pharmacy roles are diversified and have evolved significantly over the past 15 years. The 
three main roles are community, hospital and primary care pharmacy. The two which are 
relevant are discussed next. 
 
Community Pharmacists 
Community pharmacists made up approximately 72% of the pharmacy workforce in 2013 
(Phelps et al.2015). Historically, the main task of the community pharmacist was to dispense 
and supplying medicines. Currently, although these remain the main noticeable aspect of 
their role, community pharmacists also advise patients on wellbeing, the treatment of 
illnesses, sale of ‘over the counter’ remedies as well as the use of prescribed medicines 
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(RPS, 2013). This is line in with a current shift from the traditional product oriented focus to a 
patient-centered focus.  
 
However, the provision of these patient centered services remains challenging because of 
geographical and digital isolation of community pharmacists which results in limited access 
to patient medical records and other care professionals (Blenkinsopp et al. 2012). The 
restricted access to the MDT is partly because community pharmacists are generally not 
considered as a core part of the primary care team. (Hughes and McCann, 2003). Such 
views may pose barriers to building relationships with clinical colleagues, particularly GPs, 
who commonly perceive pharmacists as “shop-keepers” (Hughes and McCann, 2003). 
Nevertheless, in recognition of how crucial it is to realize the full potential of the community 
pharmacy, several schemes have been introduced over the years. 
 
Primary Care Pharmacist 1: Medicines management/prescribing advisory pharmacist  
As described in section 1.2.2 above, in the early 1990s, with the advent of fundholding and 
GPs later become providers, there was an increased realization that prescribing advice and 
medicines management by pharmacists, could enable achievement of prescribing incentive 
payments. This was accompanied by national efforts to increase the cost effectiveness of 
primary care prescribing. Efforts involved setting annual prescribing budgets for all NHS GP 
practices and the appointment of local pharmaceutical advisors.  These pharmaceutical 
advisors used detailed comparative prescribing statistics of individual GP practices and 
demographic profiles of the communities served, to drive improvement in prescribing in 
primary care. The role later developed to include the developing of prescribing guidelines 
and formularies across both primary and secondary care. 
 
However, because of limited capacity, prescribing advisers were unable to review 
prescribing in the individual GP practices for whom they had overall budgetary responsibility. 
Consequently, a new role - the GP practice-based pharmacist came into existence to bridge 
the gap. Currently, the pharmaceutical advisor role has evolved to that of a pharmaceutical 
specialist in public health with lead responsibility for establishing the pharmaceutical needs 
of their assigned population and ensuring it is delivered. This is achieved predominantly by 
commissioning appropriate services such as the IC pharmacist role for this research. 
 
Primary care pharmacist 2: (Clinical) general practice pharmacist role  
The practice pharmacist has been defined as 
 40 
 ‘A pharmacist who delivers professional services from or within a general practice 
medical center with a coordinated, collaborative and integrated approach with an 
overall goal to improve the quality use of medicines of the practice population’  
(Freeman et al 2014). 
 
As mentioned above, this role evolved from the pharmaceutical advisor role. 
Overtime however, informed by research showing that clinical pharmacy outcomes from 
hospitals could be realised in primary care, there has been a gradual transformation of the 
role priorities. The research includes for example the PINCER study which showed that a 
pharmacist led review could significantly reduce the risk of prescribing and monitoring errors 
for certain key drug classes (Avery AJ et al. 2012). These data, coupled with the national 
shortage of GPs and the increasing recognition of the pharmacist skillset, is shifting the 
focus of the practice pharmacist role to one which is more patient –centered and clinical. 
Although this role development is new in the UK, international studies show outcomes of 
improvement in medication, patient health and economy of this evolving clinical pharmacist 
in GP role (Tan et al. 2013; Dennis et al. 2009; Dolovich et al. 2008; Zermansky et al. 2001). 
However, although this new role is based in the GP practice, the scope does not fully enable 
holistic patient –centered care. 
 
Primary care pharmacist 3: Integrated care pharmacist role. 
The third primary care pharmacist role which is that of the Integrated Care Pharmacist and 
focus of this research. It has evolved from the clinical pharmacist in GP role described 
above. The three main differences are that, 
 the pharmacist is a core member of the integrated health and social MDT 
 the role functions are exclusively patient- centred; 
 care is proactively provided to select group of medium to high risk patients.  
 
Figure 1.4 below summarizes how the IC pharmacist role has developed from historic 
primary care pharmacists (PCP) roles over time.  
 
There are three fundamental reasons for this change in role function: multidisciplinary 
collaboration is required for pharmacotherapy to be fully effective as mentioned above; 
patients are living longer and requiring more health, including medication and social care 
services and consequently the need for medication is rising.  
Statistics show that almost every individual who is 65 years old and above requiring social 
carer support with their daily living activities is taking at least one prescribed medicine (DH, 
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2012). Increasingly social carers are routinely tasked with the administration and delivery of 
medication to support these patients as mentioned above. IC pharmacists provided training 
and support to the carers which has been shown to be beneficial for the patient (NICE, 
2015a) 
 
 
Figure 1.4: Development of the integrated care pharmacist role overtime 
 
 
 
1.3 RESEARCH QUESTIONS  
Two UK models of IC pharmacists in multidisciplinary team involving social care are 
described in the literature. One describes part of the pharmacist role as providing 
“professional advice and support to other health and social care professionals on the safe 
prescribing, handling and administration of medicines”as well as “facilitating collaborative 
working between multidisciplinary teams/agencies” (NICE, 2015a). 
However, although the pharmacist roles described are integrated, they do not appear to be a 
core part of a multidisciplinary team, delivering patient-centered and proactive care (NICE, 
2015a; NICE 2015b) 
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Furthermore, the pharmacist role description and evaluation is not included on evaluation 
reports of national pilots of integrated care (Daloni, 2016; NHS, 2016;  Rand et al 2012).  
Therefore, although different variants of an IC pharmacist roles are developing in retrospect, 
they are in their infancy and are neither adequately researched nor defined. Further 
knowledge is required to inform the development of the IC pharmacist role which is fully 
embedded as part of a health and social MDT. The literature highlight the need to inform the 
development of the clinical pharmacist integrated in general practice, as well as to evaluate 
its benefits and sustainability (Bond & Hopf 2014; Freeman et al. 2012; Ackerman et al. 
2010).  
 
Further research into the IC pharmacist role will help define it as well as inform the 
development of practical tools such as job descriptions, person specification templates and 
training and mentorship for the role which have all been highlighted as key role facilitators by 
existing literature (Freeman, 2016; Farrell et al. 2010). Furthermore, the knowledge from 
research will inform strategic planning and sustainability of the role. 
 
The research is also important for the following reasons: 
1. It presents the views and ensure the participation and “voice” of the patients who 
are the key “actors”, in the development of this new health and social integrated 
pharmacist roles.  
2. In line with the participatory action research design, the stakeholder participants 
will inform regular reviews and proposals to the commissioners which will support 
the wider transformation of primary care pharmacy services.  
 
To enable achievement of these aims , five research questions were  developed and are 
outlined below. 
 
Question 1: What is the role of the pharmacist in integrated care? 
Question 2: What is the stakeholder’s perception of the outcomes that the integrated care  
   pharmacist attempts to achieve?  
      Question 3: How can such outcomes be measured? 
Question 4: How does the current integrated care pharmacist perform against these  
     outcomes? 
Question 5: How can the role of the integrated care pharmacist be sustained?  
 43 
 
 
Chapter 2 
 
 
Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
CHAPTER 2:   METHODOLOGY 
 
Overview of chapter 2 
 
This chapter outlines the different methodologies and considerations used for this study. The 
chapter starts with a description of the literature review strategy. This is followed by a brief 
description of how the fictitious patient cases were developed. Next, the research philosophy 
and research design considerations are outlined. A pragmatic approach regarding adopting an 
over-arching research philosophy was taken. From an epistemological standpoint, I adopted a 
phenomenological approach because I felt it was important to gain an understanding of the 
‘lived experience’ of the stakeholders – that is the pharmacists and non-pharmacists in 
relation to working as (or with) the integrated care (IC) pharmacist.  Therefore, both 
pragmatism and phenomenology underpinned the research strategy which is a variant of 
participatory action research (PAR). This is because PAR naturally embraces the involvement 
of stakeholders in the design and execution of the research. This variant of PAR is called 
participatory mixed methods research (PMMR). In line with PMMR, a mixture of qualitative 
and quantitative methods was used. The rationale, features and quality considerations of 
these methods are reviewed. The chapter concludes with an acknowledgment of my 
reflexivity, as the main researcher. 
 
2.1 METHODOLOGY FOR LITERATURE REVIEW STRATEGY AND CASE DEVELOPMENT 
The Literature review strategy  
A literature review informed the background and development of the aims, questions and the 
methodology for this research. Following early recognition that the topic involved several 
overlapping concepts, it became apparent that a literature review strategy was required. The 
literature review enabled the existing knowledge and key themes relating to the role and 
concept of integrated care to be identified. It also facilitated the identification of other factors 
linked to the concept of integrated care, the role of the pharmacist role within this and how 
these themes are interconnected.  
 
The literature review highlighted that reducing the key issues and cost of long-term 
conditions is a national priority and requires integrated health and social care provision for 
patients. It also showed that most patients with long-term conditions are on several 
medications, which in turn may create other problems. Therefore, pharmacists as medicines 
experts, working as part of an integrated health and social multidisciplinary team can 
significantly contribute to reduce the failures whilst maximizing the benefits of 
pharmacotherapy. This should, in turn, improve the overall outcome of patients with long-
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term conditions. However, there is a knowledge gap of how the pharmacist should work to 
achieve this. 
 
There is a wealth of published literature on integrated care, integrated health and social 
care, long-term conditions, the roles of the pharmacists and multidisciplinary working. 
Therefore, to review all the relevant literature and provide a comprehensive background a 
strategy was required. The timescale that I adopted for the searches ranged from 
between1940 and 2017 so that a complete view of the history of health provision and the 
evolution of the role of the pharmacist could be obtained. 
The search terms used were 
 Integrated health and social care  
 Multidisciplinary teams 
 Integrated pharmacist  
 Primary care pharmacist  
 Clinical pharmacist in GP practices  
 Long term conditions 
 Pharmacotherapy  
 Polypharmacy  
 Pharmaceutical care  
 Medicines use reviews 
 Medicines reconciliation  
 Medicines optimization  
 Quality of GP prescribing  
 
The specific databases searched were: Medline; Embase; Social science index and Pubmed  
Furthermore, the following websites were searched: Department of health; National institute 
of clinical excellence; Social Care institute of excellence and Royal Pharmaceutical society. 
 
The searches were also supplemented with other articles identified by the authors, including 
several articles recommended by experts in the field. In addition, specific journals relevant to 
each area were searched individually and include: British Medical Journal; Pharmaceutical 
Journal and the International Journal of Integrated Care.  
 
The abstracts of all the articles were assessed for relevance after which the list was narrowed 
significantly by discarding articles not directly relevant to the role of the IC pharmacist. The 
literature on the initial list enabled definition and clarification of my research questions as well 
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as identification of what ongoing research was relevant and necessary. This relevant literature 
was searched and reviewed throughout the writing of the introduction chapter. This enabled 
iterative redrafting of the literature review, culminating in the final list of references.  
 
Methodology for development of fictitious patient cases 
 Two fictitious patient cases were created to illustrate the concept of integrated care and the 
IC pharmacist role within the integrated MDT. The entirety of the patient details and medical 
history including the medication information were based on my detailed knowledge of a variety 
of previous patient cases as well as case studies from textbooks and guidelines identified 
during the literature review. The cases illustrate the differences between integrated and 
fragmented care and the different pharmacist roles. Integrated care is as a team of health and 
social care professionals working proactivley and collaboratively to deliver coordinated, and 
personalised care that is patient centred around and designed to meet the needs and 
preferences of both the patients and their carers. Fragmented care delivery on the other hand 
is neither coordinated nor personalised and usually without a defined team.  
 
2.2 THE RESEARCH PHILOSOPHY  
As the researcher, I subscribe to the recommendation by Guba and Lincoln (1994 p.105) 
and ensured that the most suitable underpinning philosophy was chosen to guide the choice 
of research strategy. Therefore, my philosophy is reflective of the underlying assumptions 
that I made regarding the basis for the research strategy. These assumptions are 
epistemological, ontological and axiological in nature (Guba & Lincoln, 1994). 
Epistemological assumptions are concerned with what I see as representing acceptable 
human knowledge in this study of the role of the integrated care pharmacist. Ontological 
assumptions are to do with the way in which I viewed the real events during the research 
process.  Axiological assumptions are about how my beliefs and core principles guided this 
research (Saunders et al., 2015a, chapter 4 pg. 121). Although a multitude of research 
philosophies are associated with these assumptions, the most relevant are positivism, 
interpretivism (encompasses phenomenology and interactionism) and pragmatism. 
(Saunders et al. 2015; Brown et al. 2003)  
 
Positivism is associated with collecting unbiased, measurable and objective facts. By contrast, 
interpretivism, which encompasses phenomenology and interactionism, is based on the 
interpretation of everyday social roles, in accordance with the meanings humans ascribe to 
these. Pragmatism is the middle ground and advocates working with multiple philosophies if 
required, to answer the research question.  
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Personally, in line with interpretivism, I believe that stakeholder experiences and ascribed 
meanings are invaluable in the generation of knowledge.  Moreover, for this research I 
needed to accept that the outcome would have an impact upon the integrated care team itself 
and therefore it was crucial that any changes in practice should be informed by the qualitative 
data derived from depth interviews of the stakeholders. However, as a pharmacist, I believe 
that some things are factual and measurable as advocated by positivism. Furthermore, to 
answer some of the research questions, I had to acknowledge that there needed to be a place 
for utilizing quantifiable and objective unbiased data. Therefore, my personal underpinning 
philosophy is pragmatism as it allows both interpretivist as well as positivist underpinnings 
((Saunders et al.2015; Tashakkori and Teddlie, 1998:26). Figure 2.2 below summarizes the 
relationship between the research philosophy, strategy and methods. 
 
Figure 2.1: Relationship between the adopted philosophy, research strategies and 
methods for integrated care pharmacist research 
 
 
 
 
2.2.1 Pragmatism 
Pragmatism as a research philosophy argues that research is aimed at providing answers 
and therefore has little value if it provides data but fails to produce results that answer the 
research questions (Crombie, 1996).  Pragmatism allows the use of both objective data and 
subjective knowledge (mixed methods) to obtain the necessary knowledge to answer the 
research question. This is because it holds the view that answering research questions is 
paramount and therefore more important than the underlying philosophy or method 
(Tashakkori and Teddlie, 2003). Furthermore, it recommends that hypothetical concepts like 
Research Philosophy 
Research Strategy 
Research Methods 
•Pragmatism
• Phenomenology 
•Participatory Mixed Methods 
research (PMMR) 
•Qualitative:
• interviews  x 9
• Focus group x1
•Quantitative :
• Analysis of documented key 
performance indicators (KPIs) data
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‘truth’ and ‘reality’ should be discarded alongside the constraints of choosing between 
positivism and phenomenology (Tashakkori and Teddlie, 2003).  This is especially important 
for research into the IC pharmacist role, which has the overarching goal of positive 
transformation.  
 
Therefore, to gaining an understanding of the role of the IC pharmacist which was the focus 
of this research, I made the decision to adopt a phenomenological approach. 
Phenomenology would enable a description of the ‘lived experience’ of the stakeholders who 
were also research participants. The next section offers a summary of the philosophical 
position that is known as phenomenology and explains why it is especially suitable as an 
underpinning research philosophy for this study.   
 
2.2.2 Phenomenology  
Phenomenology was introduced in 1900 by Husserl as a new philosophy that was in contact 
with “concrete living experience” as opposed to “abstract metaphysical speculation wrapped 
up in pseudo-problems” (Moran, 2000). It is focused on directly investigating phenomena, 
obtaining a better picture of it and then describing it, as was consciously experienced and 
constructed by people, without necessarily attempting to identify the causes. (Denscombe, 
2014; Van Manen, 1990).  
 
Phenomenology, as an overarching philosophy, is particularly helpful in the present study 
because it enables the researcher to consider what it is like to be an IC pharmacist or health 
care professional, working alongside such a pharmacist within a multidisciplinary team 
(MDT) setting. Thus, by adopting a phenomenological approach it is possible to develop 
concepts that may be helpful regarding informing future developments in health care 
practice.  
 
Husserl guides researchers in the sense that, while thinking phenomenologically, it is 
important to “Bracket” an awareness or thought so that any personal interpretations of data 
are neither contaminated by personal experiences, predilections or viewpoints, or by existing 
theories. (Denscombe, 2014).  
 
Whilst conducting this research, I was also working within my professional role as Head of 
Prescribing of East Leicestershire and Rutland clinical commissioning group (ELR CCG).  I 
therefore worked alongside IC Pharmacists as their manager, and indirectly with the IC 
coordinators and doctors. Furthermore, I was responsible for reviewing the administrative 
documents for the project including data that was later collated into reports, which I 
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subsequently presented to the ELR CCG board sub-groups, for approval. I therefore 
acknowledge that there was potential for bias as part of this research project and accept my 
role and professional background should not be “taken for granted”, “(Benner,1994). In view 
of this, I decided to adopt the approach of Heidegger which is that of hermeneutic 
phenomenology that also incorporates pragmatism. It contrasts with the original 
‘transcendental’ version of phenomenology that was originally described by Husserl. 
By taking this approach, I could accept that my own background knowledge could be 
considered within the overall picture, as described by Benner (1994).  
 
2.3 THE RESEARCH DESIGN: PARTICIPATORY MIXED METHODS RESEARCH  
Having adopted a phenomenological approach through which I could view and analyze 
research data, I now needed to devise a practical means by which the data could be 
collected.  The purpose of this section is therefore to outline the Participatory Mixed Methods 
Research (PMMR) that I used within a framework of action research. It is logical to assume 
that like action research, PMMR is also well suited in fluctuating research settings which 
involve the development of roles or services such as this research (Babar, 2015). 
Furthermore, PMMR allowed a flexibility of methods which in turn enabled a thorough 
understanding of the issues which occurred in the complicated settings and could have been 
overlooked by other approaches. Additionally, I felt that the participatory nature of PMMR 
facilitated the co-production of knowledge by the stakeholders including both the integrated 
MDT members and the sponsor.   
There is a plethora of definitions for action research. However, the following definition 
seemed the most applicable  
“A systematic inquiry that is collective, collaborative, self-reflective, critical and undertaken 
by the participants of the inquiry. The goals…. are understanding of practice...in order to 
improve practice” (McCutcheon and Jung, 1990 pg.148).  
Action research is different to conventional research because instead of being viewed as 
undesirable and discouraged, interventions are welcome as part of research.   
The underlying intervention for this research was the new role of the IC pharmacist, for the 
generation of new knowledge to inform simultaneous service transformation. New from the 
intervention was derived from both quantitative and qualitative data as part of the PMMR 
design, described above. Quantitative data was synthetized from the Key performance 
indicators (KPIs) collected by the IC pharmacists as part of their role, whilst qualitative data 
originated from interviews and a focus group with stakeholders, regarding the role. 
This IC pharmacist intervention was operationalized in four key phases which align with the 
Medical Research Council (MRC) guidance and framework for the development of complex 
interventions. The MRC framework was deemed suitable because this research is regarding 
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a new role in the medical setting, within a program of integrated care that is also relatively 
new. It is thus logical to conclude that it is a complex medical intervention. The four key 
phases of the MRC framework are outlined below (MRC, 2000) 
i. The feasibility phase: This involved writing and presenting a business case to the ELR 
CCG board, requesting funding for the IC Pharmacists. 
ii. The development phase: This was the pre-pilot phase and involved a pre-pilot IC 
pharmacist working with the IC Coordinators for six months and documenting data that 
enabled planning for the actual pilot. The data informed the job description, required 
hours, office base and the key performance indicators to record. During this time, the 
pharmacist was based both in the CCG office and the IC team office whilst the 
memorandum of understanding with the integrated care managers, regarding office 
space and work equipment and line management responsibilities was finalised. 
iii. The Implementation phase: This was the actual active period during which most of the 
pharmaceutical care was delivered by two IC pharmacists whose recruitment and 
induction were informed by the data from the above phases.   It involved an iterative 
cycle of the four main steps of the action research intervention, which was repeated 
three monthly over nine months i.e. three quarters. I decided that as acknowledged by 
Meyer et al (2000), the cyclical and recurrent partnership working would help bridge the 
gap between theory and practice in this health care setting. 
 Step 1 - Planning: involved developing the IC Pharmacist role focus for the next quarter  
 Step 2 - Action: involved the provision of pharmaceutical care and documenting of KPIs 
as required by the evaluation policy of the sponsor  
 Step 3- Research or observation: involved analysing the documented KPIs and 
participant feedback and summarising these with recommendations in the next quarterly 
pilot project report for the strategy and planning committee.  
 Step 4 - Reflection: the quarterly pilot report was reviewed and discussed by the CCG 
and used to inform the next quarter or phase of event. 
 
IV. The evaluation Phase: This was the period when the interviews and focus groups were 
conducted at the end of the pilot. 
These phases and steps are illustrated in Table 2.1 below 
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Illustration by Naafi Okunaye 
 
Figure 2.1 above exemplifies the PMMR process for the integrated care pharmacist 
research, showing the MRC phases and associated intervention cycles. These phases are 
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depicted as distinctive phases to aid understanding. However, it must be acknowledged that 
in practice, there was some fluidity and overlap of the phases.  
In addition to the intervention processes illustrated above for the IC pharmacist research, 
there are other important characteristics of PMMR. These are partnership and participation 
and the use of quality and mixed methods. 
 
Partnership and participation  
To successfully complete participatory research and produce the required knowledge to 
effect change, it is essential for the researcher and participants to develop a partnership 
(Babar, 2015). The partnership should be built on a trusting relationship that promotes 
participation. For this research, this was enabled by co-locating the integrated care 
pharmacist in the same office as the integrated care coordinators who also enabled access 
to the other participants. Other relevant aspects of partnership include the level of 
partnership, the researchers position within the research, organization and other factors and 
how relationships where established and maintained (Babar, 2015). Regarding positionality, 
six positions are described including middle position and reciprocal collaboration (Herr and 
Anderson, 2005). Also of relevance is the researcher’s hierarchical position within the 
organizations. As the researcher for this study, my positionality was reciprocal and my 
hierarchical position was the head of prescribing. This facilitated increased participation 
because of the natural integration of my job function and that of most of the other 
participants. The associated risk of reduced pharmacist participant freedom to withhold 
consent because I was their line manager was minimalized by delegating their recruitment to 
another manager. Furthermore, the participant information and consent sheet highlighted 
their right to withhold consent with no repercussions (appendices 4 and 6). I made sure they 
were reminded of this prior to every research related meeting. 
 
To create and maintain involvement and participation, care was taken to build relationships 
based on trust, give and take and respect, from the beginning. Tactics used included 
informal liaison with gatekeepers like the coordinators, ongoing communication with emails 
and meetings, researcher pro-activeness and flexibility as recommended in the literature 
(Smith, 2010). These had to be sustained as required because the agreed goals, resources 
and processes evolved over time and required renegotiation and management of participant 
expectations. The importance of these was also impressed upon the IC pharmacists who 
were the face of the medicines quality team of the CCG within the IC programme and could 
indirectly affect partnership relationships. 
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Table 2.1 above, also show that the desired outcomes of for the IC programme for the CCG 
as sponsor necessitated the use of mixed methods for this PMMR research. These mixed 
methods were utilized to execute the four MRC phases and comprehensively answer the 
research questions. In line with action research which is about ongoing transformation, some 
of the research questions were answered during the research (Olson and Jason, 2015). 
Therefore, the mixed method methodology, which was a fundamental part of the PMMR 
strategy, is described next. 
2.3.1 Mixed Methods as part of the Participatory Mixed Methods Research  
As mentioned above, mixed methods were used for this research because they are a key 
part of PMMR and aligned with the pragmatism (Tashakkori and Teddlie, 2003). It became 
apparent from the beginning that a mix of methods would allow the flexibility to choose the 
most suitable methods to answer the research questions which are predominantly practical 
in nature. The mixed methods used were qualitative and quantitative. Quantitative methods 
were required for the role evaluation in line with the ELR CCG policy as explained above. 
Qualitative data were also required to aid understanding of the change processes and 
enable answering of the “why” and “how” research questions. These answers necessitate 
participation of the stakeholders and their qualitative narratives regarding their views based 
on their lived experience, of why and how the integrated pharmacist helps to achieve the 
outcomes of integrated care. Thus, the qualitative data, derived in this manner was designed 
to complement the quantitative data required for the CCG evaluation (appendix 13).  
 
The main disadvantage of mixed methods is that unlike designs that use single methods, 
using several methods can be painstaking and demanding during execution of the different 
phases. Furthermore, deciding the sequencing of the methods can be complicated.  
Additionally, consideration should be given to the purpose for mixing the methods.  
 
Priority and sequence of mixing  
To facilitate the sequencing decision and add rigor to the mixed methods, several typologies 
and categories are described. (Babar, 2015; Driscoll et al. 2007). The two factors to be 
considered when choosing the typology is allocating priority and deciding the order of 
implementation. The first factor considers whether equal priority is allocated to either the 
quantitative or qualitative aspect or whether one is given a greater weighting. The second 
factor is the order of implementation which could either be simultaneous or sequential. 
(Creswell, 2003; Morgan, 1998; Tashakkori & Teddlie, 1998) 
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In simultaneous studies, the data collection and analysis is parallel followed by merging of 
data derived from both, leading to a comprehensive picture. On the other hand, in sequential 
studies, qualitative and quantitative data is collected in different phases and then linked in 
different ways. Morse (1991) suggested a system to represent the different designs using 
the abbreviations quan and qual to represent the quantitative and qualitative parts, 
respectively. As per the system, the method with the greater weight is denoted in capital 
letters (i.e. QUAN, QUAL) whilst the lower weight method is written in lower case (i.e. quan, 
qual). 
For this research, sequential typology (quan→QUAL) as described by Creswell et al. (2003) 
was used. Quantitative data which had a lower weighting because qualitative methods were 
required to answer most of the research questions, was collected throughout the 9 months of 
the pilot. The higher weighted qualitative data was predominantly collected during the 
interviews and focus groups after the end of the pilot. These different methods are discussed 
next and their alignment to the research questions illustrated in table 2.1 below. 
Table 2.2 Research Methods and research questions alignment  
 Research question  Main research method utilised 
Question 1: What is the role of the pharmacist in integrated 
care? 
Qualitative: 
Interviews & focus group  
Quantitative: documented Key 
performance indicators data 
Question 2 What is the stakeholder’s perception of the 
outcomes that the integrated care pharmacist 
attempts to achieve?  
Qualitative: 
Interviews & focus group 
Question 3 How can such outcomes be measured? 
 
Qualitative: 
Interviews & focus group 
Quantitative: documented Key 
performance indicators data 
Question 4 How does the current integrated care 
pharmacist perform against these outcomes? 
Qualitative: 
Interviews & focus group 
Quantitative: documented Key 
performance indicators data 
Question 5 How can the role of the integrated care 
pharmacist be sustained? 
Qualitative: 
Interviews & focus group 
Quantitative: documented Key 
performance indicators data 
 
Purpose of mixing methods  
For this research, I considered the three common reasons for mixing methods as described 
in the literature (Pope and May, 2006). The first reason is for complementarity which is about 
using mixed methods to unveil viewpoints that are different to enable a clearer picture. The 
second is for development and involves using one method to assist another. For example, 
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utilizing in-depth interviews to inform questionnaire design. The third reason is for 
triangulation whereby the findings from two or more different methods are compared to each 
other. The reason for using mixed method for this research was for complementarity (not 
triangulation) because the interviews added more insight into how the KPI data and other 
anecdotal qualitative participant feedback could inform future practice. 
 
2.3.2 Quality Considerations for PMMR strategy and methods  
There were certain quality considerations that needed to be considered for this PMMR 
research. These are divided into three main groupings because they vary, based on the 
method; 
 Quality considerations for participatory research  
 Quality considerations for qualitative methods  
 Quality considerations for quantitative methods  
 
Quality considerations for participatory research   
Quality considerations are important for action research to counter any claims that the 
methodology was unscientific. However, the usual quality criteria of validity used by 
positivists or trustworthiness recommended by interpretivist researchers or are not suitable 
(Herr and Anderson, 2015). This is because neither consider participant engagement or 
action. Also, generalizability and representativeness were not amongst the quality 
considerations because it is argued that action research is context specific. Therefore, the 
methods should be adapted to the local context to obtain similar results. Consequently, 
different aspects of validity are proposed and those considered relevant for this research are 
discussed. 
 
The first, is outcome validity which is the achievement of the goal which was accomplished 
for this research and discussed in chapter 5 below. Democratic validity is the second and 
was achieved because the results obtained are relevant and useful in the setting of primary 
care were the stakeholders are situated. The third criteria, process validity was also realised 
because the methodology was appropriate for the research questions. A final crucial quality 
consideration is transformatory action and involves ensuring that the research leads to 
transformation and change. There was significant transformation from this research as 
evident by the fact that the two initial posts were transformed and ultimately multiplied to the 
equivalent of twelve full time pharmacists and pharmacy technician posts.  
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Quality considerations for qualitative methods  
The relevant quality considerations for qualitative methods are validity, reliability as well as 
two alternatives of trustworthiness and reflexivity (Smith, 2010). These alternatives are 
proposed because it is argued that validity and reliability should be less important as there is 
usually no measurement in qualitative research and several accounts instead of one 
absolute truth (Lincoln and Guba, 1985). The debate is that these alternatives align better 
with interpretivism, which is the underpinning paradigm.  
 
Validity in qualitative interviews and focus groups, refer to the extent to which questions can 
prompt responses that would enable the researcher to answer the research question 
(Silverman, 2006). To ensure validity, the topic guide was developed and piloted and was 
used with flexibility to ensure comprehensive discussions. To further enhance validity 
confidentiality was ensured as detailed in the ethics section in chapter two, by making sure 
that participants in interviews and focus groups could openly discuss the questions with no 
apprehension of being overhead. To ensure reliability for the qualitative methods, care was 
taken to make sure that the wording and phrasing of questions were as consistent as 
possible. The researcher also clarified any ambiguous or unclear information.  Furthermore, 
all interviews were conducted by one researcher; in similar setting for each stakeholder 
group. It was not practical to ensure the exact same location because the participants 
worked or lived in different locations.  
 
Trustworthiness consists of four Credibility, Transferability, confirmability and dependability. 
Credibility was established by presenting the results to participants for confirmation during 
the focus group to ascertain that the investigator correctly understood their world. 
Transferability which assured by providing a thick description of the process is facilitated by 
the detailed description of all processes in chapters 2 and 3. Confirmability which can be 
achieved by limiting researcher bias, was enhanced by an acknowledgment and awareness 
of my bias as described in the reflexivity section. Dependability was ensured by preserving 
all the records. It was however impossible to organise peer editing which the gold standard, 
due to time constraints is.  
 
Quality considerations for quantitative methods  
The quality considerations that were deemed relevant for the quantitative arm of this 
research were validity, reliability, generalizability and comprehensibility of the key 
performance indicator data (Babar, 2015; Denscombe, 2014)  
The concept of validity for quantitative research refers to whether an indicator that is devised 
to gauge a concept really measures it. (Bryman, 2004). For this research, validity was 
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determined by the extent to which seven of KPIs documented by the IC pharmacist as part 
of their role, supported the answering of the relevant research questions. These seven KPIs 
were. 
1. KPI 1: Return of investment of minimum 2, following pharmaceutical care  
2. KPI 2: Reduction of polypharmacy.  
3. KPI 3: Completion of clinical medication review for all referred patients 
4. KPI 4: Completion of medicines reconciliation for all IC patients as required  
5. KPI 5: Provision of domiciliary clinical medication review as required.  
6. KPI 6: Provision of repeat prescriptions review for all IC patients.  
7. KPI 7: Provision of medication training sessions to IC Coordinators every two 
months. 
KPI 1 assumed that approximately 10% of hospital admissions result from ADRs, based on a 
speculation by Pirmohamed et al (2004) that the 6.5 % figure for admissions caused by 
ADRs in their study can be doubled. The rationale is because the research did not appraise 
the burden caused by ADRs in primary care that did not lead to admissions or those that 
happened whilst the patients were in hospital. For the remainder six  KPIs, the assumption 
was made that all the data was captured correctly by the IC pharmacists. It was 
acknowledged that these assumptions could potentiality reduce the validity and reliability of 
the data. 
 
Therefore, several steps were taken to ensure that the KPIs were valid enough to answer 
the research questions. To begin with, a proposal to use these seven KPIs was presented to 
the ELR CCG committee in charge of medicines management and quality. The committee 
membership included two CCG GP (one of whom was the prescribing lead GP and chair), 
the IC team manager, two senior CCG pharmacists, the quality lead nurse and myself as the 
CCG head of prescribing. Next the proposal was debated and the seven KPIs were agreed 
as valid and suitable. Thenceforth, the documented KPIs were monitored, reviewed and 
approved quarterly and at the end of the scheme, by the same committee (Appendix 10 
details the end of scheme report). Also, any resulting proposals for further transformation 
resulting from the KPIs was agreed with the committee and presented in a new business 
case to the CCG board for approval. Finally, the data was presented and debated with the 
focus group for comment and validation.  
 
It must be acknowledged however that although the CCG committees and focus group 
agreed that the seven KPIs were the most practical, two cautionary comments are 
highlighted. The focus group emphasized the fact that KPI one could be an underestimate as 
it missed some outcomes that are not quantifiable such as the “domino effect” of changing 
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one’s practice for all subsequent patients (Appendix 10: Focus Group line 256 -262). 
Furthermore, it was mentioned by the CCG committees that admissions avoidance was used 
by several other interventions which could lead to double counting.  
 
Reliability is the extent to which data collection tools produce data that is relatively consistent 
and replicable (Silverman, 2006). Reliability was ensured for this research by using a 
standard data collection template that had was ratified by CCG committee mentioned above. 
Reliability was further enhanced through the quarterly scrutiny and challenge of the 
documented KPI data by the same committees and validation of the collated data as 
reasonable by the focus group.  
However, it must be acknowledged that because the data was not primarily collected for 
research there is a possibility that the data was not quite comprehensive. Furthermore, there 
could be some bias because of the conflict of interest of the data collectors.  
These validity and reliability issues were mitigated by the regular presentation and defending 
of the data to the multidisciplinary CCG committee and the focus group.  
The data was also considered representative because several variables were documented. 
Additionally, it was considered generalizable because it was randomly collected across all 
the geographical areas, age groups and gender type of IC patients.  
2.4 REFLEXIVITY  
Considering the interpretative underpinnings and qualitative methods used for this research, 
to acknowledge possible bias, a discussion of my reflexibility as the reporter is important 
(Smith, 2010). My reflexivity describes the self-examination process I have completed to 
acknowledge how my point of view or “conceptual baggage “has influenced the entire 
research process (Kirby and McKenna, 1989). It is important because as argued by 
Steedman (1991) “'knowledge cannot be separated from the knower'. Furthermore, 
“Personal knowledge” is one of the four levels of knowing described in nursing and it 
concerns a confrontation and portrayal of one’s real and distinct personality (Brown et al., 
2003). 
Reflexivity is also paramount for this research because it is involved with contextual 
production and reproduction of meanings.  Therefore, as is argued, acknowledging and 
raising my awareness of this will mitigate on any personal influences through all the research 
stages and reduce any effect on the outcome. This could reduce the risk and extent to which 
the findings can be deemed to be an “artefact” of the methodology (Smith, 2010). 
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Therefore, as the main researcher I acknowledge my bias which resulted predominantly from 
my 15 years of experience as a pharmacist. Of even more specific significance is the bias 
resulting from my role as Head of Prescribing of the sponsor organization, at the time of this 
research. As part of this role, one of my agreed objectives was to ensure that all schemes 
would be cost effective and would add value. Although this was a potential conflict of 
interest, it also provided the extra motivation and patience required for the PMMR strategy. 
Furthermore, it afforded me with access to the key stakeholders that enabled the pilot to 
proceed.  Also, it is my view that having a good working relationship with most of the 
participants was an advantage in making them feel less inhibited. Nevertheless, I remained 
conscious of the risk of cohesion, throughout the process and therefore took actions to 
mitigate against it. The actions included explaining to all participants verbally and in the 
participant information leaflets that they had the right to withdraw with no ramifications 
(Appendices 4 and 6). In addition, verbal and signed consent was obtained from all 
participants before the interviews and focus group (Appendices 5 and 7). Moreover, ethics 
approval was obtained from both the NHS research and the DeMonfort university ethics 
committees (Appendix 9). Detailed ethical considerations for this research is detailed in 
section 3.3 below. 
 
In addition, to further mitigate against my bias and conflict of interest, I ensured that the KPI 
data was exclusively collected by the pharmacists and there was audit trail for the 
documented data. Also, the IC Pharmacists and Coordinators co-authored/contributed to the 
quarterly reports. Furthermore, to maintain focus during the interviews and focus groups, 
topic guides were used (Appendix 8). Moreover, the focus group provided an opportunity for 
transparency because the interview and quantitative data were presented and discussed at 
the focus group. 
 
A final personal influence on the research to be acknowledged is my experience and skill in 
the fabrication of case studies, which developed during my role as a co- author of a patient 
centered pharmacology text book. As part of this role, I developed over 14 patient centered 
cases aimed at enhancing understanding of pharmacology by making it patient centered.  
This experience inspired the writing of two fictional patient cases as part of the thesis write- 
up with the aim of illustrating the concept of integrated care. 
 
To conclude, all the assumptions which I made about human knowledge coupled with the 
real experiences during the research process and how the research was guided by my 
personal beliefs and principles inevitably shaped the research questions and methodology 
as well as the interpretation, discussion and the conclusions derived from the data. 
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CHAPTER 3: RESEARCH METHODS 
 
Overview 
Chapter two presents the underpinning considerations and steps to operationalize the 
methodologies, underpinning philosophy and strategy for the research, outlined in chapter 2. 
The general considerations of the methods are discussed first. This is followed by an outline 
of the methodological stages. To conclude the chapter, the ethical considerations are 
discussed.  
 
3.1 CONSIDERATIONS FOR USE OF RESEARCH METHODS  
3.1.1 Qualitative Methods  
The qualitative methods used were semi – structured interviews and a focus group. These 
were useful to answer four out of five research questions because these were deemed more 
suitable than other methods considered such as questionnaires for several reasons. The first 
reason is that a detailed understanding of the believes, feelings and meanings the 
participants ascribed to their experiences was required to understand and inform the role of 
the Integrated Care Pharmacist (Denscombe, 2014). Interviews and focus groups give 
participants a chance to provide their interpretation in their own words, describing and 
justifying the circumstances as they see it. Secondly, it gives them the flexibility to express, 
clarify, prompt and explore information which was needed to gain a comprehensive insight 
and increase validity. Thirdly, it was determined that the patient participants who were 
predominantly elderly and relatively infirmed, could struggle to read and understand the 
issues and questions if summarised as closed questions on a questionnaire. Finally, it was 
essential to choose methods that were cost effective, flexible and simple to run, considering 
that this was an academic research with a single researcher. Therefore, the decision was 
taken to use interviews and a focus group because these would facilitate open questions, 
affordable space and equipment and time. 
 
However, it must be acknowledged that interviews and focus groups also have some 
disadvantages. Firstly, they can be time-consuming to run and subsequently analyze. 
Secondly, reliability can be reduced because of the interviewer effect which could influence 
interviewee involvement. Denscombe (2014) highlights that interviewee participation has 
been shown to be influenced by the sex, age, race, appearance and accent of the 
interviewer. This could have had an effect for this research because as the researcher who 
also conducted the interviews, I am black African whilst most of participants were 
Caucasians. Thirdly, the differing contexts of each interview which was unique, made it 
difficult to guarantee full consistency and objectivity. Fourthly, the tape recorder could have 
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led to inhibition of the interviewee and it could have invaded people’s privacy if handled 
without tact. Finally, interviews could be costly when time and travel expenses are 
considered. 
These were mitigated as follows: I prepared by reading up on the pitfalls of interviews and 
focus groups, to refresh my knowledge and experience gained during the qualitative 
interviews I conducted for the thesis for my master’s degree. I also made sure that I spoke 
clearly, was tactful and avoided prompting and putting words in the respondent’s mouth. I 
used a small unobtrusive recorder positioned discretely. The sponsor refunded my cost of 
travel.  
 
Participant characteristics 
The main data sources were the transcribed qualitative interviews with nine participants and 
one focus groups with six out of the nine participants. All the participants were based in 
primary care; the staff participants were employed by one of four different organizations as 
detailed on table 3.1 below.  
Two out of the nine participants were patients who were registered with two of the 32 GP 
practices that made up the 12 “virtual wards” of the ELR CCG integrated care programme.  
One pharmacist worked full time whilst the other worked 3 days a week and this was taken 
into consideration with work load allocation. The rest of the staff participants worked full time. 
IC General Practitioner 1 (GP1) was more embedded and proactive in integrated care than 
IC General Practitioner 2(GP2). 
Table 3.1 below presents a participant profile for the interviews and focus groups. 
 
Table 3.1: Participant Profile for Interviews and focus group   
 
Type Gender  
Virtual 
Ward  
Employer /base  
Degree of 
integration  
Hours per GP 
Practice 
Session attended   
IC Pharmacist 1 Female  
one to 
three  
ELR CCG  
IC office 
Completely  4 Interview & focus group  
IC Pharmacist 2 Female  
four to 
eleven 
ELR CCG 
IC office 
Completely  4 Interview & focus group 
IC GP1  Male  eleven  
Gp practice  
 
Completely  
        37.5 
Interview & focus group 
IC GP2 Male  four 
Gp practice  
 
Partially  
37.5 
Interview only   
IC coordinator 1 Female  one   IC office Completely  12.5 Interview & focus group 
IC coordinator 2 Female  six IC office Completely  
12.5 
Interview & focus group 
IC coordinator 3 Female  eight   IC office Completely  
12.5 
Focus group only 
Patient 1 Male  one 
Hub 4 
 
n/a n/a Interview only 
Patient 2 Male  five 
Hub 1 
 
n/a n/a Interview only 
Community nurse 
(CN) 
Female  six LPT Completely                    
12.5 
Interview only  
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The actual methods are discussed next. 
 
Interviews  
Interviews were chosen as one of the methods for the reasons outlined above as well as a 
few additional reasons. The first additional reason is because the response rate is usually 
higher than questionnaires (Denscombe, 2014) and the second reason is that there were 
three types to choose from: structured, semi-structured and unstructured. In structured 
interviews, as the interviewer, I would have kept tight control of both the questions and 
answers and have pre-coded the possible answers. The advantage is that data analysis 
would have been facilitated but the disadvantage is that the richness of the data would have 
been compromised because the amount and quality of the data would have been limited.  
Moreover, structured interviews would have restricted the perception and experience of the 
participants making it inappropriate for phenomenology which is intended to get the 
interviewee to describe and explain their thinking and experience in a way that they are 
enabled to see things from their own perspective. Furthermore, some of the other benefits 
outlined above would have been diminished. Consequently, structured interviews were 
discarded as an option. 
 
Unstructured interviews would have been the other extreme and entailed the introduction of 
a topic from which the conversation would have been anticipated to grow. The data would 
thus have been deeper as I would have been less structured allowing more open and 
broader questions. However, there is a risk that I would have lost control and failed to obtain 
answers to fundamental questions if the participants did not discuss them. A further 
disadvantage is that the data analysis would have been extremely challenging and time 
consuming. Consequently, because the study was aimed at informing the role of the 
integrated care pharmacist, obtaining relevant answers was paramount. Therefore, 
unstructured interviews were decided as being unsuitable.  
 
Semi-structured interviews were considered a compromise because although I would retain 
a list of items to be discussed or questions to be answered, a degree of flexibility in the order 
of discussions addressed, would allow the development and addressing of issues 
(Denscombe, 2007). Open questions could be used to allow the participants to explore 
matters in depth. Furthermore, they would afford participants room to mention issues they 
find important and relevant. In addition, they would be   given the chance to provide their 
version in their own words whilst describing and justifying the situation as they see it. This 
would allow for the collection of more sophisticated data (Cormack, 1990).  
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Therefore, for the reasons outlined above, semi-structured, face to face, tape recorded 
interviews were decided as the method for the data collection. Tape recording was deemed 
useful to make it possible for me to ensure that i could check my understanding of what was 
said. This is crucial because care must be taken to ensure that what is heard, is what is said 
instead of a partial interpretation resulting from assumptions or deductions. The tape 
recording could also be used to check validity, ensure reliability (if repeated) and prove key 
elements of trustworthiness (Denscombe 2014).  
 
Focus Groups 
The focus group format is usually a hybrid between unstructured and semi-structured 
interviews and have other unique advantages and disadvantages.  Focus groups were 
designed originally for market research (Babar, 2015) but overtime, they have become more 
common in health service research. The added advantage includes the fact that focus 
groups are the preferred method for exploratory research such as this research, when 
interaction between participants would produce data and insights that would be less 
accessible without group interactions.  
 
The two main additional disadvantages of focus groups which were considered are that 
firstly some participants may withhold experiences, opinions or feelings that they think might 
be unpopular, sensitive or private. Secondly, a vocal minority might dominate discussions 
making them less representative.  
For this research, these issues were addressed using an adaptation of a structured 
technique as recommended in the literature (Smith, 2010) as well as a questioning strategy 
that encouraged and facilitated free discussions (Babar, 2015; Denscombe, 2014). In 
practice these were achieved by starting the focus group with a presentation of the themes 
from the interviews. A slide of the summary was left on the screen as a holding slide to 
generate discussions. Furthermore, as the researcher and facilitator, I prompted less vocal 
participants to express their opinions and discuss freely by using a combination of open and 
prompting questions alongside the study guide in appendix 8. A co –facilitator was also 
present and provided general assistance with note taking, place mapping, refreshments and 
the overall smooth running of the focus group.   
 
3.1.2 Quantitative Method: Utilization of documented quantitative data 
The quantitative arm comprised of analysis of key performance indicators (KPI)s) data, 
which was routinely documented by the Integrated Care Pharmacists for the sponsor 
evaluation. This analysis was required to support the answering of three of the research 
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questions. Secondary analysis of existing data is common for service evaluation and audits, 
to appraise certain domains of health care such as medicines use and patient outcomes 
(Babar, 2015; Denscombe, 2014). For example, records of changes in the use of medicine 
can be analysed in line with this method, to improve medicines use. Therefore, this method 
was chosen as the most practical quantitative method. 
 
However, because the data were not collected by myself it was crucial to ensure that any 
quality concerns were suitably mitigated. These concerns include the reliability, validity, 
comprehensiveness generalizability of the data which were considered and guaranteed as 
described in section 2.3.2 above.  
 
 
3.2 RESEARCH PHASES  
 
The research was conducted in four stages as follows: - 
 Stage 1: Qualitative One -to One Depth Interviews  
 Stage 2: Utilization of documented quantitative data 
 Stage 3: Focus group  
 
3.2.1 Stage 1: Qualitative one to one interviews  
 
Recruitment and Sampling 
Recruitment of participants is a very important in research. However, deciding on the most 
effective recruitment strategy is often very challenging (Babar, 2015; Archibald and Munce, 
2015). Identifying these challenges is crucial to inform mitigation. The most common 
challenges that are relevant for this study include obtaining consent, accessing participants, 
working with gatekeepers, participant expectation, interview venue and characteristics of 
recruiter. These are discussed next. 
 
Obtaining consent  
Recruitment could be hindered if participants have concerns about confidentiality and 
become hesitant to disclose their experiences (Archibald and Munce, 2015). This was a 
potential consideration for the MDT members who were participants in this study. This is  in 
case they felt uncomfortable to fully express themselves because the researcher was more 
senior in the organization. The implication for the study would be incomplete data. Therefore, 
the patient information made it clear that participant was entirely voluntary with no 
consequences for no or withdrawn consent. 
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Accessing participants  
Occasionally the initial recruitment strategy may need to be modified to boost enrollment. 
For this study, the initial decision to send recruitment information via post was modified to 
include emails and phone calls. This significantly increased the number of participants. 
Another consideration is that participants who are easiest to recruit are often the “expert 
“and proactive participants with an agenda instead of a typical and average participant.  
Furthermore, for this study because of challenges accessing some of the participants, the 
sampling strategy was changed from purposeful to convenient sampling. There is therefore a 
risk that this reduced generalizability and increased bias of the findings.  
 
Gatekeepers  
Gatekeepers are often crucial to recruitment in gaining access to participants. However, 
there are several issues associated with gatekeepers which could hinder the process. These 
include reduced commitment of gatekeepers if they have conflicting priorities and limited 
time, and how they are perceived by participants. 
The IC coordinators for this study were gatekeepers for patient and GP recruitment. 
Although they were busy and required reminders to recruit patients, because most of the 
patients valued them, they were willing to grant consent. However, the delay let to the loss of 
some patients who could have consented because their condition deteriorated during the 
delay. Also in recognition of the potential of the patient feeling coerced, the patient 
information leaflet detailed that consent was voluntary. 
 
 Participant expectations 
This could be a deterrent for participants who are expected to participate whilst at work or 
otherwise occupied. This challenge resulted in the loss of one nurse and one IC coordinator 
who cancelled twice due to last minute conflicting work priorities. 
 
Interview location 
This has been shown to be a consideration because participants are unlikely to accept to be 
enrolled for a location they would struggle to access. The researcher for this study was 
flexible and could organise locations that suited the participants’ interpersonal relationships 
are recognized as important to recruitment, although this is not highlighted in standard 
textbooks. Important aspects regarding this are familiarity, suitability of the recruiter, and 
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existing relationships with participants or liaisons and these can be either facilitators or 
barriers. These played a key role for this study. Other similar strategies such as following up 
consented participants regularly to agree a date and enhancing relationships and trusts 
which had already been built were also utilized. Furthermore, as the recruiter I was 
enthusiastic and worked hard to show my capability. I also demonstrated other important 
qualities like such as integrity, compassion and conscientiousness which have been 
identified as enablers (Archibald and Munce, 2015) 
 
Ensuring that the participants were suitable for the study (Coyne, 1997) was deemed very 
important. Sampling was initially purposive and aimed at recruiting at least eight 
representative members of the integrated health and social multidisciplinary team, (MDT) 
plus three patients (Sandelowski, 1995). However, for practical reasons resulting from 
organizational changes, the decision was taken to progress with a convenience sample of 
two IC Pharmacists, two IC Coordinators, two GPs, two patients and one community nurse. 
The participants were selected from two different geographical locations within the clinical 
commissioning group. The selected participants consisted of the best balance to ensure 
richness of data and a good understanding of the phenomena. 
 
Recruitment of patient participants 
The inclusion criteria were that the patient must have been risk stratified as medium or high 
risk and “admitted “into one of the virtual wards of the integrated care scheme. They also 
must have been provided with a pharmaceutical care service by the IC Pharmacist. The 
sampling and recruitment steps were as follows:  
1. A list of three times the required patient participants from the pool of all patients who 
met the inclusion criteria was completed by the team leader of the integrated care, to 
ensure representation of participants fitting the inclusion criteria.  
2. A participant Information leaflet (PIL) (appendix 6), consent form (appendix 7) and a 
stamped addressed envelope was sent to every patient on the list. The PIL explained 
that patients willing to participate should send the completed consent form to myself 
using the stamped addressed envelopes. 
3. After receipt of their consent forms, patients were telephoned by the researcher to 
agree a convenient interview time and venue. This was done on a first come, first 
served basis because of time constraints.  
4. Ultimately three interviews were scheduled.  
5. One patient cancelled due to ill-health and another could only participate via 
telephone. 
6. Finally, two interviews were conducted.  
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The Topic Guide for the patient interviews was designed to include questions regarding their 
understanding and experiences of the goals of integrated care as well as the role of the 
pharmacist and any barriers, enablers, outcome measures and long term role developments 
issues. (Appendix 8)  
 
Recruitment of staff participants 
The inclusion criteria for the staff participants were that they should be a member of an 
integrated MDT, which included an IC pharmacist and Coordinator as core members. The 
recruitment steps were as follows: 
 
1. Both IC pharmacists were given a staff PIL, consent form and a stamped addressed 
envelope by the IC team lead. Their recruitment was conducted by him instead of 
myself because I was their line manager and therefore they may have felt obliged to 
participate.  The PIL explained that participation was voluntary and that if they were 
willing to take part, they should send a completed consent form to myself using the 
stamped addressed envelopes. 
2. A list and contact number and email address of double the number of other staff 
participants required was obtained from the Integrated Care Team Lead. 
3. An electronic version of the staff PIL and consent form was sent in an email to 
everyone on the list. The PIL explained that participation was voluntary and if the 
staff member was willing to participate, they should send an email and a copy of the 
signed consent form, to the address on the PIL.  
4. One integrated care coordinator and one GP emailed to express an interest initially  
5. They, were both immediately contacted by myself via email, to agree a mutually 
convenient time and place for the interview  
6. Following two reminder emails sent to the nurses on the list and other GPs and 
coordinators, one further GP, two coordinators and two nurses were recruited. 
7. Two of the appointments were rescheduled and one of the nurses and one 
coordinator cancelled. 
8. Six weeks later, seven staff participants had been interviewed 
 
The Topic guide for the staff interview included questions regarding their understanding 
of the goals of integrated care as well as the pharmacist role and the barriers, enablers, 
outcome measures, long term development and sustainability. (Appendix 8) 
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Interview Venue: 
Stakeholders were interviewed at venues agreed during the recruitment which were quiet, 
comfortable and private to minimize distractions and ensure confidentiality and reliability. 
One patient was interviewed at home and the other patient was interviewed over the 
telephone, after a failed appointment at their home and due to time constraints. Both GPs, 
one IC Pharmacist and Coordinator, were interviewed in a private consultation room at the 
GP practice., The second pharmacist and other two IC coordinators were interviewed in the 
meeting room in their team office.  The nurse was interviewed in the meeting room in the 
community nursing team office.  
 
Prior to each of the staff interviews, a sign was put up on the outside door of the interview 
rooms reading, “Please do not disturb, meeting in progress”. The researcher’s mobile phone 
was switched off for the duration of the interviews. During the interviews with the community 
nurses, there was disturbance from adjacent rooms which meant that audio recordings had 
to be abandoned.  In place of recordings, the researcher made detailed written notes. 
 
The telephone interview with the patient also presented some challenges although the 
patient was very articulate, vocal and communicative and the duration of the interview and 
sufficient data was obtained.  
 
3.2.2 Stage 2: Utilization of documented quantitative data 
As described above in section 2.3.2, the quantitative data for the research comprised seven 
key performance indicators (KPIs) derived from the key performance indicators (KPIs) 
documented by the IC pharmacists as part of their role. These are detailed in section 4.2 
below.  
These KPIs were monitored and reviewed quarterly by the ELR CCG committee in charge of 
commissioning strategy and planning. At the end of the pilot, they were collated into an end 
of scheme report (appendix 10). A key assumption in the analysis and use of the data was 
that one out of every ten medication errors /discrepancies (10%), resolved by the integrated 
care pharmacists as part of their role, and led to the avoidance of one hospital admission. 
The assumption was conceived in a meeting with the two IC Pharmacists, one IC 
Coordinator and one IC GP. It was ratified by the CCG strategy and planning committee.  
This assumption was based upon literature stating that the 6.5 % figure reported as the 
percentage of hospital admissions which are “medication related harm” can be doubled. The 
rationale for this is because the research did not appraise the burden caused by ADRs in 
primary care that did not lead to admissions or those that happened whilst the patients were 
 70 
in hospital (Pirmohamed et al. 2004). It is acknowledged that this suggestion by Pirmohamed 
et al (2004) that the percentage could be doubled, is entirely speculative.  
However, for practical reasons and because this was debated and agreed by an MDT as 
well as ELR CCG (sponsor) stakeholders, the 10% assumption was used to develop the 
formula in Figure 3.1 below. The limitations of these assumptions are presented in section 
4.2 below. 
 
Figure 3.1: Formula for calculation of hospital admissions cost avoidance  
 
The formula in Fig 3.1 was used to compute the cost of avoided admissions. These savings 
from avoided admissions was added to other savings to arrive at a figure for total savings for 
the 8.5 months’ duration of the pilot.  
 
Figure 3.2: Calculation of interim savings  
Total annualized savings = 
£55,300 (Estimated annualized savings from medicines stopped or amended)  
+ £29,030(Estimated annualized savings from unused medication from patient home)  
 + £193,536 (Estimated annualized savings from medicines related admission avoidance 
derived using formula above)  
 =£277,893 
Savings per month = £277,893 ÷ 12 = 23,157 
 
Savings for 8.5 months of scheme = 23.157 x 8.5 =£196,840 
 
 
Figure 3.3: Calculation of spend 
The total cost of the pilot = 
 £20,565 (pro- rata cost of 9 months of 0.6WTE of Band 8a – WTE cost of £45,707) + 
£27,309 ( 8 months  of 1WTE Band 8a –WTE cost of £40.964 per annum)                   
    = £47,874 (Total cost of 1.6 WTE Band 8a for 8 months)                                                                                                 
 
Then the overall cost of the pharmacists was deducted from the savings to arrive at the net 
savings. 
Cost of avoided admissions =  
1 10 x   total number of recommendations made by integrated care pharmacist x cost of 
one emergency admission  
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Figure 3.4: Calculation of net savings 
 
Net SAVINGS= £196,840- £47,874 = £148,966 
 
These figures were used to work out the overall cost effectiveness of the integrated care 
pharmacist pilot expressed as return of investment (ROI) which was of the KPIs reported in 
chapter 4. 
 
3.2.3 Stage 3:  Focus groups 
The focus group was attended by six participants: two IC Pharmacists, three IC Coordinators 
and one IC GP. 
 
Recruitment of focus group participants 
The inclusion criteria for the staff participants included that they should be members of the 
multidisciplinary team that included an IC Pharmacist and Coordinator as core members.  
The inclusion criteria for the patient participants included that participants should have 
received pharmaceutical care from an IC Pharmacist.  
The recruitment process was carried out as follows; 
1. All interview participants were invited to attend during their interviews. All nine agreed 
to be part of the focus group. 
2. Four weeks before the focus group meeting date, the seven staff participants were 
sent an email reminder with the patient information leaflet and consent form attached 
and the two patients contacted by telephone. 
3. Six participants confirmed they could attend. None of the patient could attend 
because one was not feeling well enough to travel the 40 minutes and the other had 
a competing priority. 
4.  Attempts to recruit other integrated care patients who met the inclusion criteria were 
not successful.  
5. Finally, the six participants attended the focus group. 
 
The focus group commenced 10 minutes later because one participant was delayed. I 
started with introductions to break the ice. I then followed with a presentation of a summary 
of the themes derived from the nine interviews as well as the key performance indicator 
data. These generated discussions that lasted for the remaining 75 minutes generating data 
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that contributed significantly to the themes presented in chapter four.  Refreshments were 
supplied at the start and half way through with assistance of the co-facilitator.  
 
3.3   ETHICAL CONSIDERATIONS  
In line with recommendations to consider potential ethical issues before commencing a 
research study, the relevant ethical issues were considered. This recommendation is to 
ensure the protection of both the participants and the researchers (Denscombe, 2014). 
Consequently, for this research, all the potential issues were discussed and acknowledged 
in line with the processes of the DeMonfort University and NHS research and ethics 
committees. Subsequently, ethical approval was obtained from committees (Appendix 9)  
A reflection, guided by ethical principles (Carr, 1994) and how the considerations were 
applied to my research is presented below.  
 
Recruitment: Discomfort or feeling obliged to participate 
To mitigate any perceived pressure by the participants to take part in the research, the staff 
were not recruited by their line manager. In addition, they were all given participant 
information leaflets which further emphasized their right to withdraw consent at any time 
without affecting their normal working relationship with their line manager.  
 
Safety, protection and convenience  
Safeguarding assurance for the patient participants who are vulnerable was assured by the 
fact that as the main interviewer, I possess a Disclosure and Barring Services (DBS) 
certificate which confirms that I am certified to interact with vulnerable individuals. I am also 
a registered pharmacist with the General Pharmaceutical Council. My own personal safety 
was enhanced by ensuring that my manager was aware of the time and location of the 
interview conducted at a patient’s home.  
 
Data protection and storage 
Care was taken to ensure that all the data protection requirements were fulfilled in the 
following way;  
 Only required data was assessed and this was anonymized as much as possible  
  Data were stored in encrypted memory sticks and locked in secure offices, 
accessible only to myself. Electronic records were password protected and backed 
up. Raw and analysed data will be kept for five years in accordance with university, 
CCG guidelines and requirements of the ethics committees.  
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 Direct identifiers were kept to a minimum and were separated from any traceable 
information and all the data for the analysis which I derived from the interviews and 
focus groups are presented to ensure anonymity.  
 Every step was taken to be ensured that the research complies with the Data 
Protection Act as detailed in the appendices 4 and 6. 
 
Confidentiality and Anonymity of Data: 
To ensure confidentiality, interviews were undertaken in a private meeting or consultation 
room either in at a GP practice or social care office or within the home of the patient. 
Identifier codes were used instead of participant names and all identifiable information was 
anonymized.  
 
Disclosure of bad practice 
Participants were also informed in the PIL that confidentiality could not be maintained if they 
provided information where disclosure is in the overriding public interest or where there is a 
legal duty to disclose, for example by court order and where there is a statutory basis which 
permits disclosure. They were reassured that they would be notified in the case of any 
disclosure if there is any risk to themselves or others 
 
3.4 DATA ANALYSIS 
The data analysis was divided into sections according to whether the data were qualitative or 
quantitative.  
Qualitative data Analysis 
The steps of the data analysis were completed as follows:  
1. I uploaded the interview and focus group recordings onto my laptop and stored 
electronically in labelled folders alongside copies of the notes I made during the 
interviews. The copies were also all backed up on iCloud. 
2. An independent contractor and I transcribed all the recorded interviews verbatim. The 
independent contractor was recommended by a colleague and was hired because 
my work and family constraints did not allow time to personally transcribe the 
recordings. 
3. I checked all the transcriptions against the interview notes for accuracy. 
4. I imported the transcriptions electronically into a software called Nvivo. 
5. I read the transcriptions several times, immersing myself in them such that I could 
occasionally relive the actual interviews and hear the participant voices  
6. Whilst reading through each transcript, words, phrases and sentences which 
appeared potentially significant to the participant’s perception and experiences were 
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coded and assigned to the nodes. Nodes are virtual receptacles where coded 
material is gathered in one place and assisted me to decipher and organise emerging 
patterns and ideas. The reflective diary was used to help identify significant phrases 
and non-verbal cues. The initial codes and nodes were quite many and overlapping.  
7. I re-read the transcripts several times and reorganized the themes. 
8. I drafted and presented a copy of the interim themes to my supervisor for comments 
at a meeting during which we agreed some slight alterations  
9. I reorganized the themes and coding into the final themes presented below in chapter 
four. 
 
Quantitative data analysis  
As described above, secondary data documented by the pharmacist was translated into 
seven KPIs and analysed using the methodology described in section 3.2.2 above, 
In line with the ELR CGG evaluation policy and action research. 
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Chapter 4: Findings  
 
Overview of chapter 4 
This chapter describes the findings that emerged from the mixed methods and data analysis 
described in chapter 3. The emergent themes from the interviews and focus group are 
discussed first (Original transcripts attached as appendix 10). This is followed by a 
presentation of the quantitative findings that summarize the key performance indicators data 
documented by the integrated care pharmacists during the study period. 
 
4.1 Qualitative Findings 
The qualitative methods aimed to inform the role of the integrated care (IC) pharmacist as 
well as how to evaluate, develop and sustain the role. 
 
Emergent Themes  
Six main themes, which covered the participants’ experiences and views regarding the role of 
the IC Pharmacists, were identified from the interviews and the focus group. 
These themes are:  
1. Teamwork 
2. Accessibility and visibility 
3. Resources and enablers  
4. Reflection on Integrated Care Pharmacist role functions 
5. Impact of Integrated Care Pharmacist within multidisciplinary team 
6. Evaluating performance of Integrated Care Pharmacist role 
 
This research study provides a unique insight into the perspectives and experiences of 
patients, nurses, IC coordinators, Pharmacists and GPs, about the role of the IC Pharmacist. 
Although the perspectives are similar for most of the themes and subthemes, there is a clear 
disparity of perceptions between the cohort that were fully embedded within the 
multidisciplinary team and had worked closely with the integrated care pharmacists and those 
that had not (GP2 and CN). The themes are shown in figure 4.1.  
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Figure 4.1:  Summary of themes derived from interviews and focus group
 
 
 
 
 
Theme 1: Teamwork    
Several issues relating to the functionality of teamwork emerged from the interviews and 
focus group. These included demonstrable evidence of having a unified agenda, shared 
values, understanding and an appreciation of the role of the IC Pharmacist and other 
professionals within the integrated care pathway. Additionally, working in tandem, respect 
and trust as well as inclusion of carers and patients as team members were mentioned by 
the participants.  
 
The importance of having a shared agenda and vision was acknowledged by the health care 
professionals. 
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“The experience I have had we all got on very well we were all on the same page and 
actually work well as a team. I could see that if your agendas were very different you 
might clash because we all come at something from a different angle and actually 
your motive and experience is different”  
(Appendix 10, GP 1 interview lines 190 -193)  
 
GP 1 explained why the team should also work in tandem. 
“I think it worked better because sometimes what I find is when we work separately 
changes are made to medication and the pharmacist may not necessarily understand 
why that drug was picked or the history behind it. And so, changes are made which 
then make the patient unhappy. Whereas the way we did it this time they were 
reviewed, it was all done with the patient and then we came and discussed it. And 
you could work in tandem so I think it was more successful.” 
(Appendix 10, GP 1 interview lines 138-143) 
 
The importance of respecting, understanding and appreciating the roles of colleagues when 
faced with dilemmas whilst working as part of an MDT was indirectly highlighted by IC 
pharmacist 1. 
 
“...because we have not really had many nurses involved and they are quite often … 
band seven, so they know quite a lot anyway. You always feel that you might be, it’s 
probably wrong, but you might be treading on their toes. And it’s more difficult here. 
the respiratory reviews because they are not really done very well. But you can't tell 
someone you are not doing them very well. It’s finding out how you can be a part of 
that team and influence what they are doing without criticizing what they are doing. 
(Appendix 10, IC Pharmacist 1 Interview lines 248-253)  
 
Several participants acknowledged the pharmacist’s role as medicines expert within the 
team  
“And then advocating for that, the medication aspect particularly because that’s our 
area of expertise within the multi-disciplinary environment. 
(Appendix 10, IC Pharmacist 2 Interview lines 93-94)  
 
“Support, advice, because quite often when it’s a medication related query its felt that 
the GP is the person that is going to be able to answer that query the best, whereas 
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actually a pharmacist is probably more appropriate to answer a medication related 
query than a GP” 
(Appendix 10, GP 2 interview lines 217-220) 
 
GP2 however also queried the reported overall value of the pharmacist claiming that time 
saved by pharmacists was a lot less than reported, because the GP occasionally had   to 
subsequently spend “extra” time resolving queries raised by the pharmacists for a few 
patients. This was discussed in the focus group during which GP1 expressed a contrasting 
view. GP1 argued that the pharmacist output was under-valued as any extra time spent was 
worthwhile and part of the GPs role using patients seen in outpatients as an analogy 
 
“I would have to take five or ten minutes out to speak to the pharmacist but if its 
stopping someone from having a CPD exacerbation that I need to go and do a home 
visit for and that’s going to take me 45 minutes. So, its quid pro quo…. Yes, you had 
to have the discussion and change some notes a bit and do some other things but I 
can't think of an example where I thought it made my life that much more difficult “  
(Appendix 10, GP 1 in focus group lines 309-315) 
 
“… It’s my role as GP to my patients in outpatients, I have to change the notes, 
update the notes and implement it. It’s no different, all …. That the pharmacist is 
going to the house - speaking to them - looking at their meds coming back and 
saying this is what I advise, update the notes. It’s not any different”  
(Appendix 10, GP 1 in focus group or interview lines 357-358)  
 
GP1 was more integrated within the MDT and had much more of an established professional 
relationship with trust and respect with the pharmacist and other MDT professionals than 
GP2. It was also expressed that where a key MDT member e.g. GP was not engaged, it was 
difficult to make progress.  
 
“Also, one or two GPs are not too quite on board so it’s difficult to proceed without 
the rapport.”  
(Appendix 10, IC Coordinator 2 interview lines 350-351)  
 
Teamwork was facilitated when clear benefits that would result from the changes proposed 
by the pharmacist had been experienced. This often brought the other MDT professionals to 
the same page. 
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“Initially I was unsure what a pharmacist could contribute because there was no 
description of their responsibilities so it took me a while to appreciate what they could 
bring on board as I always thought they mostly dispensed medication and a chemist 
could do that. However now I have worked with our pharmacist I can see the significant 
contribution”  
(Appendix 10, Community Nurse Interview lines 58-62). 
 
Participants also explained how working as a team would support holistic care delivery 
through delegation and use of individual skills to achieve the common goal.  
 
“I think it’s useful in terms of getting a bit more of a holistic care. So, the problem is at 
the moment patients have more and more problems, we have less and less time and 
so in a perfect world some of the more complicated patients you would want to spend 
half an hour or forty minutes with them, look through all the aspects of physical 
mental health all the sorts of signs, now the house is, how they are. But the reality is 
you don't have that much time and where integrated care comes in you have got the 
skills of lots of different people, plus the time that they can then actually look at it 
properly. And so, it’s just good at getting a sort of more rounded holistic care”. 
 (Appendix 10, GP 1 interview lines 19-26)  
 
Furthermore, working as part of a team increased the pharmacist’s awareness of other 
services and resources available to patients. It also increased their appreciation of the role of 
the social care coordinators.  
 “I didn't realize you could get an assessment and find out what would be useful for 
people. So, the coordinators know a lot about everything they really do, and it’s not 
until you talk to them that you know what is available for patients. And I think that 
awareness …that you can talk to other people about somebody and they will have an 
idea that you didn't know existed. Or if you did know you wouldn't know how to 
access it. So, there are all sorts of things that I didn't know was available for patients. 
So, I think the coordinator is really useful because otherwise you are going to end up 
still working in your own little area,” 
 (Appendix 10, IC Pharmacist 1 interview lines 316 to 332)  
 
The importance of communication was mentioned several times as important for team work 
because there was a communication breakdown because the IC pharmacists were unable to 
attend multidisciplinary team meetings regularly due to insufficient capacity and conflicting 
priorities. 
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“Yes, I send my cases to R (IC Pharmacist 2) I don't actually get to meet her and she 
is not able to come to the meetings so there is, that is a problem because there is a 
lack of communication. And at that surgery they don't get to understand how it all fits 
in with the team”.  
(Appendix 10, IC Coordinator 2 interview lines 205-208)  
 
Finally, the carer’s roles as part of the MDT was acknowledged by both patients whose role 
within the MDT was also recognized following prompting. 
“... also my wife- she looks after me, she is my main carer, and she really looks after 
me as my main carer” 
 (Appendix 10, IC Patient 1 interview lines 25-26) 
 
“I think maybe yes, I hadn’t thought about patients being part of the integrated care 
team, particularly if you had expert patients. So, for example you have a patient with 
COPD who is identified as somebody who you would want to proactively manage an 
expert patient would be excellent at being able to promote self-care and self-
management, so yes, I hadn't thought of that” 
(Appendix 10, GP 2 Interview lines 115-119) 
 
Theme 2: Visibility and accessibility  
Ensuring regular and reliable direct access and visibility of the pharmacist and all MDT 
members was a facilitator mentioned by all participants. The funding for the pharmacist role 
which was the research focus was four hours per week on average for each virtual ward or 
hub which was made up of  approximately three practices. This equated to a half day each 
week per practice which was insufficient for full integration because some of the MDT 
members would either forget there was a pharmacist or decided it was safer not to assume 
they would be available.  
The knock on effect of thisro was highlighted by Patient 1  
 
“I can’t contact her – well I can contact her but I have to go through the system of our 
doctor through reception to ask for her and I might have to go through MH (GP 
practice) because the system they use… could go to any of the receptionists of the 
three surgeries and somebody in the other branches might not know who she is 
because she is only based at one. That’s the only downfall I feel- its contacting her 
directly 
 (Appendix 10, IC Patient 1 Interview lines 170-175) 
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The IC Coordinators also expressed the importance of pharmacist visibility and accessibility  
 
“Yes, when the two pharmacists worked in our office you knew that they were there, 
and you could get them if you needed them” 
 (Appendix 10, IC Coordinator 2 interview lines 233-234) 
 
“I think more access would be good as she only worked twice a week and could not 
attend all MDTs. So, one is reluctant to refer any patients in case there is a delay as 
it is hard to predict when she will get to it, though she did try to respond to all queries 
when she was around. It would also be useful to work in the same office.  
(Appendix 10, Community Nurse interview lines 143-145) 
 
Accessibility to the GP was another barrier mentioned by all the pharmacists and 
coordinators because the pharmacist and coordinators are not based at the GP surgery.   
 
“But to be able to just catch somebody if you are not based in a surgery you can't just 
catch them with a, like I know Dr. M (name withheld for confidentiality) he is around 
about 2 o’clock so I can race down if I have just got one query and he can just 
answer it for me. Whereas some of the others I have just asked the technicians to 
book me a block half hour next week so I can just go to one GP and just work my 
way through everything I need to. So, I think you just need to be able to be around 
and if you are not that’s a big barrier” (Appendix 10, IC Pharmacist 1 interview 
287-291)  
 
The coordinators and pharmacists mentioned that the pilot made the coordinators more 
accessible to the pharmacists which indirectly facilitated access to patients.  
 
Obtaining access to the practice was another barrier experienced by some of the 
participants. 
 
“I guess one barrier mentioned by my colleague is difficulty in getting access in the 
practice- access to the working space like a desk or a computer. Some practice 
receptionist is not very accommodating so you could have wasted trips”  
(Appendix 10, IC Coordinator 2 interview lines 347-351) 
 
Finally, Patient one suggested that all patients and not only the frail and elderly should have 
access to the pharmacist. 
 83 
 
“I am a pensioner but there are people younger than me on medication who need the 
service and should have it. You need a mixture of ages – no point having all old 
people or you would be there all day” 
 (Appendix 10, IC Patient 1 Interview lines 361-363)  
 
Theme 3: Resources and enablers  
The absence of sufficient amounts of numerous key resources was identified as a barrier. 
These included funding, regular ongoing and embedded pharmacist capacity, information 
technology, training and role development. A few enablers such as co-location of the MDT, 
transformation of the role, updating the referral routes and re-positioning the pharmacist in 
the pathway, were recommended to optimise the output.  
 
The community nurse touched on all this during her interview when she was asked what 
barriers she had experienced whilst working with the integrated care pharmacist. Availability 
of more funding would enable increased capacity with more pharmacist hours per practice to 
reduce spreading a few pharmacists thin across multiply practices from extensive 
geographical locations. One pharmacist per practice as a minimum was suggested to 
provide the required capacity. 
 
“...More funding would be great to have one in every practice every day of the week 
just like other health professionals if you think that most patients are on medicines” 
(Appendix 10, Community Nurse interview lines 145-150) 
 
More capacity would also make it possible for more patients to be “admitted” to the virtual 
ward and benefit from the integrated care and pharmacist service. 
 
“Well it would be lovely if every surgery had a pharmacist and again to know that you 
could get in contact with that pharmacist where they are, where they are based. And 
you do know that you are fitting in with the other work that they are doing at the 
moment. When we had them before that was what they were doing, it was just great.”  
(Appendix 10, IC Coordinator 2 interview lines 308-311) 
 
Finances would also provide more time for the pharmacist to provide domiciliary visits when 
required as this was mentioned as an enabler. 
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“And I suppose time is a massive, massive thing, if you are going out to patients 
homes it takes a long time to review them when you are in their home.” 
 (Appendix 10, IC Pharmacist 1 interview lines 292-293) 
 
“They are probably not as relaxed (at the surgery) and they haven't got all their 
medicines and you can't see the situation that they live in. And that makes a lot of 
difference because S (IC Coordinator 1) has come back from a couple and she said 
its chaos in that house, there is stuff everywhere, she says it’s no wonder they don't 
know what they are taking. You just get a feel for that person better in their home. 
But I think you only really need that for the difficult patients”  
(Appendix 10, IC Pharmacist 1 interview lines 302-305) 
 
The less difficult patients could receive pharmaceutical care by attending appointments or 
drop in clinics at the practice.  
 
“Yes, that’s what I would like to do moving forward, rather than, home visits will,….. 
but if I can get people to come in and see me I was thinking about trying to do some 
drop in, bring your bag”  
(Appendix 10, IC Pharmacist 2 in focus group lines 454-459) 
 
 It was also expressed by the IC Pharmacists and Coordinators that being based in the same 
location (co-location) would be a facilitator because everyone becomes more familiar and 
approachable. 
 
“I think it fits it really well the model of being in the GP practice because you are in 
there with the healthcare professionals and the patients as well as the professionals 
find it quite useful...” 
 (Appendix 10, IC Coordinator 1 lines 30-32)  
 
The professionals all thought that co-location would reduce the challenging process of 
organizing access to the practice for the IC Pharmacists and Coordinators who were based 
in the IC team office.   
 
All participants said they would like the role to continue and be developed and they made 
numerous suggestions of key enablers. This included transforming/assimilating the role 
which would entail creating a clinical pharmacist in GP practice role that included and 
prioritized the role functions of the IC pharmacist as well as a pharmacy technician support 
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role. It was suggested that these new roles would facilitate sustainability of the role 
functions.  
 
 
“..You have got everyone else as part of a team within a practice you haven't got 
pharmacists and pharmacist has never been seen as part of the team, they just are 
somebody who works in the shop. Or if it’s prescribed advice then its someone who’s 
on your back to make you reach indicator targets and save money. But there has 
never really been anybody that has said well have you thought about looking at this, I 
just think you need to be part of the team. So to develop the role you need to make 
patients and members of health care team know what pharmacists can do. And you 
can only do that by having someone in here and doing it. So its chicken and egg isn't 
it, you can't show somebody what you can do unless you are in there and you can't 
get in there because no one is willing to take a punt are they and say let’s see if this 
works. … 
(Appendix 10, IC Pharmacist 1 interview lines 339-345) 
 
“..But having tried working with pharmacy technicians, it’s probably better to delegate 
this to them than the coordinators. …..and if there was anything we thought just by 
looking at it they want to talk to a patient  we would tell the technicians  and then they 
would go and do that before their visit. So, then they would know, they would be sort 
of pre-armed. But then additionally we would also have referrals after they had been 
into the home, that was more about physical issues and getting mixed up and it 
wasn't so much about reviewing their medicine and saying what they were and 
weren't taking. But having new technicians they are probably better placed to do that 
than the coordinator. Because there is always a problem with an additional 
knowledge set that they hadn't got, and to a certain extent the techs (pharmacy 
technicians) could probably answer some of those questions.  
…” 
(Appendix 10, IC Pharmacist 1 interview lines 184-193) 
 
Nevertheless, there were concerns that it might not be doable for the proposed GP hub 
practice pharmacist to do it all. However, it was concluded that it might be possible if the role 
were embedded in such a way that some of the functions were routine.  
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“…But whether you can do that and be part of a group of practices and just cover 
integrated care or poly pharmacy or whatever I think it’s too big a role to be in a 
practice and do all the CCG work and the prescribed. So basically, just making sure 
that you have got proper prescribing within a practice and individual medication 
reviews. Because once you do the bulk of the work it’s just maintenance really and 
new patients and medicines reconciliation when patients come into practice all that 
sort of thing...” 
(Appendix 10, IC Pharmacist 1 interview lines 348-353) 
 
Overall however, they felt it was inevitable that the role function would become embedded as 
part of the role of a pharmacist, based in a GP practice. 
“My feeling is that in five to ten years’ time every single practice will have a full-time 
pharmacist that is the way it’s going. And in which case the model of integrated care 
is going to use the practice pharmacist isn't it? So, in an ideal world you may have a 
dedicated pharmacist to the integrated care bit. I suspect the realistic …it’s just going 
to become the new model, the standard….”  
(Appendix 10, GP 1 in focus group lines 1245-1251) 
 
Another process related change suggested was to position the pharmacist earlier in the 
pathway. 
“I think what might help facilitate it is if there was a discussion with the pharmacist 
before they went. It might speed up their process because I think sometimes they 
come back and a lot of the questions were like I could have let them know before 
they went. So actually, I wonder if the process would be better if we discussed the 
patient, the pharmacist and the GP, in the meeting you discussed the patient, just 
had a look at the medicines before and highlighted perhaps things that I think are 
issues and what they think are issues. And if there is any immediate odd prescribing 
say you can say well the reason for that is because so and so. And it might make the 
pharmacist’s job easier because they go out with the knowledge”  
(Appendix 10, GP 1 interview lines 227-235)  
 
Regarding Information technology, insecure emails was raised several times as a barrier  
“There is a problem with things like secure emails, sending the information across to 
the pharmacist. At the moment, I send it to through our social care emails to our team 
support who then has got secure email and then sends it out to R (Pharmacist 2). So 
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that’s a problem, it is the confidentiality and data protection I think really, one of the 
biggest barriers” 
 (Appendix 10, IC Coordinator 2 interview 216-220)  
 
 
Other facilitators suggested included broadening the identification process to include more 
patients as well as having several other practical and flexible options for the location of the 
medication review e.g. over the phone, drop in clinics, bespoke clinics and domiciliary as 
required 
 
 
Theme 4: Reflection on Integrated Care Pharmacist role functions 
All the participants shared their opinions regarding the role functions of the IC Pharmacist. 
These subthemes included pharmaceutical care, medicines information, triage, education 
and training and awareness raising, prescribing, auditing, cost rationalization and waste 
reduction. Pharmaceutical care was comprised of example de-prescribing, empowering 
patients, medication reviews, safe prescribing and making every encounter count. 
 The IC coordinators shared their experiences of how the IC pharmacist provided 
pharmaceutical care and occasionally rationalizing cost simultaneously. 
 
“There was a case where [the] pharmacist was going in and looking e.g. - meds not 
ordered for long time to understand what was going on - if not taking meds to dig 
further and find out is it side effect or what exactly going on - someone on diabetes 
getting prompt to check if taking insulin - do they suffer from pain and are they taking 
any medication for it -do they use inhalers? If so what colors and how often 
(Appendix 10, IC Coordinator 1 interview lines 174-180) 
 
“They will go through the medication that patients are on as a matter of course. So, 
when I send out a letter, once a patient has said yes they want me to go and see 
them, I then send that information to R (IC Pharmacist 2) and then they look at all the 
medication just to make sure that they are not on something they have been on for 
years that they don't need to be. They can look by the various results whether they 
are taking the medication. …I would imagine well I know they do they look at cost as 
well. Things like the nutrition drinks I know some are on and they were able to put it 
down to the powdered ones which are cheaper.” 
 (Appendix 10, IC Coordinator 2 139-146). 
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Medicines reconciliation was also a key service delivered by the pharmacist as part of 
pharmaceutical care. 
“Yes (responding to question regarding whether medication in Figure 4.1 below 
belonged to one patient) she (patient) had been in and out of hospital quite a few 
times and every time she came out of hospital they gave her some different stuff. So, 
it was changed so she didn't want to take that but then she also had trays from 
hospital that were different to the trays she had previously from her GP so she had 
stacks of trays as well. Not sure which one she should be taking and then things that 
had been stopped but carried on being ordered. There were more cupboards with 
pills in than there were cupboards with food in the kitchen.” 
 (IC Pharmacist 2 in focus group line 181-186) 
 
Figure 4.2:  Obsolete medication recovered from a patient’s home following 
medication review by IC Pharmacist 2  
 
 
The community nurse also explained how the IC pharmacist provided education and training 
using dossette box as an example. 
 
“.. They (IC pharmacists) came along and things like dossette boxes it (medication) 
went in to explain why they think dossette boxes are not always such a good thing. 
Some patients need them, explaining that, it made sense. To a lot of people, it’s like 
oh dossette box that’s the answer but there is more to it than that.  So yes, that was 
really interesting, yes, any sort of information that you can get has got to be good. So 
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yes they (IC pharmacists) were always able to help out and explain things to us.” 
(Appendix 10, Community Nurse Interview lines 223 -227) 
 
GP 1 illustrated the legacy effect following the IC pharmacist education of MDT colleagues.  
“I think it’s educational for us all because all of us are involved in prescribing, using 
drugs and noticing the side effects and whether they are being used properly…. But 
even from a nurse point of view I would think they are involved in suggesting drugs or 
often with dressings …And I think so all of us could get something out of 
it.  Particularly education but also, I think if nothing else it reminds you that you need 
to be aware of the effect the drugs are having and the cost and the side effects and 
all those sorts of things. So actually not only for the patients you discussed but when 
you go and look at other patients it helps those ones …for example with something 
about metformin and B12 deficiencies which I had never come across but that was 
picked up in one of the med reviews and actually that’s been useful in seeing other 
patients so it does spill on to other people.  
 (Appendix 10, GP 1 interview lines 170 -181) 
 
The IC coordinators and community nurse found the medication related summary prompts 
the pharmacist developed and handed out to them following educational sessions as “aide 
memoires’ to be very useful. 
 
“The pharmacist developed this into prompts for us to check when we go to patient. 
With us not having a medical background, it was great to get this advice from 
someone else”  
(Appendix 10, IC Coordinator 1 lines 182-183) 
 
Theme 5: Impact of Integrated Care Pharmacist role  
Every single participant reported satisfaction with the IC pharmacist role and repeatedly 
expressed that the role should be sustained and rolled out. Of note is the fact that when 
asked for any further comments as the final question of the interview, all non-pharmacist 
participants spontaneously requested that the role be reinstated. Throughout the interview 
and focus group, they highlighted the positive impact that the pharmacist input had for all 
stakeholders. The positive impact included patient satisfaction and empowerment, increased 
medication safety including de-prescribing, financial savings, bridge building function, extra 
support and time saved for MDT and awareness raising of the pharmacist skills.   
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“…it was really good when we had the pharmacist input and then when they left it 
was a big hole in our role really”.  
(Appendix 10, IC Coordinator 3 at focus group lines 56-58)  
 
Both patients shared their experience of satisfaction and empowerment following medication 
reviews by the IC pharmacist. 
 
“She went through all the medication I was taking at that particular time and it has 
been reduced – which is great for me because if I don’t need to, I don’t want to be 
taking them. People should not be taking tablets they don’t need to be taking” 
(Appendix 10, IC Patient 1 interview lines 279-284)  
 
“She also gave me a medicine reminder chart and helped me write in it. I use it to fill 
my dossette box myself and my daughter use it to help sometimes. So, someone 
who helped with my medicine”. 
 (Appendix 10, IC Patient 2 interview lines 105 -107)  
 
Patient 2 also shared how the pharmacist advocated for him 
“She also was kind and told the chemist driver to wait because sometimes by the 
time I get to the door they had gone and I had to keep ringing the chemist as I ran out 
sometimes.” 
(Appendix 10, IC Patient 2 interview line 107 -109) 
 
The impact the IC pharmacists made on raising awareness regarding medication and falls 
risk was described by GP1 
“Yes, because I found doing the project i learned about falls risk I can say before I 
joined the project I didn't know anything about it and I think a lot of GPs I came 
across the patch they have heard of it but not actively stopping things because they 
didn't necessarily know how. And when you add it all up and show someone a 
particularly at risk patient I think people become a little bit more aware. And being in 
the know, now I can see GPs who are leading on that risk there she is a lot more 
proactive at reviewing medication with the falls risk. And things like that you wouldn't 
be able to quantify”  
(Appendix 10, IC Coordinator 2, line 265-271)  
 
The GP explained how the pharmacists made a positive impact to the care of almost every 
patient they discussed.  
 91 
 
“I can't think there was one patient that we discussed that there wasn’t a change 
made to their medication or an improvement made or a problem found. So, I think 
that alone highlights, if you can look at all those, there wasn’t any that they looked at 
said the patient understands everything they are taking, they have got no side effects 
and all these drugs are perfectly safe. There was no one patient that happened to. I 
think what stuck out to me was that the fact that oh gosh there is a role for this 
because it does make a difference. And not just from a cost point of view but actually 
just from a best care and safety point of view I think it makes a difference to the 
patients”  
(Appendix 10, GP 1 interview lines 297-304)  
 
The pharmacists were also described by social coordinators as having a bridging role in the 
MDT, binding health and social professionals together. 
  
“And it was only when we got K (IC Pharmacists 1) and R (IC Pharmacist 2) that you 
realised what a big role, what a big contribution they make to our job. I think it’s as 
well just somehow having R (Pharmacist 2 at the meeting with the doctor it just 
seems to make it a complete picture almost.  I do tend to feel in other surgeries 
(without IC pharmacists) that I am still sitting there with my social care hat on and 
there is the health. But with R (IC Pharmacist 2) there, she seemed to be the person 
that joins us together”  
(Appendix 10, IC Coordinator 2 lines 336-341)  
 
Their value also immediately became apparent to MDT members who encountered their role 
and input for the first time. 
“Yes, when I had my meeting with Dr. S and R (names withheld for confidentiality) 
they really interact well, it makes such a difference having R (IC Pharmacist 2) there. 
…. and also, the clinical lead nurse she sits in it and she was like wow this has been 
a real education” (Appendix 10, IC Coordinator 2 lines 185-189) 
 
Furthermore, the community nurse explained how useful it would be to have regular ongoing 
access to one pharmacist per GP practice. 
 
“Well it would be lovely if every surgery had a pharmacist and again to know that you 
could get in contact with that pharmacist where they are, where they are based. And 
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you do know that you are fitting in with the other work that they are doing at the 
moment. When we had them before that was what they were doing, it was just great.”  
(Appendix 10, Community Nurse lines 212-215) 
 
However, three out of the ten participants described some less positive aspects, although 
most of these had to do with the overall integrated care service and not the pharmacist role 
specifically. The first aspect was that a patient got bewildered by too many visits from care 
professionals. 
 
“It’s too many people coming and I feel bewildered. Every day someone else comes 
and I don’t know who, which is why I did not open the door when you came last 
week. One person came and when they heard the dog bark before I opened the door 
they had left and I had been waiting all day so they could look at the railing “ 
(Appendix 10, IC Patient 2 interview lines 116 -119). 
 
This patient’s experience was discussed in the focus group and the coordinators 
acknowledged that some patients could initially have more visits that reduce overtime. 
However, the coordinators always endeavored to streamline any visits to ensure that all 
necessary prior communication with the patient as required. 
The second concern was conflicting advice given to patient 1 by the integrated care 
pharmacist and the community pharmacist. Following discussions in the focus group it was 
concluded that this is a possible risk when patient care is delivered by multiple professionals. 
This does not always mean that any one is incorrect as it is likely that the advice was 
accurate at that point in time and context and could have changed with circumstances. 
It was suggested that to mitigate, health and social professionals should explain to patients 
that advice can change with time as more facts or up to date results become available.  
 
Theme 6:  Evaluating performance of Integrated Care pharmacist role 
All ten participants included patient feedback amongst their list of how to evaluate the role. 
Other methods suggested was using quantitative matrices like cost savings, time saved and 
staff feedback. 
 
“I think feedback from patients is definitely a big one, it would be interesting to re 
review the changes and what happens to those changes that are made that are 
actioned by pharmacists. I think feedback is the biggest thing, that’s all I can think of” 
(Appendix 10, IC Pharmacist 2 interview lines 207-209)  
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However, cost savings and other quantitative methods or financial savings was deemed 
inappropriate. 
 
“…. I think feedback from patients the users and the rest of the team is the biggest 
indicator of whether something is working or not. And you can't do that in the short 
term. I don't think you can do it by numbers of inventions or amount of money saved, 
I think you just do it by asking somebody do you feel better about your medicines, do 
you feel more able to cope, do you feel healthier because you are not taking 
something or you are taking something. And I suppose you can't quantify that can 
you, in terms of questionnaires and that sort of thing”  
(Appendix 10, IC Pharmacist 1 interview lines 327 -333) 
 
This aligns with the findings of the evaluation of the IC pharmacist role in line with the East 
Leicestershire and Rutland CCG evaluation policy described below. 
 
 
4.2 Quantitative findings   
The quantitative findings were derived following analysis of seven KPIs data routinely 
documented by the integrated care pharmacist for the sponsor -ELRCCG evaluation, as 
described in sections 2.3.2 and 3.2.2 above. This was in line with the sponsor evaluation 
policy. 
Table 4.1 is a collation of the comprehensive data collected by the IC pharmacists over the 
entire eight and a half months’ duration of the pilot. 
 
Table 4.1: Comprehensive data collected by IC Pharmacists  
 Description  TOTAL 
 
Total number of patient reviews 
 
238 
Number of reviews conducted in 
patient's home 
Number of telephone reviews   
20 
 
56 
Number of reviews with 
suggestions made 
209 
Total number of suggestions made 708 
Number of suggestions agreed 541 
Number of suggestions disagreed 34 
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Number of suggestions awaiting 
GP respond 
133 
The number of patients reviewed 
who have been recently discharged 
from hospital whose medicines 
have been reconciled 
23 
Number of Antipsychotics and 
Benzodiazepines stopped                                       
(not indicated for psychosis) 
0 
Number of drugs changed 
(dose/strength/form) 
66 
Prescription directions changed 
(including amendments to 
dossette) 
6 
Quantity changed/synchronised 27 
Repeat lists tidied/repeats stopped 89 
Monitoring suggested  
i) Follow up/review due 45 
ii) Blood pressure 8 
iii) Blood test 29 
Unnecessary medicines stopped  
i)Total stopped 54 
ii) Average per patient stopped  
iii) Range                                                                                      
(of medicines stopped per patient) 
1-4
Falls Prevention  
i) Anxiolytics (reduced/stopped) 11 
ii) Anti-muscarinics 
(reduced/stopped) 
7 
iii) Analgesics (optimised) 23 
iv) Antihistamines 
(reduced/stopped) 
7 
v) Antidepressants 
(reduced/stopped) 
3 
vi) Antihypertensives (optimised) 4 
vii) Diuretics (reduced/stopped) 2 
viii) Calcium and Vitamin D (started) 8 
High risk drugs  
Warfarin  
NOACS  
Methotrexate 2 
NSAIDS 2 
Important information 
communicated 
 
i) Allergies  
ii) ADR 42 
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The data was summarised into the seven relevant KPIs detailed in table 4.2 below. 
 
 Table 4.2: Summary of outcome of key performance indicators 
 
 
Assumptions for Key Performance Indicators  
The seven KPIs detailed above were based on three main assumptions. The first 
assumption was that all integrated care patients have a medium to high risk of hospital 
admissions. This is because the risk stratification tool used to identify the patients was 
underpinned by the Johns Hopkins University Adjusted Clinical Groups (ACG) algorithm an 
established tool that identifies multi morbidity and other indicators as drivers for emergency 
admissions. The second assumption is that as described in section 3.2.2 above, 
approximately 10% of hospital admissions result from ADRs. This was based on speculation 
by Pirmohamed et al (2004) that the 6.5 % figure for admissions caused by ADRs in their 
study could be doubled. Their rationale for this suggestion is that the research did not 
appraise the burden caused by ADRs in primary care that did not lead to admissions or 
those that happened whilst the patients were in hospital (Pirmohamed et al. 2004). Thirdly, it 
was assumed that the cost of an emergency admission is £1792. This figure was validated 
 Key performance indicator 
 
(238 IC patient reviews resulting in 708 
suggestions) 
Outcome 
Achieved  
Yes/No 
Figure/Percentage  
1 Achievement of return of investment of minimum 2 
Calculations  
1) Net Savings 
£196,840 (Total savings by IC pharmacist for 8.5 
months) 
– £47,874(Total IC Pharmacist cost for 8.5months)  
  = 148,966 
2) Return of investment £148,966 ÷£47,874 x 100% = 
311 % 
Yes   
3.1 
(311%) 
 
 
£625.9 per patient 
2 Reduction of polypharmacy  
 
Yes  54 drugs  
 
3 Completion of clinical medication review for all referred 
IC patients 
Yes  100% 
4 Completion of medicines reconciliation as required  
 
Yes  23 out of 238 
(9.6%) 
5 Provision of domiciliary clinical medication review as 
required  
Yes  20 out of 238 
(8.4%) 
6 Provision of repeat prescriptions review as required Yes  89(out of 238 37%) 
7 Provision of medication training sessions to IC 
coordinators every two months 
Yes  4 
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by the CCG finance team, based on the average actual cost from the relevant health care 
resource group codes. 
 
These assumptions raise some discussions and have some implications for the findings. To 
begin with, the suitability of using admissions avoidance could be debated considering that 
the evidence base to use it as an outcome of clinical medication reviews by pharmacists in 
the UK is not robust (Blenkinsopp et al, 2012). However, Zermansky and Silcock (2009) 
highlighted some consistency in aggregated data showing that falls and reduced admissions 
could have been reduced alongside modest savings, following medication reviews. Another 
consideration is that admissions avoidance is used by several other healthcare interventions 
and this could increase the risk of double counting.  Consequently, other options like 
counting patients on high risk medication such as warfarin or measuring changes in clinical 
markers (such as control of HbA1c in people with diabetes) or quality of life indicators were 
considered as options. However, these were deemed impractical because of the limited 
patient numbers and time constraints. Therefore, in consideration of the point raised by the 
focus group participants that 10% could be an underestimate of savings, if the “domino 
effect” of a lifelong change in practice is considered (Focus group line 256 -262), KPI one 
was deemed suitable. 
 
Limitations  
However, there are some limitations to be acknowledged, regarding the use of this KPI data 
as the quantitative data for this study. Firstly, the KPI data was derived from secondary 
analysis of data collected as part of the IC pharmacist role functions. Therefore, there is a 
possibility that the data could be biased because of the conflict of interest or incomplete. 
These risks were partly mitigated by using a standard template. Furthermore, the data was 
jointly collated by both IC pharmacists after which it was presented and challenged by a 
sponsor committee. Secondly, the data was neither sufficient nor suitable to be used for 
statistical tests which is the gold standard for quantitative data. Thirdly as explained above 
the use of the first KPI which was return of investment of 10% is potentially controversial 
pending robust research outcomes.  
 
However, these limitations were mitigated by obtaining approval from the sponsor 
organization to use the KPIs as mentioned previously which is in alignment with the action 
research design. The fact that these assumptions were also utilized on the successful 
business case to secure ongoing funding for more of these roles further confirms that these 
limitations could be theoretical in nature and deemed negligible in practice. 
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Summary 
The qualitative findings highlight the considerations which patients and their professional 
carers believe should inform how the social/health integrated care pharmacist role should be 
developed, sustained and evaluated. The six themes derived from the qualitative methods 
were: teamwork; accessibility and visibility; resources and enablers;reflection on the role 
functions;Impact of the role and  evaluating performance of the role. These added more 
insight into how the quantitative data could be utilised to sustain and develop the IC 
pharmacist role. 
 
Similarly, the quantitative findings complement the qualitative data by providing figures to 
exemplify the role function and impact of the IC pharmacists. Furthermore, the quantitative 
findings illustrate the recommendations from the qualitative findings on how to evaluate the 
role performance using KPIs. All KPIs were achieved, including a return of investment of 
31%, a reduction of polypharmacy by de-prescribing 54 drugs, completion of clinical 
medication reviews in 100% of patients, repeat prescriptions reviewed in 37% of patients 
and the provision of four medication training sessions for the IC coordinators.  
 
Therefore, it can be concluded that the qualitative and quantitative findings achieved 
complementarity of mixed methods (not triangulation). These findings are discussed 
alongside existing evidence in the next chapter 
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Chapter 5: Discussion 
 
5.1 INTRODUCTION TO DISCUSSIONS  
Integrated care in the context of this study as described in chapter one, is a multidisciplinary 
team (MDT)  of health and social care professionals, working proactivley and collaboratively, 
to deliver coordinated patient centered care, which is designed to meet the needs and 
preferences of both the patients and their carers (NHS England, 2016). Patients and 
practitioners both agree that integrated health-social care provision empowers the patient 
and provides better outcomes. Consequently, integrated care programs have become 
mandatory and are rapidly developing across the United Kingdom (Rand et al.2012; NHS, 
2016). 
However, although the pharmacist role within these integrated care programs is increasingly 
recommended and described, research to adequately inform the role, the impact it achieves 
and how it should be developed and sustained in the UK has not been found in the literature.  
 
This chapter presents a discussion of the new perspective informed by the findings of this 
study, under the six themes identified in chapter four. These are: effective teamwork; 
accessibility and visibility; resources and enablers; reflection on the integrated care 
pharmacist role functions, impact of the role within the multidisciplinary team and evaluating 
the performance of the role. 
 
5.2 DISCUSSION OF FINDINDGS 
 
Theme 1: Teamwork 
The findings highlight key factors that are essential in the views of the participants, to ensure 
that the multidisciplinary team within which the pharmacist works, can achieve its goals. 
These factors include having a shared agenda, goals and visions, working in tandem, having 
respect, awareness and an understanding of the different MDT roles as well as 
communication.  
 
These factors are like those that are highlighted by Mitchell et al (2014) as important for a 
team which they define as “two or more people who are allocated definitive roles or functions 
and are interdependent on each other as they interact dynamically and flexibly to achieve 
mutual goals for a specified period” (Mitchell et al.,2014). In alignment with the findings from 
this study, Mitchell et al (2014) also highlight that a high-performing team is crucial for the 
delivery of   patient-centered, integrated, and effective care.  
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Similar factors were shown by Jorgenson et al (2014) in their qualitative study of 
pharmacists during their integration into 23 existing primary care teams in Canada. The 
study design was one-on-one telephone interviews with pharmacists, doctors and nurse 
practitioners from the 23 teams. Thematic analysis of the interview transcripts was utilized by 
four different researchers to determine key themes. Amongst the seven emergent themes 
were relationships, trust and respect and pharmacist role definition. The conclusion was 
drawn that these were very important facilitators to support the integration of the 
pharmacists. 
 
The strengths of the study include the fact that different sizes and types of primary care 
practices were included which increases generalizability of the findings. Furthermore, bias 
was hugely reduced by using four researchers for the thematic analysis.  There were also 
some limitations of the study. Firstly, the study was conducted in Canada which has a 
different health system to the UK which diminishes the transferability of some aspects of the 
findings. Secondly the participants did not include patients or social support worker who are 
key participants for this study. Thirdly, telephone interviews could have slightly reduced the 
quality of the data because the interviewer could have missed non- verbal communication 
cues. However, most of the emergent themes were similar to the findings of this study.  
 
The Royal Pharmaceutical Society (2013) in its description of medicines optimisation, 
specifies that “… a holistic approach…and partnership between clinical professionals and a 
patient” is required. Furthermore, the society specifically highlights that medicines optimisation 
involves professionals across the health and social care system working together 
collaboratively and much more closely with patients. Numerous studies highlight that 
pharmacists have the skills and experience to optimise medicines outcomes in different ways 
(Freeman et al. 2016). Therefore, it is logical that pharmacist is a core member of the 
integrated health and social multidisciplinary team providing patient centred and coordinated 
care for patients with long term conditions. This would ensure the required access to the rest 
of the multidisciplinary team and patient medical records as well as capacity, to execute the 
required strategies.   
 
The predominant focus of pharmacy roles is pharmacotherapy management in 
pharmaceutical care provision. Pharmacotherapy as described in chapter one, is a complex 
process, involving “players” from a multitude of different disciplines. These multidisciplinary 
players include doctors, nurses, pharmacists as well as social carers. Literature findings are 
like the participant views in describing that to maximize the outcomes of pharmacotherapy for 
patients with chronic disease, it is imperative that these multidisciplinary “players” interact as 
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part of a cohesive multidisciplinary team with mutual respect, trust, communication and 
collaboration. (Kassianos et al.2015; De Stampa et al.2014; Weiss, 2007; San Martín-
Rodríguez, 2005; Murphy, 2004). Other studies highlight that shared goals and values which 
are other factors suggested by the study participants are also crucial.(Freeman et al. 2016; 
Kassianos et al.2015; Weiss, 2007; San Martín-Rodríguez, 2005; Murphy, 2004).  
 
Both the literature and this study highlight inadequate understanding, respect and 
appreciation of the pharmacist role as a barrier. It can be argued that inadequate respect for 
the pharmacist role was shown by GP2’s comment that the IC pharmacists did not save GP 
time. This could be interpreted as signifying that in his perception, pharmacists are 
subordinates as opposed to partners to the GP. This is supported by a qualitative study that 
describe how GPs have professional hierarchical dominance over pharmacists because they 
have the power to “define the limits “of the pharmacist’s work (Hughes and McCann, 2003).  
A community pharmacy participant in the above study explained that pharmacist and GPs 
are not equal because despite their degrees, pharmacists must impotently wait for GP 
prescriptions to start their work. 
 
Elston & Holloway (2001) describe how conflict can be created amongst GPs, nurses and 
practice managers because of “professional identities” and “traditional power structures”. In 
the present study, IC Coordinator 2 alluded to this “power structure when she mentions how 
her job was made complicated by non-engagement of some GPs. However, as expressed 
by the participants in this research study, this barrier can be reduced by improving 
communication and increasing role awareness and appreciation.  
 
An inadequate understanding of the role is described in the study by Hughes and McCann 
(2003) in which a GP admits a lack of awareness of what the pharmacist training and 
continuing professional development entails. The GP in the study is of the impression that a 
significant percentage of pharmacy training is about sales of items like lipstick and cough 
linctus and that their knowledge is not necessarily updated. 
In similarity to the literature, most of the participants in the present study admitted having made 
the same assumptions when they were initially informed that an IC pharmacist would join the 
team. However, as shown by the findings, after the IC pharmacist showed them that they could 
optimise patient medication, their MDT colleagues became more aware and appreciative of 
them as team members.  
 
The IC pharmacists in this study took the decision to create and circulate an outline of their 
main role pathway (appendix one), soon after commencing the role. The pathway was 
 102 
consulted and agreed with the MDT before it was finalized. This strategy is like the strategy 
utilized by a team of Australian pharmacists integrating into a GP practice. The pharmacists 
in the study raised awareness, trust and respect of their role at the outset by scheduling 
individual meetings with MDT members during which they explained and discussed their job 
descriptions (Jorgensen et al. 2014). In addition, they provided the MDT colleagues with a 
copy of their job role summaries. Freeman et al (2016) in their study, also suggests how 
pharmacists can ensure that they can be utilized in patient centered roles without being 
viewed as being a threat. They achieved this by explaining how pharmacists could free up 
time they spend on medicines management so they could focus on their main roles. In 
another study, pharmacist integrating in a UK practice are advised to start by clarifying their 
role remit and priority with the GPs, making sure it matches their skillset (Jorgenson et al. 
2014). This was also suggested as a way forward by participants in this study. 
 
A unique aspect of the present research study is that the IC pharmacist had core 
membership and integration within health and social care MDTs instead of just integration 
within the GP practice, which is the case in many of the studies previously described.  
Therefore, the findings add to existing knowledge by describing how the IC pharmacist can 
work with a social support worker within an MDT setting to provide pharmaceutical care.  
This joint working between the IC pharmacist and coordinator is very important considering 
that the input of social support workers in domiciliary medication administration as well as 
error rates is up to 33% and increasing (Parand et al.2016). Actions suggested to reduce the 
rates are carer training, home medication checks, communication and deprescribing. The IC 
pharmacists in this study provided all of this as part of their role. 
 
 
Parand et al (2016) also highlighted that a significant number of the errors were made by 
informal carers who were relatives or friends.  Also, it is estimated that between three and 
five people will be carers sometime in their life in the United Kingdom. Furthermore, it is 
predicted that because of the aging population and drive to maintain care in the community, 
the percentage of carers will increase by 60%, during the next thirty years. This is relevant 
for this research because the findings highlight that patients suggested that carers should be 
considered as part of the MDT, which was not the case for the ELRCCG integrated care 
programme. Therefore, the available evidence research draws attention to the fact that the 
IC pharmacist role should potentially include medication related education and training for 
non-professional carers. Further research is recommended to inform the role of the IC 
pharmacist in supporting non-professional carers.  
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Theme 2: Accessibility and visibility 
All the participants explained how increased accessibility or visibility of the professional MDT 
members and the patients would make them more efficient and consequently improve patient 
outcomes of integrated care. IC Pharmacist 1 described how occasionally when she worked 
at one of her practices, she planned her lunch/tea breaks to coincide with that of the GP lead 
for integrated care. This increased mutual accessibility to discuss patient medication related 
queries for which she needed the GPs input to resolve. This action increased rapport and 
became their informal meeting time. Unfortunately, because IC pharmacist 1 only went to the 
practice maximum twice a week, this access route could not be maximized as she could have 
done if all the MDT members had been co-located at the GP practice.   
 
A similar approach was deployed by a team of Australian pharmacists to improve integration 
in the GP practice where they were employed (Jorgenson et al. 2013). They called the 
approach “strategic loitering” whereby they commandeered a workstation for themselves 
within or near a busy area of clinic such as the nursing station, instead of a private room tucked 
away. To make themselves even more visible and approachable, they also purposefully 
attended team meetings, ward rounds and even social events like lunches with other team 
members, regularly.  
 
The participants of this study also highlighted that accessibility and visibility would be 
improved by co-locating all the members of the MDT team at the GP surgery. The benefits of 
co-locating pharmacist in GP practices were published over two decades ago by Campbell 
and Saulie (1998) who highlighted in their United States of America based study, that 
pharmacists providing pharmaceutical care in a physician’s office removed or reduced a lot 
of the barriers to pharmaceutical care. This is supported by an Australian study that 
suggested that the irrelevance of pharmacists to patients was reduced when the pharmacist 
is employed by the practice. This international picture is mirrored in the UK where over the 
years, the numbers of practice based clinical pharmacists have increased as the role aim 
has shifted from prescribing budget rationalization to more patient centered outcomes. 
Currently, NHS England is working to fulfill its commitment made in the “General Practice 
Forward View” publication to fund over 1,300 clinical pharmacists based in GP practices by 
March 2019 (NHS England, 2014). Therefore, the number of pharmacists co-located in 
practices is rapidly growing.  
 
Co-locating the MDT at the GP practice also increases access to patients records which was 
mentioned as an issue if the GP receptionist who is usually the gate-keeper withheld access 
to the practice for the pharmacist or IC coordinator who were not based at the practice. Lack 
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of access is described by Freeman et al (2012) in their study including 58 participants in five 
focus groups aimed at seeking stakeholder’s opinions regarding integration of pharmacists in 
GP practice. A further advantage of co-location described in the literature and indirectly 
alluded to in the present study is the increase of tacit knowledge which is knowledge that is 
hard to transfer to the next person by spoken or written text (Goffin, 2011).  Personal contact 
and regular interaction that would happen if the IC pharmacist was based in the practice for 
example is required to transmit tacit knowledge which would in turn improve rapport. 
 
To conclude, there are several studies supporting the findings from the present research that 
explain why and how pharmacists in working in GP practices (including IC pharmacists and 
the new clinical pharmacists in the NHS England scheme), could increase their integration 
within the MDT and the GP practice. Therefore, in future pharmacists should increase 
accessibility and visibility by being innovative, proactive and purposeful. 
 
Theme 3: Resources and enablers  
The study findings bring to light or underline in some cases, several resources and enablers 
that the participants emphasize would enable and facilitate sustainability of the role. The 
resources include funding and information technology (IT). These resources would enable the 
facilitators required to sustain the role as recommended by the participants. These facilitators 
include training, liaising with community pharmacy, re-positioning the pharmacist in the 
pathway and co-located, fully integrated and resourced GP hub pharmacy team, in addition, 
teamwork, accessibility and visibility would be enhanced through co-location as described 
above. 
 
The literature highlights several barriers that will be eradicated by these resources and 
enablers including funding shortage, administration, inter-professional divisions, perverse 
financial incentives, and inadequate access to patient records (DH et al 2017).  These 
individual resources and enablers are discussed below individually  
 
Funding  
The importance of funding is supported by other research that concluded that lack of 
guaranteed and continuous funding for the integration of pharmacist is the biggest barrier to 
realization of this important goal (Tan et al. 2014; Freeman et al. 2012). The quantitative data 
also supported how funding is key, as evident from the fact that the first key performance 
indicator(KPI) to convince the sponsor which was East Leicestershire and Rutland CCG (ELR 
CCG), was the confirmation of significant savings i.e. a return on investment of minimum two.  
The study findings pointed out that to sustain the role, minimum one IC pharmacist per GP 
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hub was required. Therefore, 12 pharmacists in total would be essential for ELR CCG. It was 
estimated that the minimum required funding to employ 12 pharmacists would be £491,568 
(£40.964 x 12 hubs) per year. This is a significant cost and it was therefore crucial to ensure 
the maximum role performance by delivering the other key facilitators emphasized by the 
stakeholders. Furthermore, it was important to convince the sponsors of why allocating 
£491,568 to IC pharmacist roles should be prioritised over other conflicting priorities. In line 
with the action research methodology, the sponsor procedure was followed and a 
comprehensive business case including details of the other facilitators described below was 
completed and presented to the sponsor funding committee.  
 
Information Technology 
Another important enabler suggested by all stakeholders is information technology such as 
access to medical records, email, and direct phone numbers for the IC pharmacists and 
coordinators. It was explained that more IT would improve communication which will in turn 
support teamwork. Access to medical records is mentioned in the literature as one of the 
barriers to community pharmacists getting more involved in clinical roles requiring access to 
patient notes (Blenkinsopp, 2012). Another important IT tool mentioned as important by the 
participants is the “tasking” functionality on the GP IT systems which they used as it facilitated 
and expedited communication resulting in more timely resolution of outstanding queries. This 
research is the first published study to advocate the use of this enabler to improve the 
effectiveness of a health and social integrated care team. 
 
Community Pharmacy  
The involvement of community pharmacists in IC was suggested as a possible enabler by 
the pharmacists. This aligns with recommendations in the literature (Jorgenson, 2013) 
explaining how liaising with the community pharmacist would improve communication and 
uptake of existing community pharmacy services like the New Medicines Service which 
could improve adherence (Elliott et al. 2008,). More liaison would support the current shift 
from the traditional product oriented focus to a patient-centered focus for community 
pharmacy. Furthermore, community pharmacist is the specified role in one of the few 
national publications that specifically recommends a pharmacist in integrated care. (NICE, 
2015).  
 
However, the degree of integration possible is limited by the digital isolation of community 
pharmacists which results in limited access to patient medical records and other care 
professionals (Blenkinsopp et al. 2012). It was also acknowledged following discussion 
during the focus group that because most GP practice populations were served by 
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numerous pharmacies, it would be impractical for all these pharmacists to attend MDTs and 
be fully involved. Another reason for their restricted access to the MDT is partly because 
community pharmacists are generally not considered as a core part of the primary care team 
(Hughes and McCann, 2003). A compromise suggested by the IC pharmacists is that 
community pharmacists could be commissioned to provide domiciliary medicines reviews 
and other functions if IT access could be facilitated. This was also taken forward for 
discussions. 
 
Training  
Training for the pharmacist team was also mentioned by both GPs as a facilitator for the 
role. They explained that primary care training would be beneficial as well as ongoing 
continual development support like the quarterly sessions organized by the CCG for all other 
health professionals. This is supported by literature highlighting that pharmacist providing 
clinical roles as part of integrated GP practice teams need an understanding of primary care 
and an appreciation of the other roles and challenges they face. They also need to be 
assertive and proactive (Ackerman et al.2010).  
 
Re-positioning the IC pharmacist input in the pathway 
It was highlighted by the several participants that it would be useful to change the integrated 
care pharmacist role pathway to ensure that the pharmacist reviewed patient notes jointly 
with the coordinator and GP before completing the medicines review. The IC pharmacists, 
coordinators and GP1 all thought that this would save time and prevent queries down the 
line. This practical suggestion is an exclusive contribution of this study because current 
published studies regarding the IC pharmacist or similar roles do not mention this.  
 
Transforming IC pharmacist role into GP hub clinical pharmacist role supported by pharmacy 
technician  
Following discussions by the stakeholders regarding how best to mitigate the funding barrier 
whilst progressing the other facilitators, it was agreed that the most practical and affordable 
course of action at the time would be to assimilate the IC pharmacist role functions within a 
clinical GP pharmacist hub role. The role would be full time and embedded within the 
practice. This had been recommended by the participants as an option, if the other 
supporting facilitators could be guaranteed. These other relevant facilitators included 
sufficient capacity, co-location of the MDT and integration within the GP practice and 
creating the role of a support pharmacist technician.  
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The role function of pharmacy technicians in clinical pharmacy is outlined by Boughen et al 
(2017) as including domiciliary medicines reviews, and medicines management in care 
homes. Other relevant non-clinical advanced tasks mentioned are complaints management 
and training and development support. Although most of the current evidence for this clinical 
pharmacy technician role is in secondary care, it is being extrapolated to primary care.  
 
It was suggested by the IC pharmacists that a pharmacist and technician working as a team 
full time and supported by administrators would ensure capacity to deliver both the patient –
centred and integrated care MDT directed role functions of pharmacists. Patient directed roles 
include clinical medicines and deprescribing reviews, including domiciliary, medicines 
reconciliation.  MDT directed functions are MDT meeting input, training and education. 
Furthermore, if supported by the other facilitators it was mentioned that the “hub” team could 
also fulfil some of the practice/practice system directed functions. Practice/practice system 
directed functions are auditing and cost-effective switches, managing repeat prescriptions to 
reduce waste and developing formularies. It was cautioned during the focus group that this 
role transformation could dilute the IC pharmacist role delivery. However, following a 
discussion regarding the issue it was concluded that all the tasks could be delivered if the 
teams had sufficient capacity for the patient population. Furthermore, it was highlighted that 
as an embedded team with routines and processes, several of the function would be set up 
and just require maintenance.  
 
Consequently, following stakeholder reflection, six months after the start of the study, the 
decision was taken to transform the IC pharmacist role to a full-time GP hub clinical pharmacist 
role, working in a team with a support technician at month nine. The stakeholders were 
convinced that this would represent a practical culmination of all the resources and enablers 
suggested above. It was also considered that transforming the role would provide more 
alignment to national plans, to promote more clinical pharmacists in general practice to fulfil 
similar functions as a major solution to help resolve the GP shortage in the UK as outlined in 
the NHS five years forward view (NHS,2014). In similarity to the proposed hub clinical 
pharmacist role, the emerging clinical pharmacist in GP practice is also a further evolution of 
the primary care pharmacist role. Both roles are partly derived from the practice pharmacist 
role which had in turn developed from the pharmaceutical advisor role as illustrated in figure 
5.1 below.  
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Figure 5.1: Evolution of the GP hub clinical pharmacist role 
 
  
 
This proposal for the GP hub pharmacy team called the GP hub medicines quality team was 
thus progressed in two phases: 
 
Phase 1 
 Four teams commenced the new roles as a 12-month pilot. Each team was assigned to 
a GP hub, supported by practice administrative staff. The teams were employed by the 
ELR CCG and seconded and embedded as part of the GP practice team. The role remit 
was the delivery of patient, MDT and practice directed functions as described above and 
in appendix 12. The job outline of the hub pharmacy team emphasised that the 
integrated care role function should be a role priority. To fulfil these role functions, the 
GP hub pharmacist role should therefore be a core member of the practice social and 
health integrated MDT to ensure holistic patient –centered care. The pharmacist and 
technician team would be based at the GP practice as recommended by the study, 
instead of the IC office. Although it was acknowledged that mutual visibility and 
accessibility to the IC Coordinators would diminish, the overall benefits would be better. 
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Furthermore, the long-term plans were to co-locate the IC coordinator at the GP practice 
eventually. 
 The pilot evaluation after the 12 months (appendix 13) provided key recommendations 
that informed stage 2. The two most important recommendations were that more 
capacity was required and practice ownership and acceptance of the team was required.  
 
Phase 2  
 Informed by the evaluation results of phase 1, a business case highlighting the need for 
more capacity was submitted to ELR CCG. Funding was requested for one full time 
pharmacist and technician per practice focusing predominantly on patient and MDT 
functions. The business case was approved with some caveats for implementation. This 
included practices working together in hubs to pool resources and enable bigger 
pharmacy teams. Furthermore, to increase practice ownership, the funding was given to 
each practice to use exclusively to employ the pharmacist and technician. Each team 
would be provided administrative support by the practice administrative staff who also 
received medication training provided by the CCG  
Practices were also encouraged to contribute funding to employ more pharmacist and 
technicians and to bid for NHS England funding for more clinical pharmacists to join the 
team. 
However, a key deviation from the business case was that the teams were requested to 
also prioritize the practice /practice system functions due to external pressures to make 
financial savings to help bridge the national NHS funding deficit. 
 The teams were also supported through the provision of mandatory quarterly continual 
professional development training funded by the CCG. 
The first training session included a joined presentation by the main researcher and the 
integrated care team lead highlighting the interim results of the study and the importance 
of prioritizing the integrated care role functions. They were also given the contact details 
of their IC coordinators to set up a meeting. A similar presentation was delivered to all 
the CCG prescribers at their session which was planned on the same day. 
 
Although phase 2 has not been formally evaluated, literature reports support the 
recommendations for more capacity, for example aligning with the NHS England scheme, to 
get a bigger team to optimise outcomes. Helmsley (2017) describe a model of a team of six 
pharmacists, three senior pharmacy technicians and eight administrative medicines 
management operators working in a GP practice hub in Lancashire. Two pharmacists out of 
the six are funded as part of the NHS England scheme.  Also in support of more funding for 
a dedicated role is an integrated care pharmacist scheme based in London that bares 
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similarity to the IC pharmacist role in this research. (NICE 2016). This model describes how 
the initial part time post was doubled to a dedicated full time post which was further 
increased to 1.5 whole time equivalent. The evaluation highlights the need for senior 
pharmacist supervisory support. The NHS England clinical pharmacist in GP surgery 
scheme also specifies a senior pharmacist as part of the team, supporting the more junior 
team. The literature also describes a model of vertical integrated care across primary and 
secondary care, including a fully embedded pharmacy team working across both sectors 
(Baqir, 2018). This is however in its infancy and neither adequately described, evaluated or 
researched. Furthermore, a vertical integration model is not currently developed in 
Leicestershire. Therefore, there is no supporting framework for any integrated care 
pharmacy role functions. However, it is recommended that this model which theoretically 
represents complete integration should be considered for the future. 
SUBMIT 
Following the above review of the findings from the ELR pilot scheme alongside models in 
the literature, a new model which brings together all this element is suggested as a pilot for 
action based research in the short to medium term. The recommended model would include 
a dedicated specialist integrated care pharmacist role embedded within and supported by a 
GP hub pharmacy team with other pharmacists and technicians like the minimum capacity of 
one whole time equivalent pharmacist and technician per 30,000 population (Duggan et al. 
2017).  The action research will inform local practitioners to enable a decision regarding 
which model of integrated pharmaceutical care would be the most suitable to meet the 
requirements of the local population.  
 
Theme 4: Reflection on Integrated Care Pharmacist role functions 
This study found that the predominant role of the IC pharmacists was to provide 
pharmaceutical care to IC patients and medicines related information, training and support to 
all health and social multidisciplinary team members. The participant experiences and 
perceptions confirmed that the IC pharmacist provides pharmaceutical care by completing 
distinct role functions. These functions included clinical medicines and deprescribing 
reviews, medicines reconciliation, medicines information and adherence support. Both 
patients highlighted how useful they found the medication record card the IC pharmacist 
completed for them. However, it was apparent that two of the stakeholders who were less 
integrated with the MDT (General practitioner 2 and the community nurse) required more 
time to be convinced that the role of the IC pharmacist could fulfil these functions.  
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Although the types and degrees of integration are different, the discoveries from this study 
reflect the role of the integrated care pharmacist that has been documented in the literature. 
A meta-analysis of 38 studies showed positive results for both primary outcome as well as 
clinical markers measures related to LTC management and quality use of medicines (Tan et 
al 2014), for pharmacists co-located and integrated in general practice delivering a variety of 
interventions. Furthermore, the IC pharmacist role outcomes as shown by the evaluation KPI 
support the increasing acknowledgement that pharmacotherapy outcomes can be optimized 
by pharmacists as medicines experts, working within integrated health and social 
multidisciplinary teams, in new roles (Daloni et al 2016, Freeman et al 2016, Stone and 
Williams 2015).  
The evidence also supports the strategies/approaches mentioned by the participants which 
were utilized by the pharmacist to perform the roles. These include medication reviews, 
medicines reconciliation, patient counselling, and increased communication, education of 
stakeholders, process optimisation and risk management (2010 Barber et al. 2009). As 
discussed in chapter one , although medication reviews have been shown to lead to a 
reduction in polypharmacy and an increase in the use of more appropriate medicines 
formulation and choice, robust evidence of admissions avoidance and cost savings have 
only been demonstrated with medicines reconciliation  (Mekonnen et al. 2016; Blenkinsopp, 
2012, Holland et al. 2007).  
 
In their meta- analysis to ascertain whether pharmacist –led medication review which had 
only been shown to improve prescribing outcomes also reduced hospital admissions and 
deaths in older people, Holland et al (2007) searched 11 electronic databases. The inclusion 
criteria included randomized controlled trials in any setting, of patients over 60 years, with 
the aim of improving drug regimens and patient outcomes. They concluded that pharmacist-
led medication reviews neither reduced mortality nor hospital admission in older people. The 
limitations of the study however included the fact that only 17 of the 32 studies provided data 
on the primary outcome of hospital admissions and some did not include numerical data 
despite reporting that no difference was observed. Furthermore, only a small proportion of 
studies fulfilled all the quality criteria which raises the question of whether some of the 
studies may have been susceptible to bias. A very relevant limitation for this study is the fact 
that studies designed to improve knowledge and adherence were not evaluated although 
these might have a considerable qualitative impact on older patients, and it would be best to 
use qualitative methods to evaluate them. This study findings have shown that stakeholders 
hold the view the medication reviews indirectly prevent hospital admissions.  
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The Blenkinsopp (2012) literature review discussed in chapter one had similar findings to the 
existing published literature. However, the publication did not include the number and 
inclusion criteria of studies reviewed. The publication recommended multi-professional 
involvement in clinical medication reviews which is very relevant to this study which has 
shown that stakeholders believe that the IC who worked as part of an integrated MDT, 
improved patient outcomes. 
 
The pharmacists in this study highlighted that clinical medication reviews could be completed 
at scheduled IC pharmacist drop- in clinics whereby patients would bring their medication for 
clinical medication review by the pharmacist. Patients unable to attend would get domiciliary 
reviews. There are a few literature citations of positive outcomes from medication reviews for 
example the Guys and St Thomas scheme reporting 207 medication reviews and identifying 
467 medicines related problems (2.3 problems per patient).  
 
Medicines reconciliation is a form of medication review which as mentioned in chapter one, 
has been shown to prevent harm and medication errors by both primary and secondary care 
prescribers (CQC 2009). A recent systematic review and meta-analysis to reduce hospital 
admissions (Mekonnen et al, 2016) provided evidence for a reduction in hospital admissions, 
which has been hard to find for other forms of medication review. Mekonnen et al (2016) 
involved 21,342 patients across 17 studies, eight of which were randomized, as part of their 
meta-analysis. The results were a substantial reduction of 67%, 28% and 19% in adverse 
drug event-related hospital revisits (RR 0.33; 95% CI 0.20 to 0.53), emergency department 
(ED) visits (RR 0.72; 95% CI 0.57 to 0.92) and hospital readmissions (RR 0.81; 95% CI 0.70 
to 0.95) in the intervention group than in the usual care group, respectively. There was no 
statistically significant difference following the subgroup analysis. There were two key 
limitations to the study. Firstly, some of the outcomes evaluated showed a huge difference in 
the statistics which could not be explained. Secondly non-controlled studies were also 
included which could have increased the overall bias. Medicines reconciliation was one of 
the main roles of the IC pharmacist that contributed the positive outcomes. 
  
In addition, there is de-prescribing which is a process by which unnecessary drugs identified 
using some validated criteria such as Beers (American Geriatric Society,2012) or 
STOPP/START are considered for discontinuation in agreement with the patient. The 
benefits of deprescribing have been described in a study of 70 older patients prescribed on 
average 7.7 drugs of which 58% were discontinued, with an 81% success rate, no long term 
adverse effects as well as approximately 90% health improvement (York Health Economics 
Consortium, 2010). It is recommended that patients at increased risk of polypharmacy like 
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integrated care patients should have a medication review regularly with a view to stop 
medication which is no longer appropriate Burge et al (2012).  
 
Medicines related training and education for those involved in medicines prescribing and 
administration was reported to have bene very useful by the participants. This is supported 
by the literature highlighting that administration errors for home medication made by carers 
could be a severe patient safety problem (Parand et al.2016). They found that the errors 
made are like those in other settings and recommend that the domiciliary setting should be 
prioritized for developing interventions such as training, to patient safety.  
 
 A supporting study is the Care Home Use of Medicines Study (CHUMs) which showed that 
69.5% of care home residents had one or more medication errors (Barber et al. 2009). The 
main causes of harm caused by medication as shown by the study were prescribing, 
monitoring, administration and dispensing. Relevant factors for this research shown to 
contribute to the harm mentioned above in the CHUMS study were: high workload of staff, 
insufficient medicines training; absence of team work among staff, practice and pharmacy; 
disorganized ordering systems; incorrect medicine records and preference for verbal 
communication; and challenges with filling and checking medication administration systems. 
Although error rates were not measured in this study, the findings show that knowledge of 
MDT staff, some of whom would administer home medication increased.  
 
Additionally, a major implication of the changes in the NHS regarding handing over 
responsibility for social funding for the frail to the social system is that the roles of community 
social carers has expanded significantly as they inherit the traditional duties of district nurses 
for patients not eligible for NHS health funding. Amongst these inherited duties, are certain 
aspects of medicines management. To ensure safety, training, team work and support is 
required.  As a result, pharmacist and social carers work increasingly in collaboration to 
support patients. The nature of the collaboration is evolving with the change in responsibilities 
devolved to the social carers and the pharmacist. Part of the training provided by the integrated 
care pharmacist covered the importance of robust communication and documentation, 
checking for incomplete or incorrect information on discharge letters, checking and recording 
allergy status, checking for incorrectly prescribed or dispensed drug, strength or frequency. 
This study findings showed that most of the MDT stressed that this role function is important 
to take forward. 
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Another study highlighting the benefits of the provision of medicines related education, is 
PINCER which was shown to contribute significantly to reduce medication errors in GP 
practices (Avery et al.2012). It was a large cluster randomized partially blinded study 
whereby practices were allocated to either a simple feedback which was computer-
generated for at-risk patients (control) or a pharmacist-led information technology 
intervention (PINCER), composed of feedback, educational outreach, and dedicated 
support. The primary outcome of the study was the percentage of patients who had had any 
of three clinically important errors at 6 months after the intervention. The clinically important 
errors were: non-selective non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to 
patients with a history of peptic ulcer without co-prescription of a proton-pump inhibitor; β 
blockers prescribed to patients with a history of asthma and patients prescribed long-term 
angiotensin converting enzyme (ACE) inhibitor or loop diuretics to patients 75 years or older 
without assessing their urea and electrolytes in the preceding 15 months. 72 general 
practices with a total of 480,942 patients were randomized. At the six months' follow-up, the 
patients in the PINCER arm were significantly less likely to have been prescribed a non-
selective NSAID if they had a history of peptic ulcer without gastro protection (OR 0·58, 95% 
CI 0·38–0·89); a β blocker if they had asthma (0·73, 0·58–0·91); or an ACE inhibitor or loop 
diuretic without appropriate monitoring (0·51, 0·34–0·78).  
 
The main strengths of PINCER include the sample size and random allocation which makes 
it generalizable. Bias was reduced by the partial blinding and computer allocation. 
Furthermore, the outcomes were clinically relevant outcomes and tested. It is also possible 
that the overall effect could have been underestimated because the feedback used for the 
control practices is actually superior to the standard. However, PINCER had some 
limitations: there was some variation between the practices and those that signed up were 
likely to be training practices; the study was only powered for an assessment at 6 months 
and the PINCER outcome of medication error was a surrogate marker for adverse drug 
reaction. Finally although it has been shown to be effective in behavior altering (Thompson 
et al.2000), the cost-effectiveness of the educational outreach used has not been evaluated. 
 
Educational outreach, is similar to the training method used by the IC pharmacist and the 
findings of this study highlight that this was also effective. 
 
Although all these studies are useful in confirming some of the study findings regarding the 
role, none of them contain any detail of what the IC pharmacist role entails and how it is 
delivered, as perceived and experienced by a wide range of key stakeholders. (NHS, 2015; 
Rand et al. 2012). Consequently, this study makes a significant contribution to existing 
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knowledge by detailing what the stakeholders including patients, perceive as the important 
role function are and how they are delivered.  
 
Furthermore, unlike the other published studies and schemes, this study shows how the 
integrated care pharmacist can work in an MDT with a social care support worker as 
coordinator to achieve outcomes. Furthermore, the pharmacists shared an office with the 
social support workers /coordinators for and developed a close relationship with them. In 
addition, they supported them with training provision, discussing each patient before visit 
and providing summary cards and a reactive query answering. This liaison with the social 
coordinator is important for three fundamental reasons: It is becoming increasingly evident 
that multidisciplinary collaboration is required for pharmacotherapy to be fully effective; 
patients are living longer and requiring more health (including medication) and social care 
services and consequently the need for medication is rising.  
 
Statistics show that almost every individual who is 65 years old and above requiring social 
carer support with their daily living activities is taking at least one prescribed medicine (DH 
2012). Increasingly social carers are routinely tasked with the administration and delivery of 
medication to support these patients. Studies have shown that pharmacists can support 
social carers to improve the safety of these tasks (Barber, 2009). 
Therefore, practitioners tasked with planning integrated care schemes, should consider the 
importance of including pharmacists as a core members of the integrated care MDTs. They 
should also plan regular medication training and support sessions for the MDT especially the 
social support workers and nurses. 
 
Theme 5: Impact of Integrated Care Pharmacist within multidisciplinary team 
There was a consensus among the stakeholders that the impact of the IC pharmacist role was 
predominantly positive. Their input increased patient and multidisciplinary team (MDT) 
satisfaction and empowerment, increased medication safety, financial savings, bridge building 
and time saving. Finally, the participants reported that the pharmacist performance against 
the outcomes was excellent. This was supported by the quantitative data, although the data 
should be confirmed in a larger study utilizing more direct indicators. 
 
Both patients described how the medication review and receipt of the medication record cards 
(Appendix 3), alongside an explanation of their medication, empowered and enabled them to 
improve the way they took their medication. This shows that patients recognize that 
pharmacists working in integrated MDTs can have a positive impact on their adherence and 
outcome. This finding is consistent with Bell et al (2007) highlighting how adherence is more 
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desirable than compliance because it includes active discussion, giving the patient the 
freedom to make choices. Adherence is described as the ‘extent to which the patient’s 
behavior matches agreed recommendations from the prescriber’ (Horne et al. 2005). The 
patients in this study, following active discussions with the IC pharmacist wrote down and 
followed the prescribers’ recommendations. The patient’s feedback that the medication record 
cards empowered them, is in line with findings from Smith et al (1997) demonstrating that 
patients like to receive written information regarding their medication. 
 
In addition, the nurse and integrated care coordinators emphasized that the medication 
summary information handouts the pharmacist produced for them as aid memoires, 
significant empowered them to have discussions with patients. These discussions as 
explained by Bell et al (2007) could improve adherence. To further illustrate this positive 
impact of the IC pharmacist, the IC coordinators all had examples of how patient harm was 
reduced and adherence improved following the pharmacist input. 
 
 An additional dimension regarding the extent of the pharmacist’s impact was mentioned by 
GP1 who stated that the actual outcomes achieved by the pharmacist’s input was 
significantly more than could be recorded. He explained that this was because of the 
snowball effect of changing practice forever after education by the pharmacist on a specific 
area pharmacist.  
 
The above positive experiences are supported by a published study that showed that 
pharmacists integrated in GP practices providing pharmaceutical care improved outcomes 
such as reduced medicines problems, more timely outcomes, reduced polypharmacy and 
increased adherence, (Freeman et al. 2014). Several other studies have shown that 
pharmacists are integral in ensuring safe, clinically effective and cost- effective use of 
medicine (Jorgenson et al. 2013; Duerden, 2013; Avery et al. 2012; Blenkinsopp et al.2012; 
Dennis et al. 2009). However, none of these studies include the views and experiences of 
non-pharmacist or GP stakeholders such as patients, nurses and social support workers.  
Therefore, this study also contributes the perspective of these other stakeholders. 
 
A distinctive additional knowledge from this study which is not mentioned in any of the 
published literature is the fact that that the IC pharmacist’s presence at MDT meeting 
bridged the gap between health and social. The IC coordinator elucidated how the usual 
“them and us” disappeared when the pharmacist was present. There is a lot in the literature 
describing how the “berlin wall” and turf wars between health and social is compromising 
patient care (Clements, 2010). The fictitious patient cases described in chapter one further 
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illustrate how this can affect the outcome of pharmaceutical care. This study shows how the 
pharmacist’s impact goes beyond the pharmaceutical to enable other wider goals of 
integrated care. 
 
Theme 6: Evaluating the performance of Integrated Care Pharmacist role 
The participants recommended that the role should be evaluated predominantly using 
patient feedback, supported by MDT opinion and patient outcome measures. The 
quantitative findings indicated that key performance indicators could be used to support 
short term and local evaluation of the role.  
 
All participants held the view that the outcomes contributed by the integrated care 
pharmacist should be measured by utilizing patient feedback. Additionally, MDT feedback, 
monitoring patient improvement as well as using KPIs such as cost savings and GP time 
saved. The KPIs used for this research, were also suggested as tools to measure outcomes. 
However, although the KPIs used are suitable for small action research, bigger interventions 
would require outcome measures with more rigor for quantitative research. 
 
Existing literature describe some results which are partially consistent with this study 
findings. Deeks et al (2018) for example, estimates that dependent on the exact role 
function, 37.4 hours per month of GP time could be estimated as saves by a pharmacist 
working 37.5 hours per week. Several participants in this study went further and emphasized 
that the real positive impact of the IC Pharmacist is under-measured because their input 
results in a permanent positive change in the professionals practice preventing numerous 
subsequent patient harm. 
The study findings also aligned with the debate regarding why pharmacist input is measured 
by these matrices whilst the input of other care professional colleagues e.g. nurses, GPs, 
social carers are not. Further research including more pharmacist and patient input 
regarding how to measure the outcomes, would help clarify this debate. 
 
This research provides a successful methodology of quantifying of the pharmacist input to 
reduce hospital admissions in addition to the medication cost which is usually the only 
savings calculation in pharmacy practice. Of importance is the fact that admissions 
avoidance from pharmacist input was calculated, presented and accepted by 
commissioners. This enabled significant transformation and sustainability of the role 
because without assurance of a return on investment, the pilot would probably have failed 
the evaluation considering the cost pressures on commissioning groups. This is significant 
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considering that interim reviews of national pilots that do not include an outcome for 
pharmacist and thus not very useful to inform pharmacist role planning 
 
This methodology could be utilized by pharmacist to strengthen their arguments in written 
funding request reports regarding potential or actual outcomes of their practice research, 
making their rationale more robust and convincing to commissioners.  
However, further quantitative research is recommended to triangulate the findings and 
support and promote change in practice. 
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Chapter 6: Conclusion  
 
Introduction  
The primary aim of this study was to understand and inform the new role of the IC 
pharmacist and how to develop and sustain it. Qualitative and quantitative methods were 
utilized within a variant of action research design called participatory mixed method 
research. The former utilized interviews and a focus group to produce data which culminated 
into six main themes following analysis. The later was secondary analysis of KPI data 
routinely documented by the IC pharmacist for sponsor pilot evaluation. The individual 
findings of the mixed methods achieved complemented each other to fully answer the five 
research questions as summarised on the table below. 
 
 The role of the IC pharmacist as informed by this research, is to provide pharmaceutical 
care to the integrated care patient cohort as well as medicines related information, training 
and support to all health and social multidisciplinary team members. The IC pharmacist 
provides pharmaceutical care predominantly by completing clinical (level 3) medication and 
de-prescribing reviews, medicines reconciliation, medicines information and adherence 
support tools such as medication record cards and summary sheets. The provision of these 
role functions results in increased patient and multidisciplinary team (MDT) satisfaction and 
empowerment, increased medication safety, financial savings, bridge building and time 
saving.  
 
Additionally, key resources and enablers to increase performance and therefore 
sustainability of the role were identified by the participants. These include funding, 
information technology, effective teamwork, increased visibility and accessibility and training, 
pharmacy technician support and transforming the role into the GP hub clinical pharmacist 
role. A key enabler constructed from the study finding and current literature to make the job 
role more sustainable was to embed the role function within a new model of a GP hub 
pharmacy (also called medicines quality) team. Furthermore, it was recommended that the 
role should be evaluated predominantly using patient feedback, supported by and MDT 
opinion and patient outcomes. Further to this, participants reported that the pharmacist 
performance against the outcomes was excellent. These qualitative findings were supported 
by quantitative data collected as key performance indicators which could also be used to 
support short term local evaluation of the role. 
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6.1 CONTRIBUTION TO KNOWLEDGE   
This study made some new significant additions to knowledge regarding the role of the IC 
Pharmacist. Firstly, this integrated care pharmacist pilot unlike other published research of 
integrated care, provides a description of what the IC Pharmacist role is and how it is 
delivered, as perceived by non-pharmacist or GP stakeholders, including patients and social 
community support workers (NHS, 2015; Rand et al. 2012). The study findings elucidate 
exactly what role functions the participants thought were important and explained why they 
had that believe. Additionally, they described the positive impact of these roles, based on 
their experience and how these could be evaluated and sustained. The second addition is 
knowledge of how the integrated care pharmacist could work with a social care support 
worker within a multidisciplinary team to provide support to optimise patient care. The third 
contribution is the findings that the medication record cards and medication summary cards 
significantly empower IC patients and professionals respectively. Fourthly, a locally “tried 
and tested” methodology to enable quantification of hospital admissions avoidance savings 
resulting from the role of the IC Pharmacist has been made available. This could be used to 
supplement the medication cost savings which is the predominant cost savings calculated in 
pharmacy practice. Including an estimated figure for the IC Pharmacists’ input to admissions 
avoidance in the business case to the commissioners, enabled funding that led to significant 
transformation and sustainability of the integrated pharmaceutical care in East Leicestershire 
and Rutland. The fifth contribution is the bridge building effect that the IC pharmacist 
inadvertently had on the “berlin wall “between health and social which existed within the 
MDTs. This is beneficial for the delivery of the wider integrated care goals. The final 
additional contribution to knowledge is how the recommended priority role functions could be 
delivered within other IC models or programmes, if the other enablers are guaranteed.  
 
In overall conclusion, in line with action research, action was achieved ultimately by 
transforming and expanding two IC Pharmacist roles to twelve teams of pharmacists and 
pharmacist technicians, based at and embedded into a wider GP team providing holistic 
integrated health and social pharmaceutical services to all patients in East Leicestershire 
and Rutland as part of a model that continues to be evaluated and updated as required. 
Furthermore, additional knowledge was contributed by bringing to light the views and 
experiences  of non – GP or pharmacist members of health and social intergrated 
multidsiciplinary teams especially those of patients, regarding what exactly the IC 
Pharmacist role is, how it is delivered, what outcomes it delivers and how the role functions 
can be evaluated and adapted to increase sustainability.  
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6.2 RECOMMENDATIONS FOR FUTURE RESEARCH  
This study represents a starting point that should be used to explore this developing role of 
the IC Pharmacist. The following is recommended as work that could be developed to inform 
the future. 
1) Qualitative research to Inform the ongoing roles of the GP hub clinical pharmacist and 
pharmacy technician, which were derived from the IC Pharmacist role. Research is 
required to inform these two new roles and how to further develop the model overall. 
 
2) Action based research of a pilot of a model of a dedicated IC Pharmacist role, 
integrated within and supported by a GP hub pharmacy team including pharmacists 
and technicians. This model has been described in the literature and would align with 
the ongoing NHS England scheme to increase the number of clinical pharmacists in 
general practice. The proposed model would be like that of other allied professional 
roles that make up multidisciplinary teams of the NHS integrated care programme. 
The action research would inform how to develop a local version of this literature 
acclaimed model. 
 
3) Comparative research to ascertain which of the two models (GP hub pharmacy team 
delivering the functions of the IC pharmacist role or dedicated IC Pharmacist role 
embedded) is more effective at achieving the goals of integrated care. 
 
4) Exploratory local research to inform how to deliver integrated pharmaceutical care as 
part of vertical (across primary and secondary care) integrated care programmes. 
 
These will inform and support local practitioners in deciding which of the different models 
would be the most suitable to meet the pharmaceutical and wider requirements of the local 
population.  
 
Word count: 41,444 
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Appendix 1: Outline of pathway of Integrated Care Pharmacist’s key role  
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Appendix 2: Template of integrated care pharmaceutical care plan  
Pharmacist Medication Review Record & Plan (Pharmaceutical Care Plan) 
Name and NHS 
Number 
xxx GP Practice xxx 
Address xxx Pharmacist 
Completing 
Review 
xxx 
Community 
Pharmacist Address 
xxx Date of Review  
Current Medical 
Problems 
 
Recent Monitoring  
(U+Es, LFTs, 
Lipids, BP etc) 
 
Known 
allergies/sensitivitie
s/contra-indications 
 
 
Medication 
Medicine 
 
Dose and 
frequency 
Understanding of 
medicine purpose 
Problems experienced 
    
    
    
    
    
    
    
    
    
* These tablets are no longer prescribed 
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Comments 
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Patient Understanding of Medicines 
Question Y/N Comments 
Do you take all the medicines listed?   
Do you administer your medicines yourself or does 
someone help or prompt you? 
  
Do you know what each medicine is for?   
Are you taking any other medicines not prescribed by 
your doctor? E.g. OTC medicines or herbal remedies. 
  
Are you taking any medicines prescribed and supplied 
by the hospital? 
  
Where do you keep your medicines in the home?   
Do you have a green bag?                                              
(supply one with an explanation if the patient does not 
have one) 
  
Do you have any medicine in the home that you no 
longer use?                                                                
(medicines that have been stopped or that the patient 
could not tolerate) 
  
Do you have too many of some medicines and not 
enough of others?                                                   
(synchronise medicines where possible) 
  
Do you have any specific concerns about your 
medicines? 
  
 
Additional comments 
(Are there any signs/symptoms which need to be brought to the attention of the GP?) 
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Access Issues 
How do you order and collect prescriptions?  
Do you remember to order your medicines?  
Have you recently run out of any medicines?  
Do you order all of your medicines together or at 
different times? 
 
Do you use a regular pharmacy for all your 
prescriptions? 
 
How do you order and collect your prescriptions 
from the surgery? 
 
Does the pharmacy order your prescriptions for 
you? (record detail of how this works) 
 
Do you collect your medicines from the pharmacy 
or are they collected by someone else? 
 
Does your pharmacist deliver your medicines?  
 
 Comments 
 
 
 
 
Actions required                           Y/N Intervention 
Score 
Actions required                                Y/N Intervention 
Score 
Prescription ordering 
service? 
  Prescription delivery 
service? 
  
Prescription collection 
service? 
  Prescription 
synchronisation? 
  
Other (specify)? 
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Physical Issues 
Can you read all the labels on your medicines?  
Can you open the containers?  
Can you push tablets or capsules out of blister 
packs, pick up small tablets, halve tablets? 
 
Can you measure liquid medicines?  
Can you use eye drops and inhalers correctly? 
(demonstrate) 
 
Can you swallow your medicines without 
difficulty? 
 
 
 
Compliance Aids 
Do you ever forget to take your medicine?  
What methods do you use to help you remember 
to take your medicines? 
 
Does anyone help you to take your medicines? 
Who? 
 
Does the person who helps you with your 
medicines remind you to take it? Or actually give 
it to you? 
 
Is the person who helps you available every day? 
(Evenings and weekends covered?) 
 
Do you have a compliance aid already? What type 
is it and who fills it? 
 
Who initiated use of the compliance aid?  
Check state of compliance aid (clean, labelled 
etc?) 
 
What about any medicines that are unstable in a 
compliance aid? (see list) 
 
 
Comments 
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Actions required                           Y/N Intervention 
Score 
Actions required                                Y/N Intervention 
Score 
Link medication to daily 
routine? 
  Supply medication 
reminder chart? 
  
Supply medication 
administration records? 
  Supply medicine in multi-
compartment compliance 
aid? 
  
Other (specify)? 
 
Review recommendations for GP approval 
 Recommendation and rationale Agreed by GP? 
(initial and 
date) 
Intervention 
Score 
1 
 
   
2    
3    
4    
5  
 
  
 
 
GP and reviewing pharmacist verification 
 
GP Signature Date 
 
Pharmacist Signature Date 
Next Review Due 
(6 months if >75 and on 4+medications, 12 months if <75) 
 
 
Additional Information 
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Referral received  
Patient Contacted  
Medication Review Completed  
Recommendations agreed and actioned and 
review recorded on GP clinical system 
 
Follow up completed (if applicable) 
Delivered Dossette and explained use. 
 
 
Costs/savings associated with recommendations 
Total costs/savings associated with recommendations agreed 
 
 
 
Value of medicines removed for disposal 
 
 
 
Date:    _________________________________________________________ 
 
 
Name of Pharmacist: ___________________________________________________ 
 
Name of Coordinator: __________________________________________________ 
 
Name of GP:   ______________________________________________________ 
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Appendix 3: Template of medicines record and reminder chart for integrated care 
patient 
 
  INTEGRATED CARE PATIENT MEDICINES RECORD CHART 
Patient Name ____________________Date completed _________Review Date _______ 
Name, 
strength and 
form of 
medicine 
What it’s for 
How much to take & when  
Breakfast Dinner Tea 
Bed 
time 
Comments 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
      
 
If your medication is interfering with your daily life, ask if it is possible to change the type or dose to suit you. 
If you have any questions about your medicines ask your doctor or pharmacist. 
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Appendix 4: Staff participant information leaflet 
                                                                          
 
 
 
STAFF PARTICIPANT INFORMATION SHEET 
Version 4  
08th January 2016  
Version Number  Date  Comments ( descriptions of changes and amendments  
Version 2 14/12/2015 Version 1 annotated as per request in REC conditional  approval  letter 27/11/2015  
Version 3  21/12/2015 Version 2 -annotated with comments in response to REC email 17/12/ 2015 
Version 4 08/01/16 Comments for REC on version 3 removed and information re use of quotes as per REC request added 
 
Title of Project:  
An Action Research evaluation of the contribution to patient care, made by a pharmacist 
within an Integrated Care Model.  
 
Name of Investigator: Phyllis Navti  
 
Job Titles: Head of Prescribing, East Leicestershire and Rutland CCG & part time Senior 
Lecturer, De Montfort University  
 
Who is organising and funding the research?  
The research is not funded by any organisation. It is being undertaken as part of a doctorate 
degree in pharmacy practice which is paid for by De Montfort University of Leicester , where 
the main researcher works as a Senior Lecturer in Pharmacy Practice and Clinical Pharmacy  
 
Invitation paragraph  
You have been invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Ask me if there is 
anything that is not clear or if you would like more information.  
Please take time to decide whether you wish to take part or not.  
 
Thank you for reading this. 
 
What is the study about?  
Patients with long term conditions make up 70% of the government overall spend on health 
and care. These patients receiving care in the community, often state that they do not feel as 
if they are treated as a whole person because treatment is usually focused on individual 
diseases and the NHS teams and social carers do not often communicate with each other or 
work together. It is proposed that the outcome for these patients will be better if their care is 
coordinated, integrated and holistic across general practitioner teams and social care, 
instead of the current fragmented care.  
 
It is also proposed that this coordination should include medication because most patients 
will be on several medications. It is important that the patients and everyone providing care 
for them know and understand the basics of what medication the patient is taking. It is 
therefore proposed following a pre-pilot, that a pharmacist as part of the integrated care 
team can undertake medication reviews and support the patient and other members of the 
multidisciplinary team with information/advice regarding medication. However, the best way 
for the pharmacist to provide this support and how the support should be measured is not 
yet determined for East Leicestershire and Rutland Health and Social Care.  
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Therefore, you are being asked to take part in this study which will help understanding and 
development of the role of the integrated care pharmacist across East Leicestershire and 
Rutland Clinical Commissioning Group and social care. The study will also seek to 
understand the implications of rolling it out and develop a process for evaluation of the role.  
 
What does the study involve?  
The study will include one interview session lasting approximately 30-45 minutes and an 
invitation to attend a focus group a few months later.  
During the interview you will be asked about your experience of the role of a pharmacist as 
part of the integrated care team. You will also be asked for any suggestions you might have 
about developing and evaluating the role. The information you provide at the interview will be 
used to develop a data collection tool to collect data that will be discussed during the focus 
group.  
The interview will be at a location convenient for you e.g. a meeting room in your workplace 
or a base nearby.  
 
All those who take part in an interview will be invited to attend a focus group at a future date 
at an NHS or social care venue, if they wish. The focus group will take place a few months 
after and will also be organised to take place in a meeting room at either an NHS or social 
care office. It is envisaged that the focus group would last for 60-90 minutes and drinks and 
snacks will be provided.  
 
Why have I been invited?  
You have been invited because you have worked alongside the pharmacist to provide 
integrated care to patients  
 
Do I have to take part?  
It is up to you to decide whether to take part. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign the consent form attached. If you decide 
to take part you are still free to withdraw at any time before data analysis has started, without 
giving a reason. Please note that there are limits of confidentiality as specified below  
 
 
Will my taking part in this study be kept confidential?  
Care will be taken to ensure that all the data protection requirements are fulfilled in the 
following way  
• Only required data will be assessed and this will be anonymized as much as possible 
and data will be stored in encrypted sticks and locked in secure offices accessible 
only to chief investigator and her supervisor.  
• Direct identifiers will be kept to a minimum and will be separated from any traceable 
information. These identifiers will be destroyed in the long run and only fully 
anonymized data will held for the required duration.  
• Transcripts derived from audio recorded files from the interview and focus group will 
be edited to ensure that participants’ names are removed or replaced by coded 
identifiers or pseudonyms of the participants. The audio record files  will be locked up 
in the Chief Investigators (CI) NHS secured office in a  drawer which will only be 
accessible by the CI. 
• The data will only be kept for the minimum period necessitated by the academic 
requirements  
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•  Only Anonymous data will be shared if required for research purpose  and only for 
the following reasons  
 to ensure that research is open to peer scrutiny  
 to optimise the use of good quality research data  
 to support policy and other decision-making  
The write up will not reference any comments to the professional to ensure that views 
remain anonymous considering the small numbers.  
 
Please be aware that confidentiality cannot be maintained if you provide information where 
disclosure is in the overriding public interest or where there is a legal duty to disclose, for 
example by court order and where there is a statutory basis which permits disclosure.  
Please be reassured that you will be notified in the case of any disclosure if there is any risk 
to yourself or others. 
 
I am interested in taking part, what do I do next?  
Participants will be accepted on a first come first served basis although the chief investigator 
will use her judgment in order to obtain a balanced representation of participants, for 
example by gender, length of work experience and professional background.  
If you are interested in taking part and would first like to discuss your involvement with the 
researcher, please contact Mrs Navti by telephone or email (see details at end of this 
information sheet).  On the other hand, if you feel that you are already fully informed about 
the study, please sign and return the enclosed consent form. 
 
Via post: 
 
Please complete the attached consent form, put it in the attached envelop and either hand it 
to the coordinator (for GP and nurse participants) or post it using the stamped and 
addressed envelope to  
 
Phyllis Navti  
East Leicestershire and Rutland CCG  
Bridge Park Road  
Thurmaston LE4 8BL  
 
OR  
 
Via Email  
Please email a request for an electronic version to 
Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk  Please complete the electronic 
consent form and email to Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk  
 
 
What if I agree to take part and then change my mind?  
You can withdraw from the study at any time before data analysis starts, without giving a 
reason.  
 
What are the possible disadvantages and risks of taking part?  
There are no disadvantages or risks apart from the time you provide when you take part in 
the interview and focus group. 
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What are the possible benefits of taking part?  
You may help to improve the way integrated care is delivered across East Leicestershire and 
Rutland so that it is done in a truly multidisciplinary and integrated way.  
 
What if something goes wrong? / Who can I complain to?  
If you have a complaint regarding anything to do with this study, you can initially approach 
the lead investigator. If this achieves no satisfactory outcome, you should then contact the 
Administrator for the Faculty Research Ethics Committee, Research & Commercial Office, 
Faculty of Health & Life Sciences, 1.25 Edith Murphy House, De Montfort University, The 
Gateway, Leicester, LE1 9BH or hlsfro@dmu.ac.uk  
 
What will happen to the results of the study?  
The results could be submitted for publication or used in a report. Some of the data will 
inform a focus group of health and social care workers and patients. A summary of the final 
results will also be sent to you for your information. Non-identifiable quotes may be 
published in articles or used in conference presentations. 
 
Who has reviewed the study?  
This study has been reviewed and approved by De Montfort University, Faculty of Health 
and Life Sciences Research Ethics Committee and the NHS Research Ethics committee  
Contact for Further Information  
Phyllis Navti  
Email: Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk  
Phone: 01162955168  
 
Thank you for reading this information and for considering taking part in the study. 
 
Please complete the attached consent form if you would like to take part. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 155 
 
Appendix 5 
 
 
Staff participant 
consent form 
 
 
 
 
 
 
 
 
 156 
Appendix 5: Staff participant consent form 
 
 
STAFF CONSENT FORM 
Version 3  
08thJanuary 2016 
Version Number  Date  Comments (descriptions of changes and amendments  
Version 2 21/12/2015 Version 1 with changes as per request in REC conditional approval letter 27/11/2015 and REC 
email 17/12/ 2015 and option to send completed form via email  
Version 3  08/01/2016  Tracked changes for REC accepted and imbedded   
 
Title of project:  
An Action Research evaluation of the contribution to patient care made 
by a pharmacist within an Integrated Care Model  
 
Name of researcher: Phyllis Navti 
 
Please initial all boxes if you agree 
 
1. I confirm that I have read and understood the information sheet [version 3 
January 2016] for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason. 
    
3.      I agree that non-identifiable quotes may be published in articles or used in  
   conference presentations. 
 
4.      I agree to the interview being digitally audio recorded 
(The transcripts derived from audio recorded files from the interview and focus group will be edited to 
ensure that participants’ names are removed or replaced by coded identifiers or pseudonyms of the 
participants) 
 
5.      I understand that data collected during the study may be looked at by a  
         Supervisor from De Montfort University. 
 
6.     I agree to take part in this study 
 
      
_________________________  ________________  _____________ 
Print name of participant   Date     Signature 
__________________ 
Telephone Number of participant  
________________                    ________________  ____________ 
Print name of person taking consent    Date     Signature 
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Thank you for completing the consent form. 
Please either  
 
1) Send via Post 
Place completed form in the attached envelop and hand to the coordinator (for GP 
and nurse participants) or post using the stamped and addressed envelope to  
 
Phyllis Navti  
East Leicestershire and Rutland CCG  
Bridge Park Road  
Thurmaston LE4 8BL  
 
OR  
 
2) Send via email  
 
By requesting an electronic version by emailing 
Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk and then completing the electronic 
consent form and emailing to Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk 
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Appendix 6: Patient participant information leaflet 
 
 
PATIENT PARTICIPANT INFORMATION SHEET 
Version 4  
08th January 2016  
Version Number  Date  Comments (descriptions of changes and amendments  
Version 2 14/12/2015 Version 1 annotated as per request in REC conditional approval letter 27/11/2015  
Version 3  21/12/2015 Version 2 -annotated with comments in response to REC email 17/12/ 2015 
Version 4 08/01/16 Comments for REC on version 3 removed and information re use of quotes as per REC request added 
 
 
 
Title of Project:   
An Action Research evaluation of the contribution to patient care made by a pharmacist 
within an Integrated Care Model. 
 
Name of Investigator: Phyllis Navti  
 
Job Titles: Head of Prescribing, East Leicestershire and Rutland Clinical Commissioning 
Group & part time Senior Lecturer, De Montfort University  
 
Who is organising and funding the research? 
The research is not funded by any organisation. It is being undertaken as part of a doctorate 
degree in pharmacy practice which is paid for by De Montfort University of Leicester , where 
the main researcher works as a Senior Lecturer in Pharmacy Practice and Clinical Pharmacy  
 
 
Invitation paragraph 
You have been invited to take part in a research study.  Before you decide whether to take 
part, it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully.  Ask me if there is 
anything that is not clear or if you would like more information.   
 
Take time to decide whether you wish to take part or not.   
 
Thank you for reading this. 
 
What is the study about? 
The study is about getting the views and opinions of patients and staff, to help understand 
and develop the role of the pharmacists who work as part of the integrated care team, 
across East Leicestershire and Rutland Clinical commissioning group and social care. 
 
What is the integrated care team? 
The Integrated Care Team is a group of GPs, nursing staff, a pharmacist, health & social 
care coordinators and administrators who look after patients to help them stay well for longer 
and avoid the need for hospital care. The team develops a personal plan to meet specific 
needs of patients. The team also: 
 
o Tries to help to resolve any issues that are preventing patients from staying well 
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o Provide patients with information about self-help groups, so that they can meet others in 
similar situations  
 
o Refer patients to local services that can help them care better for themselves, including: 
 Education about long term conditions 
 Information about lifestyle choices 
 How to get the right equipment to keep independent 
 How to manage medicine 
 
 By looking after patients in this way we can make sure that patient needs are taken care of 
quicker, while reducing the amounts of visits by different people. 
 
Why is the study important? 
Patients with long term conditions receiving care in the community are stating that they do 
not feel as if they are treated as a whole person. This is because treatment is usually 
focused on individual diseases and social needs and the National Health Service (NHS) and 
social carers do not often communicate with each other or work together. Patients could end 
up receiving several phone calls or visits about a single condition instead of one single 
contact to look after all their needs. It is proposed that the benefits for patients will be 
improved by integrated care which is described above.   
 
It is also proposed that this coordination should include medication because most patients 
will be on several medications. It is important that the patients and everyone caring for them 
know and understand the basics of what medication the patient is taking. It is proposed that 
a pharmacist as part of the team could link patient care by reviewing all medication the 
patient is taking and support the patient and other carers with advice regarding the 
medication. However, the best way for the pharmacist to provide this support and how to 
check if it is useful, is not yet known. 
 
Therefore you are being asked to take part in this research study which will help to 
understand and develop this role of the pharmacist working as part of the integrated care  
team. The study will also seek to understand what it means to expand the pharmacist role 
and test if it is providing any benefits to patients.   
 
What does the study involve? 
The study will include one interview session lasting approximately 30-45 minutes and an 
invitation to attend a focus group a few months later. 
 
During the interview, you will be asked about your experience of the role of a pharmacist as 
part of the integrated care team. You will also be asked for any suggestions you might have 
about improving the role and how to and check if having the pharmacist is useful.    The 
information you provide at the first interview will be used to develop a data collection tool to 
collect data that will be discussed during the focus group. 
The interview will be at a location convenient for you eg a meeting room at your Gp surgery 
or a social care office close to your home or in your home if you are unable to attend 
otherwise and are comfortable with this. 
 
All those who take part in an interview will be invited to attend a focus group at a future date 
at an NHS or social care venue, if they wish. The focus group will take place a few months 
after and will also be organised to take place in a meeting room at either an NHS or social 
care office. It is envisaged that the focus group would last for 60-90 minutes and drinks and 
snacks will be provided 
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Why have I been invited? 
You have been invited because a pharmacist has been part of the Multidisciplinary team that 
has provided care for you 
 
Do I have to take part? 
It is up to you to decide whether to take part. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign the consent form attached. If you decide 
to take part you are still free to withdraw at any time before data analysis has started, without 
giving a reason. Please note that there are limits of confidentiality as specified below  
 
 
 
Will my taking part in this study be kept confidential?  
Care will be taken to ensure that all the data protection requirements are fulfilled in the 
following way  
• Only required data will be assessed and this will be anonymized as much as possible 
and data will be stored in encrypted sticks and locked in secure offices accessible 
only to chief investigator and her supervisor.  
• Direct identifiers will be kept to a minimum and will be separated from any traceable 
information. These identifiers will be destroyed in the long run and only fully 
anonymized data will held for the required duration.  
• Transcripts derived from audio recorded files from the interview and focus group will 
be edited to ensure that participants’ names are removed or replaced by coded 
identifiers or pseudonyms of the participants. The audio record files will be locked up 
in the Chief Investigators (CI) NHS secured office in a drawer which will only be 
accessible by the CI. 
• The data will only be kept for the minimum period necessitated by the academic 
requirements  
•  Only Anonymous data will be shared if required for research purpose and only for 
the following reasons  
 to ensure that research is open to peer scrutiny  
 to optimise the use of good quality research data  
 to support policy and other decision-making  
 
 
Please be aware that confidentiality cannot be maintained if you provide information where 
disclosure is in the overriding public interest or where there is a legal duty to disclose, for 
example by court order and where there is a statutory basis which permits disclosure.  
Please be reassured that you will be notified in the case of any disclosure if there is any risk 
to yourself or others. 
 
I am interested in taking part, what do I do next?  
Participants will be accepted on a first come first served basis although the chief investigator 
will use her judgment to obtain a balanced representation of participants, for example by 
gender, length of work experience and professional background.  
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If you are interested in taking part and would first like to discuss your involvement with the 
researcher, please contact Mrs. Navti by telephone or email (see details at end of this 
information sheet).  On the other hand, if you feel that you are already fully informed about 
the study, please sign and return the enclosed consent form. 
 
Via post: 
 
Please complete the attached consent form, put it in the attached envelop and post it using 
the stamped and addressed envelope to  
Phyllis Navti  
East Leicestershire and Rutland CCG  
Bridge Park Road  
Thurmaston LE4 8BL  
 
OR  
 
Via Email  
Please email a request for an electronic version to 
Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk . Please complete the electronic 
consent form and then email to Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk  
 
What if I agree to take part and then change my mind? 
You can withdraw from the study at any time, without giving a reason.  
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks apart from the time you provide when you take part in 
the interview and focus group. 
 
What are the possible benefits of taking part?  
You may help to improve the way integrated care is delivered in East Leicestershire and 
Rutland so that it is done in a truly multidisciplinary and integrated way.  
 
What if something goes wrong? / Who can I complain to? 
If you have a complaint regarding anything to do with this study, you can initially approach 
the lead investigator-Phyllis Navti (details below). 
 
If this achieves no satisfactory outcome, you should then contact the Administrator for the 
Faculty Research Ethics Committee, Research & Commercial Office, Faculty of Health & 
Life Sciences, 1.25 Edith Murphy House, De Montfort University, The Gateway, Leicester, 
LE1 9BH or hlsfro@dmu.ac.uk  
 
What will happen to the results of the research study? 
The results may be submitted for publication in a peer reviewed journal or used in a report. 
Some of the data will inform a focus group of health and social care workers and patients.  A 
summary of the final results will also be sent to you for your information. Non-identifiable 
quotes may be published in articles or used in conference presentations. 
 
Who is organising and funding the study? 
The study is not funded by any organisation. It is being undertaken as part of a doctorate 
degree in pharmacy practice which is paid for by De Montfort University of Leicester where 
the main researcher works as a Senior Lecturer in Pharmacy Practice and Clinical Pharmacy  
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Who has reviewed the study? 
This study has been reviewed and approved by De Montfort University, Faculty of Health 
and Life Sciences Research Ethics Committee and the Leicestershire, Rutland and 
Northampton NHS Research Ethics Committee. 
 
Contact for Further Information 
Phyllis Navti 
Email: Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk  
Phone: 01162955168 
 
Thank you for reading this information and for considering to take part in the study. 
 
Please complete the attached consent form if you would like to take part. 
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Appendix 7:  Patient participant consent form 
 
                                   PATIENT CONSENT FORM 
Version 3  
08th January 2016  
Version Number  Date  Comments (descriptions of changes and amendments  
Version 2 21/12/2015 Version 1 with changes as per request in REC conditional approval letter 27/11/2015 and REC 
email 17/12/ 2015 and option to send completed form via email  
Version 3  08/01/2016  
 
Tracked changes for REC accepted and imbedded   
 
Title of project:  
An Action Research evaluation of the contribution to patient care made 
by a pharmacist within an Integrated Care Model  
 
Name of researcher:                   Phyllis Navti 
 
Please initial all boxes if you agree 
          
3. I confirm that I have read and understood the information sheet [version 3; 8th 
January   2016] for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
4. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason. 
    
3.      I agree that non-identifiable quotes may be published in articles or used in  
   conference presentations. 
 
4.     I agree to the interview being digitally audio recorded  
(The transcripts derived from audio recorded files from the interview and focus group will be edited to 
ensure that participants’ names are removed or replaced by coded identifiers or pseudonyms of the 
participants) 
 
5.    I understand that data collected during the study may be looked at by a  
         Supervisor from De Montfort University. 
 
6     I give consent to the researcher to access my medical record for the purpose   
       of this research 
 
7.     I agree to take part in this study 
 
_________________________  ________________  _____________ 
Print name of participant   Date     Signature 
__________________ 
Telephone Number of participant  
_________________________  ________________  _____________ 
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Print name of person taking consent Date     Signature 
 
 
Thank you for completing the consent form 
 
Please either  
 
1) Post the completed form using the stamped and addressed envelope to  
 
Phyllis Navti  
East Leicestershire and Rutland CCG  
Bridge Park Road  
Thurmaston LE4 8BL  
 
OR  
 
2) Send via email  
 
By requesting an electronic version by emailing 
Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk and then completing the electronic 
consent form and emailing to Phyllis.navti@eastleicestershireandrutlandccg.nhs.uk 
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Appendix 8:  Topic guides for interviews and focus group 
 
Topic Guide for Semi Structured Interview for Stage 1 
Interviewee Identifier code:______________ 
Verbal Introduction: 
I am Phyllis Navti the main researcher. 
Thank you for accepting to take part in this study and for taking the time to attend 
this interview today. 
The interview will last 30-45 minutes  
Thanks for accepting that I record the interview. 
 
Are you ok if I also take a few notes? 
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Resources  Patient Guide Questions  Pharmacist’s Guide Questions  Other Stakeholder guide questions  
 Have you heard about IC care? Health care is about providing care for 
patients- where do you think IC fit into 
this? 
Health care is about providing care for 
patients- where do you think IC fit into 
this? 
 (only if 
required 
ie do not 
know what 
IC care )   
Copy of 
appendix 
one – IC 
leaflet  
Health care is about providing care for 
patients- where do you think IC fit into 
this? 
What do you think IC is? 
What does IC mean to you? 
What does IC mean to you? What does IC mean to you? 
 Who do you think is part of the IC team? 
Prompt re other health care professionals 
working together  
 What do you think they do? 
Who do you think is part of the IC team? 
 What do you think they do? 
Who do you think is part of the IC team? 
• What do you think they do? 
 Who do you think should be part of the IC 
team? 
 Patients? 
 Community pharmacist? 
Who do you think should be part of the IC 
team? 
 Patients? 
 Community pharmacist? 
Who do you think should part of the IC 
team? 
 Patients? 
 Community pharmacist? 
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 What do you think having an IC 
pharmacist means to a patient? 
What do you think having an IC 
pharmacist means to a patient like 
yourself? 
 What should they do/how should 
they work?  
 Likes  
 dislikes 
What do you think having an IC 
pharmacist means to a patient? 
 What should they do/how should 
they work?  
 Advantages 
 disadvantages 
What do you think having an IC 
pharmacist means to a patient? 
 What should they do/how should 
they work?  
 Advantages 
 disadvantages 
  What do you think having an IC 
pharmacist means to other members of 
the team? 
What do you think having an IC 
pharmacist means to other members of 
the team? 
 Can you think of anything that would help 
the work of the integrated care 
pharmacist? 
 
Can you think of any barriers/facilitators to 
the work of the integrated care pharmacist 
Can you think of any barriers/facilitators 
to the work of the integrated care 
pharmacist? 
 How do you think the role should be 
assessed to see if it improves patient 
care? 
How do you think the role should be 
evaluated? 
 how evaluate  
How do you think the role should be 
evaluated? 
how evaluate 
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 Do you think the role should be kept going 
in the future? 
  
How do you think the role could be 
developed? 
 
How do you think the role could be 
developed?   
  
How do you think the role could be 
developed? 
 
How do you think the role could be 
developed?   
 
 Any other comments? Any other comments? Any other comments? 
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Topic Guide for Focus group  
 
Verbal Introduction: 
 
Thank you for accepting to take part in this study and for taking the time to attend the 
initial interview and this focus group today. 
 
The focus group will last 60 – 90 minutes. 
 
Thank you for accepting that I record the interview. 
Are you ok if I also take a few notes? 
 
Just to introduce who is here I have made large cards with everyone’s name and 
whether they are staff or patient. 
 
The plan will be  
1) Presentation of findings derived from interviews  
 
2) Presentation of quantitative data summary  
 
3) Discussions arising from the presentations  
 
 
Reserve prompts  
 
Any updates or changed views or additions to following questions from interview? 
 
Where do you think IC fit into this? 
 
What does IC mean to you? 
Who do you think is part of the IC team? 
What do you think they do? 
Who do you think should be part of the IC team? 
Patients? 
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Community pharmacist? 
What do you think having an IC pharmacist means to a patient? 
What should they do/how should they work?  
Advantages 
disadvantages 
What do you think having an IC pharmacist means to other members of the team? 
Can you think of any barriers/facilitators 
Do you think the role should be evaluated/developed  ? 
how evaluate  
how develop? 
How sustained? 
 
Any other comments? 
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22 December 2015  
Mrs. Phyllis Navti  Head of Prescribing and  
Senior Lecturer  East Leicestershire & Rutland Clinical Commissioning Group,  
Bridge Park Business  Park, Bridge Road, 
Leicester  LE4 8BL  
 
Dear Mrs. Navti, 
 
Study title: An Action Research evaluation of the contribution to patient care made by 
a pharmacist within an Integrated Care Model  15/LO/2132  
REC reference: Protocol number: IRAS project ID: HLS1437 174726  
 
Thank you for your letter of 21 December 2015, responding to the Proportionate Review 
Sub-Committee’s request for changes to the documentation for the above study.  
The revised documentation has been reviewed and approved by the sub-committee.  
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter. The expectation is that this information will be 
published for all studies that receive an ethical opinion but should you wish to provide a 
substitute contact point, wish to make a request to defer, or require further information, 
please contact the REC Manager Georgina Castledine, nrescommittee.london-
harrow@nhs.net. Under very limited circumstances (e.g. for student research which has 
received an unfavourable opinion), it may be possible to grant an exemption to the 
publication of the study.  
 
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
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documentation as revised.  
Conditions of the favourable opinion  
The REC favourable opinion is subject to the following conditions being met prior to the start  
of the study:  
1. The point regarding the intended use of quotes was misunderstood. The consent form 
provides for use of non-identifiable quotes, therefore please add this to the PIS.  
You should notify the REC in writing once all conditions have been met (except for site 
approvals from host organisations) and provide copies of any revised documentation with 
updated version numbers. The REC will acknowledge receipt and provide a final list of the 
approved documentation for the study, which you can make available to host organisations 
to facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions.  
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned.  
Management permission should be sought from all NHS organisations involved in the study 
in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise).  
Guidance on applying for HRA Approval (England)/ NHS permission for research is available 
in the Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity.  
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
Sponsors are not required to notify the Committee of management permissions from host 
organisations.  
 
Registration of Clinical Trials  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant is 
recruited but no later than 6 weeks after recruitment of the first participant.  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part 
of the annual progress reporting process.  
To ensure transparency in research, we strongly recommend that all research is registered 
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but for non-clinical trials this is not currently mandatory.  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials 
will be registered, however, in exceptional circumstances non-registration may be 
permissible with prior agreement from the HRA. Guidance on where to register is provided 
on the HRA website.  
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the  
 
Ethical review of research sites  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” above).  
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Approved documents  
The documents reviewed and approved by the Committee are:  
Document  
  
Version  
Date  
Evidence of Sponsor insurance or indemnity (non-NHS Sponsors only) [Copy of DMU insurance 
Sponsor]    
Interview schedules or topic guides for participants [Topic guide for interview and focus group for 
integrated care pharmacist]  
1  22 November 2015  
IRAS Checklist XML [Checklist_21122015]  
 
21 December 2015  
Other [Patient PIS IC pharmacist research]  1  02 November 2015  
Other [Staff consent form Integrated care pharmacist research]  1  22 November 2015  
Other [IC research Patient PIS]  3  21 December 2015  
Other [IC pharmacist research staff consent form]  2  21 December 2015  
Other [PN to REC letter summarizing completed actions as requested in REC letter of 27/11/15 and 
Email 17/12/15 ]  
1  21 December 2015  
Participant consent form [Patient consent form for IC Pharmacist research]  V1  21 November 2015  
Participant consent form [IC pharmacist patient consent form]  2  21 December 2015  
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Participant information sheet (PIS) [staff PIS IC pharmacist research]  1  02 November 2015  
Participant information sheet (PIS) [IC research Staff PIS]  3  21 December 2015  
REC Application Form [REC_Form_23112015]  
 
23 November 2015  
Research protocol or project proposal [Evaluation of role of IC pharmacist]  1  02 November 2015  
Summary CV for Chief Investigator (CI) [CV Phyllis  
Navti]  
1  02 November 2015  
Summary CV for supervisor (student research) [Peter Rivers CV]  1  16 June 2015  
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK.  
After ethical review  
Reporting requirements  
The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a 
favourable opinion, including:  
   Notifying substantial amendments    
   Adding new sites and investigators  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   Notification of serious breaches of the protocol    
   Progress and safety reports    
   
Notifying the end of the study  The HRA website also provides guidance on these topics, which is updated in the light of  
changes in reporting requirements or procedures.  
Feedback  
You are invited to give your view of the service that you have received from the Nakyour views known please use the feedback form available 
on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance  
We are pleased to welcome researchers and R & D staff at our NRES committee members’ training days – see details at 
http://www.hra.nhs.uk/hra-training/  
With the Committee’s best wishes for the success of this project.  
Yours sincerely  pp.  Miss Shelly Glaister-Young Vice Chair  
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Email: nrescommittee.london-harrow@nhs.net  
Copy to:  
Dr Peter Rivers   
Mrs Rose Streeton, Northamptonshire R&D Service  
    
    
15/LO/2132 Please quote this number on all correspondence  
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Appendix 11: End of scheme report for Integrated Care Pharmacist Pilot (Abridged & 
adapted for confidentiality and relevance) 
EAST LEICESTERSHIRE AND RUTLAND CLINICAL COMMISSIONING GROUP 
STRATEGY, PLANNING AND COMMISSIONING COMMITTEE MEETING 
 
Front Sheet 
 
REPORT TITLE: End of scheme report for Integrated Care Pharmacy Pilot  
MEETING DATE: (Removed for confidentiality ) 
REPORT BY: KC/RS /PN (abbreviated for confidentiality)  
SPONSORED BY: TS (abbreviated for confidentiality) 
PRESENTER: PN (abbreviated for confidentiality) 
 
 
PURPOSE OF THE REPORT: 
      
This report is aimed at providing a summary of the of key performance indicators(KPIs) delivered 
by the Integrated Care Pharmacists (1.6WTE)  
 
Background  
 
Medicines Optimisation is defined as “a patient-focused approach to getting the best from 
investment in and use of medicines ….and requires a holistic approach, an enhanced level of 
patient centred professionalism, and partnership between clinical professionals and a patient” 
(Royal Pharmaceutical Society of Great Britain 2013). The RPS also states that MO involves 
professionals across the health and social care system working together collaboratively and 
much more closely with patients. 
 
Shared principles and outcomes of both Integrated care and medicines optimisation, include 
patient centred care, increased adherence, holistic approach, partnership working, reduction in 
medicines waste and medication related admissions.  
 
A pharmacist from the Integrated Care Pharmacy Service Team was allocated to each of the 
localities. 
 
Key performance indicators achievement: 
All KPIs were achieved as detailed table one below  
 
Table 1: Summary of key performance indicators 
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Key activities 
 
November 14 – July 15 (abridged – full report available) 
 
 Integrated care pharmacists developed workflow process for undertaking project 
following previous pilot work. Establish referral process from Care Co-coordinators but 
also directly from GPs and other practice clinical staff 
 Clinical medication reviews & Domiciliary visits of opt in and referred patients 
 Pharmaceutical care plans developed 
 Visits to practices made to arrange patient record access (including remotely), feedback 
method (meetings, MDT, paperwork), record keeping & “closing the loop”. 
 Key performance indicator 
 
(238 IC patient reviews resulting in 708 suggestions) 
Outcomes 
Achieved  
Yes/No 
Figure 
(Percentage)  
1 Achievement of return of investment of minimum 2 
Calculations  
Net Savings 
£196,840 (Total savings by IC pharmacist for 8.5 
months*) 
– £47,874(Total IC Pharmacist cost for 8.5months)  
  = 148,966 
Return of investment £148,966 ÷£47,874 x 100% = 3.1 % 
 
Yes   
3.1 
(311%) 
 
£625.9 per 
patient  
2 Reduction of polypharmacy  
 
Yes  54  
(22%) 
3 Completion of clinical Medication Review for all referred 
patients 
 
Yes  100% 
4 Completion of Medicines Reconciliation for all integrated 
care patients as required  
 
Yes  23 
(9.6%) 
5 Provision of domiciliary Clinical Medication review as 
required  
 
Yes  20 
(8.4%) 
6 Provision of Repeat prescriptions review for all IC patients  
 
Yes  89(37%) 
7 Provision of medication training sessions to integrated care 
coordinators every two months 
 
Yes  4 
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 Attendance at Integrated Care Co-coordinators team meetings to liaise and improve 
cross team working, including educational input around compliance aids and drug use 
overview 
 Follow up of medication reviews through various means (GP feedback on written 
reviews, “task” through SystmOne, attendance at MDTs and one to one with IC 
responsible GP) 
 Liaise with community pharmacies 
 Presentation of Integrated Care & Polypharmacy work streams to Locality meeting and 
ELR CCG Medicines Quality Strategic Group (MQSG) and Strategy Planning and 
Commissioning Group(SPCG) 
 Action and follow up of medication reviews including coding, telephone calls to patients, 
liaison with community pharmacy and other appropriate agencies. 
 Attendance at bimonthly hub meeting for sharing cross department practice information 
 Costing of waste drugs from patients’ home & disposal 
 Development of laminated record cards for patients  
 Development of medicines summary aides for coordinators and district nurses 
 
Barriers 
 
 Access to clinical systems and key stakeholders and establishing work flow has been a 
rate limiting step. 
 Large geographical area, a phased approach may have been better 
 Issues with liaising with GP’s, low GP feedback 
 
 
Table 2: Key Performance Indicators (KPIs) monitored to demonstrate progress 
 
 Description  TOTAL 
 
Total number of reviews 
 
238 
Number of reviews conducted in 
patient's home 
Number of telephone calls made  
20 
 
56 
Number of reviews with suggestions 
made 
209 
Total number of suggestions made 708 
Number of suggestions agreed 541 
Number of suggestions disagreed 34 
Number of suggestions outstanding 133* 
The number of patients reviewed 
who have been recently discharged 
from hospital whose medicines 
have been reconciled 
23 
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Number of Antipsychotics and 
Benzodiazepines stopped                                       
(not indicated for psychosis) 
0 
Number of drugs changed 
(dose/strength/form) 
66 
Prescription directions changed 
(including amendments to dossette) 
6 
Quantity changed/synchronised 27 
Repeat lists tidied/repeats stopped 89 
Monitoring suggested  
i) Follow up/review due 45 
ii) Blood pressure 8 
iii) Blood test 29 
Unnecessary medicines stopped  
i)Total stopped 54 
ii) Avg per patient stopped  
iii) Range                                                                                      
(of medicines stopped per patient) 
1-4
Falls Prevention  
i) Anxiolytics (reduced/stopped) 11 
ii) Anti-muscarinics 
(reduced/stopped) 
7 
iii) Analgesics (optimised) 23 
iv) Antihistamines 
(reduced/stopped) 
7 
v) Antidepressants 
(reduced/stopped) 
3 
vi) Antihypertensives (optimised) 4 
vii) Diuretics (reduced/stopped) 2 
viii) Calcium and Vitamin D (started) 8 
High risk drugs  
Warfarin  
NOACS  
Methotrexate 2 
NSAIDS 2 
Important information 
communicated 
 
i) Allergies  
ii) ADR 42 
 
FINANCIAL AND FUNDING INFORMATION 
 
Savings  
Total annualized savings 
 Estimated annualized savings from medicines stopped or amended** =£55,300 
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 Estimated annualized savings from unused medication from patient home =+ £29,030 
 Estimated annualized savings from medicines related admission avoidance***= + £193,536 
 =£277,893 
Savings per month = £277,893 ÷ 12 = 23,157 
 
Savings for 8.5 months of scheme = 23.157 x 8.5 =£196,840 
 
 
Expenditure  
The total cost of the pilot = 
 £20,565 (pro- rata cost of 9 months of 0.6WTE of Band 8a – WTE cost of £45,707) + £27,309 (8 
months of 1WTE Band 8a –WTE cost of £40.964 per annum)                   
    = £47,874 (Total cost of 1.6 WTE Band 8a for 8.5 months (8 and 9 months averaged to 8.5)                                                                                                 
 
Net savings 
 
Net SAVINGS= £196,840- £47,874 = £148,966 
 
Notes  
*Outstanding suggestions are generally due to one of the following 
1. Due to being agreed for action at next routine appointment (possible role for pharmacist 
once more fully integrated into practice team) 
2. Waiting for next MDT 
3. Work still required at practice level to improve feedback loop 
4. All the above factors would be improved with a permanent pharmacist in practice 
 
**Savings calculated for KC for February 2015 and extrapolated to include total interventions 
***Admission avoidance: 
By definition, all integrated care patients are at risk of admissions as the risk stratification tool 
links to a history of hospital admission. Approximately 12% of hospital admissions could be 
assumed as  “medication related harm” eg ADR, adherence or errors ( Pirmohamed et al., 2004) 
.  Cost of an emergency admission is £1792 on average. Assumes 10% of accepted 
interventions have prevented an emergency admission. 
~Calculated from waste collected from domiciliary visits, and assuming similar waste for all 
patients reviewed  
 
Quality Outcomes 
 
1. Improved adherence with medication through confidence building and education 
2. Improved links with local pharmacies 
3. Sign posting to services, such as clinical waste collection 
4. Supporting carers/relatives to improve adherence  
5. Pharmacist monitoring support 
6. Integrated care team working in its fullest sense to optimise patient care 
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7. This service is different to MURs and NMS provided by community pharmacists (access 
to medical records, integration with wider multidisciplinary team eg GP, nurse, OT, 
domiciliary visits) 
 
 
 
Exit Strategy 
 
1. The integrated care role and work streams will be a key part of the next phase – the 
newly created Hub pharmacist posts, which will address geographical issues and 
integration within the MDT and practice team. All the learning from this pilot will be 
applied  
2. Including a pharmacy technician as part of the next phase will allow for some of the 
quality outcomes to be more appropriately managed and impact positively on salary 
costs. 
3. Roles for community pharmacy have also been identified. 
4. Explore reviewing contracts with domiciliary care agencies to ensure medicines quality 
delivered as per required standards 
5. Complete action plans for different members of the MDT and present to the groups eg 
GP practices, community pharmacy forum, district nurses and domiciliary carers  
 
 
 
 
 
RECOMMENDATIONS: 
The East Leicestershire and Rutland CCG Strategy, Planning and Commissioning 
Committee is requested to: 
 
RECEIVE FOR INFORMATION  
 
REPORT SUPPORTS THE FOLLOWING STRATEGIC AIM(S) 2014 – 2015: (tick all that apply) 
Transform services and enhance quality of 
life for people with long-term conditions 
 
x Improve integration of local services 
between health and social care; and 
between acute and primary/community 
care. 
x 
Improve the quality of care – clinical 
effectiveness, safety and patient experience 
x Listening to our patients and public – 
acting on what patients and the public tell 
us. 
x 
Reduce inequalities in access to healthcare  Living within our means using public 
money effectively 
x 
Implementing key enablers to support the strategic aims (e.g. constitutional and governance 
arrangements, communications and patient engagement). 
 
x 
 
EQUALITY ANALYSIS (Respond by inserting /completing one of the three statements 
below, delete the one that does not apply) 
1. An Equality Analysis and due regard to the positive general duties of the Equality Act 
2010 has been undertaken in the development of this report and its influence on the 
recommendation(s) is evidenced in section(s) XXX / paragraph(s) XXX  / Appendix 
XX / the Equality Analysis is attached. 
Or 
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2. An Equality Analysis and due regard to the positive general duties of the Equality Act 
2010 has not been undertaken in the development of this report as it is judged that it 
is not proportionate on the basis that XXXXX. 
 
This completes the due regard required.  
Or 
 
3. Further equality analysis is required and it is recommended that the ELRCCG Board 
receives this in [date]” 
 
 
RISK ANALYSIS AND LINK TO BOARD ASSURANCE FRAMEWORK: 
Questions to consider (text in red should be deleted as these are only prompts): 
 Does the report align to corporate risks identified in the Board Assurance Framework? 
 Does the report support in mitigating the risk(s) identified? 
 Does the report highlight a new risk(s)? if so please quantify the risk using the 5 x 5 risk 
matrix or discuss with the Corporate Affairs Team. 
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Appendix 12 
 
 
Monitoring form for 
GP Hub Medicine 
Quality Team pilot
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Appendix 12: Monitoring form for GP Hub Medicine Quality Team pilot  
 
 
TEMPLATE MONITORING DOCUMENT FOR GP HUB MEDICINE QUALITY  TEAM 
 
 
Project Name:  GP Hub Pharmacist Scheme    Date: _____________________ 
 
 
 Overall Project Status (RAG): Red or Amber or Green (Please delete as appropriate) 
 
Progress Chart for Key Deliverables (Key: Black – Time estimate, Green – On target, Amber – Slightly off target, Red – Seriously 
off target) 
 
 
 
ID TASKS Month 1  Month 2  Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
1 Meet all GP 
prescribing leads  
and agree process  
                                            
    
2a Integrated Care 
Medicines Review – 
Meet all  care 
coordinators / Band 
7 Nurse and agree 
process for referrals  
                                                
b Conduct medication 
reviews for 
highlighted patients  
                                                
HUB 
/PRACTICE 
NAME: 
 
AUTHOR (S):  
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ID TASKS Month 1  Month 2  Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
c MDT feedback of 
reviews, liaise with 
co-ordinator & 
implement actions  
                                                
3a Formulary 
Adherence Reports 
and highlight areas 
of switching to 
formulary & most 
cost effective 
therapy  
                                                
b Engage & develop 
Pre-agreements to 
pre-authorise levels 
of MQT intervention 
                                                
4a Review current 
Medicines 
Reconciliation policy 
and develop one if 
necessary  
                                                
b Discuss and agree 
the process of 
coding and updating 
discharge letters 
with staff and GP 
prescribing lead 
                                                
c Review discharge 
letters and update 
medications on GP 
record system  
                                                
5a Polypharmacy 
Rationalisation -  
Discuss with GP & 
Integrated care 
team high risk 
patients for 
Medication review.  
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ID TASKS Month 1  Month 2  Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
b Polypharmacy 
Rationalisation 
prescribing reviews 
in Care Homes 
                                                
c Highlight adherence 
to NICE care homes 
Quality standard 
                                                
d Discuss findings 
with key 
stakeholders & 
implement findings 
                                                
6a Shared Care 
Governance – Audit 
adherence to GP 
responsibilities on 
shared care 
                                                
b Highlight number of 
patients on LMSG 
Amber drugs who 
require monitoring 
                                                
c Set up a robust 
recall process to 
ensure GP 
responsibilities on 
shared care 
delivered 
                                                
7a Traffic Light Drugs – 
Formulary 
Adherence - Identify 
patients currently 
prescribed LMSG 
Red and Black 
drugs 
                                                
b Reduce prescribing 
of LMSG Red and 
Black drugs by 
stopping and re-
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ID TASKS Month 1  Month 2  Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
directing prescribing 
to secondary care 
c Discuss initial 
results with GP 
prescribing leads 
and educate GPs 
(discuss at practice 
meetings) 
                                                
9a 
 
Completion of 
Baseline of 2 
Quality Audits  (due 
Sept 2015) develop 
action plan 
                                                
b Completion of Re-
Audit of 2 Quality 
Audits (due March 
2016) & assess 
outcomes 
                                                
c Submit the required 
evidence for both 
Quality audits (due 
March 2016) 
                                                
10
a 
Pharmacist Led 
Consultations: 
Evaluate demand 
and process to 
incorporate clinic 
slots  
                                                
b Patients referred to 
Pharmacist for clinic 
or tele-consultations 
                                                
11 Assist GP and 
patients in UHL 
Specials Trial Pilot 
(for Oakham only) 
                                                
 
  
198 
 
    
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Activities – Month 1 
 
 
 
 
 
 
 
Other Activities – Month 3 
 
 
 
 
 
 
 
Other Activities – Month 2 
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Add boxes as required  
 
Risks and Issues 
 
Risk/Issue Description Risk Score Mitigation  Risk 
Lead Impact Likelihood Score 
 
 
 
 
     
 
 
 
 
     
 
 
 
 
     
  
Other Activities – Month 4 
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Month 1 Month 2 Month31 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 
PROJECT SPEND 2014/15
COMMENTARY TO SUPPORT CURRENT FINANCIAL POSITION
ELRCCG:
Collaborative:
Local Authority:
Total:
CONFIRMED SLIPPAGEPOTENTIAL SLIPPAGE
TOTAL ANTICIPATED 
SPEND
TOTAL SPEND TO DATE
CONFIRMED 
ALLOCATION
TOTAL ANTIICPATED 
SAVINGS
Total
Forecast Spend 
Actual Spend
Variance on Plan
Cumulative Total
 
 
 
Key Performance Indicators (KPIs) monitored to demonstrate progress 
The Key Performance Indicators have been divided into two main groups: 
A. Productivity and Prevention Key performance Indicators 
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B. Productivity and Prevention Key performance Indicators 
 
 A) Productivity and Prevention Key performance Indicators  
  Month 
1  
Month 
2 
Month 
3 
Month 
4 
Month 
5 
Month 
6 
Month 
7 
Month 
8 
Month 
9 
Month 
10 
M 
Month 
11  
Month 
12 
TOTAL 
 
1. Medicines Reconciliation  
 
i. Number of discharge letters 
reviewed & updated 
             
ii. Number of discrepancies 
identified and resolved  
             
iii.GP time saved  
 
             
iv. Audit of Meds Rec 
showing improvement from 
baseline  
             
 2. Pharmaceutical care   
Includes Integrated care role functions, drop-ins,care homes  and domiciliary  medication reviews  
i). Total number of patient 
interventions for all reviews  
             
Integrated Care role functions  
ii)Number of integrated care 
interventions 
             
iii) Number of MDT meetings 
attended  
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iv) Number of medication 
training sessions to MDT 
             
Care homes role functions  
v. Number of care home 
patient interventions 
             
vi) Number of medication 
training sessions to care 
home staff 
             
Others 
v. Number of Pharmacist led 
polypharmacy clinic 
consultations  
             
vi. Total monthly cost savings 
from medication reviews  
             
3. Shared Care Governance  
i) GP time saved               
iii. Bi annual Shared care 
audit of  rheumatology  and 
antipsychotic Shared care 
agreements with action plans  
& flagging sec comm care 
issues  
n/a n/a n/a n/a n/a Baseli
ne 
audit 
and 
action 
plans  
n/a n/a n/a n/a Re-
audit 
summ
ary 
and 
action 
plans 
  
4.  Formulary Adherence and QIPP actions  
 
i. prescribing spend ( add 
when data available 6 weeks 
after)  
             
ii. Number of patients 
identified for therapy change 
             
iii. Number of patients 
actioned 
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iv. Total monthly savings 
from schemes 
 
             
5. Additional medicine quality area related to QOF/LTC/QIPP  selected by Practice/hub 1 
i              
ii.              
6. Additional medicine quality area related to QOF/LTC/QIPP  selected by Practice/hub 2 
i.              
ii              
7. Additional medicine quality area related to QOF/LTC/QIPP  selected by Practice/hub 3 
 
i.              
ii.              
 
2) Quality Prevention Key performance Indicators 
 
  Month 
1  
Month 
2 
Month 
3 
Month 
4 
Month 
5 
Month 
6 
Month 
7 
Month 
8 
Month 
9 
Month 
10 
M 
Month 
11  
Month 
12 
TOTAL 
 
8. Quality audits 
Quality 1 - Antibiotic Audit 
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GP time saved ( Time to 
complete audit requirements) 
             
ii. Number of self-limiting 
leaflets coded 
             
iii. Improvement  from 
baseline for Antibiotic volume 
QIPP indicator  
             
Audit evidence  submitted  n/a n/a n/a n/a n/a Baseli
ne 
audit 
and 
action 
plans  
n/a n/a n/a n/a Re-
audit 
summ
ary 
and 
action 
plans 
  
Quality 2 – example Hypnotic audit  
i) GP time saved for Baseline               
ii) Number of reviews              
iii) Monthly savings              
ii) GP time saved for re-audit              
iii) Audit evidence  submitted  n/a n/a n/a n/a n/a Baseli
ne 
audit 
and 
action 
plans  
n/a n/a n/a n/a Re-
audit 
summ
ary 
and 
action 
plans 
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Exceptional incidents & additional information 
(Add boxes as required) 
 
 
 
 
 
 
 
Add boxes as required  
 
 
 
 
 
 
 
 
 
 
 
Incident 1 
Date:  
Incident Description and outcome:  
Incident 2 
Date:  
Incident Description and outcome:  
Incident 3 
Date:  
Incident Description and outcome:  
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1.  Executive 
Summary 
This report presents the findings from an independent review of East Leicestershire and 
Rutland CCG’s (ELR CCG) pilot of Medicines Quality Team (MQT) staff operating within 
GP practices (Pharmacy Hub Teams). Adopting a mixed methodological design, the research 
was designed to establish the perceptions and experiences of key stakeholders associated with 
the pilot scheme and to inform potential expansion of MQT work to the remaining GP hubs 
in ELR CCG. The research was undertaken during April-May 2016 by De Montfort 
University and Qualicis Research on behalf of ELR CCG. 
Qualitative data collection was in the form of one-to-one, semi-structured interviews, 
conducted with a representative sample of 16 staff that had been associated with the pilot 
scheme. Spread across three GP hubs within ELR CCG, participants included Prescribing 
Leads, Practice Managers, pharmacists, pharmacy technicians and other additional 
stakeholders (agreed with the CCG). The quantitative element to the research utilised a 
structured questionnaire that was sent to GP practice staff by the ELR CCG in order to gauge 
opinion of the extent of success of the MQT project.  
 
Key Findings 
 
Value and impact of Pharmacy Hub Teams  
All participants - GPs, Practice Managers, Pharmacy Hub Teams and other stakeholders – 
understood the rationale and motivation behind the pilot scheme well. There was a very 
positive outlook with respect to an expectation of clinical contributions from the pharmacy 
team alongside cost and time-saving aspects of the role.  
Prior to implementation of the pilot scheme, participants were generally positive about the 
initiative. GPs in particular expressed keenness to achieve an impact on their workload and 
time. Most participants talked positively about the integration of Pharmacy Hub Teams 
within their practices and alluded to issues related to individual personalities and 
relationships as a major contributor to successful collaborative working. Factors that were 
considered to have a potentially inhibitory impact upon the integration of the Pharmacy Hub 
team centred upon opinion that the scheme would benefit from pharmacy staff being 
employed for a greater number of hours per week in GP surgeries in order to more fully 
realise the potential of an integrated Pharmacy Hub Team.   
The overall accessibility of pharmacy staff was highlighted as a key benefit both in terms of 
planned and impromptu interactions between the pharmacy team and practice staff. The 
notion of pharmacy staff ‘being a team’ was often expressed by GPs and Practice Managers 
and there were numerous references to the unique area of expertise of individual pharmacy 
team members. Members of the Pharmacy Hub Teams, themselves, reflected upon feeling 
empowered through being more involved in the care of patients such as by having access to 
patient notes and clinical history as well the role being rewarding through medical staff 
having faith and confidence in their ability.  
Accessing health and social care insights 
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Opinion within one of the GPs Hubs suggests that the full potential of the pharmacy team 
could not be realised because the MQT was not contracted for sufficient number of hours. 
There was some variation, within Hubs, of the initial experience when pharmacy team 
members were introduced to the practices that may partly have been the result of some 
unavoidable sickness within the pharmacy team in one Hub.  
It was readily apparent that participants could point to specific perceived clinical ‘benefits’ of 
the Pharmacy Quality Hub by citing examples of good practice. With regard to assessing the 
impact of the pharmacy team on Key Performance Indicators (KPIs) opinions were generally 
positive although some participants expressed scepticism regarding whether the statistics (e.g. 
estimates of GP time saved) were a true reflection of practice.  Some participants were not 
convinced that time-saving figures were a true reflection of workload. By contrast, others 
played down the importance of such figures by arguing that there was a range of 
unquantifiable activities in addition to the time-saving aspects that added value to pharmacy 
involvement.   
 
Sustainability of Pharmacy Hub Teams 
Overall, there was a highly positive reflection of the MQT among practice stakeholders that 
bodes well for achieving longer-term sustainable working relations between Pharmacy Hub 
Teams and GP practices. This was evidenced by a strong sense of confidence of practice staff 
in the clinical abilities of individual MQT members. Also, mutual respect had developed in 
some Hubs that resulted in a feeling of empowerment of the pharmacy team and an 
acceptance of them by the practice team of which both qualities are desirable in order to 
achieve sustainable long-term working relations. In instances where individual members of 
the pharmacy team ‘gelled’ well with practice staff and were considered to be ‘good team 
players’ – the potential for sustainability was greater. Moreover, where pharmacy staff took a 
proactive approach to problem-solving, there was considerable appreciation of their worth 
within the practice.  
Factors that acted as barriers, and therefore learning points to address in terms of the future 
sustainability of the scheme, arose from opinion, expressed strongly by a minority of 
participants, of contrasting agendas or priorities between practices and the ELR CCG. Such 
issues tended to relate to differences in opinion with regard to whether the role of the MQT 
was primarily to pursue a perceived CCG agenda of cost-saving activities (e.g. in relation to 
the drug budget) or, by contrast, for pharmacy teams to absorb some drug-related clinical or 
prescribing activity that has traditionally been the responsibility of doctors. There were some 
practical issues associated with the provision of resources such as computer and telephone 
access and training for the pharmacy team which was a source of frustration in one Hub 
during the early stages of the pilot scheme but such issues are not likely to impact on the 
longer term sustainability of the scheme.  
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